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Chapter 1 
PATHOPHYSIOLOGY of the ADULT RESPIRATORY DISTRESS 
SYNDROME (ARDS) and MULTIPLE ORGAN FAILURE (MOF). 
1.1 CLINICAL RELEVANCE 
Numerous advances in the management of severe illness have resulted in the 
successful resuscitation of patients with severe trauma, extensive burn-wounds, acute 
necrotizing pancreatitis and systemic sepsis. Many of these patients now survive the acute 
episode but have a potential risk to succumb later from complications such as the Adult 
Respiratory Distress Syndrome (ARDS) (1,2). Mechanical ventilation with positive end 
expiratory pressure (PEEP) increases the chances of these patients to survive this highly 
lethal complication, but sequential failure of multiple organ functions (MOF) may 
subsequently occur. Lethality of this MOF syndrome still is 60 %, despite all efforts the 
last 20 years. ARDS and MOF patients are responsible for about 70 % of the patient -
ventilator days in an intensive care unit (ICU). As their mean ICU admission time is 26 
days, this group of patients puts a heavy burden on health care (3). 
1.2 CLINICAL FEATURES 
The sequence of events leading to ARDS, MOF and sepsis is best illustrated by 
an extensive case report Furthermore, this case report illustrates that MOF is an extremely 
complex problem, affecting all organ systems and functions without exception. 
CASE REPORT WITH PERMISSION OF THE AUTHORS (4) 
An 18-year-old youth was hit by a car when riding his bicycle. He was admitted 
to another hospital with a systolic blood pressure of 70 mmHg, a left-sided tension 
hemopneumothorax and 6 fractured ribs, a hemoperitoneum, an unstable pelvic fracture 
and a fracture of the left scapula (injury severity score (ISS) = 59). Blood loss through a 
thoracostomy tube was so brisk that a thoracotomy had to be performed for hemostasis. 
Laparotomy revealed a laceration of the inferior mesenteric artery and an extensive 
retroperitoneal hematoma. The artery was ligated and no ischemia of the large bowel 
resulted. The blood pressure returned to normal and an adequate diuresis followed. Seven 
liters of blood were administered during the first 24 hours. Subsequently the patient was 
carefully observed while breathing spontaneously. 
Two days later the respiratory rate increased to 261 min, expectoration was 
insufficient, and the patient's condition deteriorated rapidly. Blood gas analysis 
demonstrated respiratory failure. The patient was intubated and artificially ventilated. 
This resulted in temporary improvement of the arterial blood gas values. Three days later, 
insufficient arterial oxygenation despite artificial respiration was the reason for 
transferring the patient to our hospital. On admission, a left-sided tension pneumothorax 
was relieved by a new thoracostomy tube. After this, the pulse rate remained high and an 
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adequate blood pressure could be maintained only by large volumes of intravenous 
infusion. A second laparotomy was performed and the spleen wets removed because of a 
ruptured subcapsular hematoma. Complete inspection of the abdomen revealed no other 
abnormalities, except those already known. The displaced pelvic fracture was then reduced 
by suspension in a sling and traction to one leg. 
After laparotomy, high volume (12 liters/minute) artificial ventilation with 100 % 
oxygen and 20 cm PEEP was necessary to obtain а РаО
г
 of 8 кРа. Antibiotic prophylaxis 
with cephalosporin and intravenous hyperalimentation were started. During the following 
5 days, FÌO2 could progressively be diminished to 40 % and PEEP to 12 cm. The 
thrombocyte count remained below 50,000 during the next 7 days. From then on the 
leukocyte count slowly increased from 72,500 to 70,000. Core temperatures were between 
37.2° С and 39.8° С Ten days after injury, bacterial culture of the sputum revealed a 
growth of E coli which was also cultured in the urine two days later. Pus from an infected 
maxillary sinus also contained E coli. The nasal tube was changed for an oral tube and 
gentamycin was started. Weaning from the ventilator proved impossible. A tracheostomy 
was performed and artificial ventilation continued. Sputum cultures on day 17 showed a 
multiresistant E. coli; on day 24 Klebsiella pneumoniae; and on day 38 Klebsiella 
pneumoniae and Pseudomonas aeruginosa. Daily blood cultures remained negative until 
day 42 when Staphylococcus albus was cultured. 
Extensive pulmonary fibrosis resulted in pulmonary hypertension with 
cardiopulmonary failure, not responding to treatment with digitalis. Progressive renal 
failure developed starting on day 19, with blood urea values up to 43.5 mmol/1 and high 
serum potassium levels, necessitating hemodialysis on five occasions between the fourth 
and sixth week. Jaundice developed, with the following laboratory findings: serum 
bilirubin 414 Uli (82 % indirect bilirubin), alkaline phosphatase 152 Uli, LDH 830 UU, 
SCOT 36 UU and SGPT 24 UU. After a temporary improvement, the liver function deteri­
orated. At 7 weeks a tender mass could be felt in the right subcostal area, and acalculous 
cholecystitis was confirmed echographically. 
Other disorders found in the patient, included spontaneous hemorrhage from the 
rectum, lungs, nose and ears, requiring blood transfusions; multiple petechiae, a 
spontaneous hematoma in the right hypogastrium, hemorrhagic tracheitis with extensive 
ulceration, bilateral otitis media needing paracentesis, ulceration and spontaneous 
perforation of the cornea despite adequate local care, and extensive herpes zoster. 
Because of the "destroyed lung", operation for the cholecystitis was not performed and the 
patient died 58 days after injury from causes not directly related to the primary injuries. 
At post mortem, there was extensive consolidation of both lungs which weighted 
1200 g and 990 g. The kidneys were large and swollen. The liver weighted 2580 g. An 
acute phlegmonous necrotizing cholecystitis was present, with recent perforation and 
biliary peritonitis. A bile thrombus was present in the cystic duct. The major intra- and 
extra-hepatic bile ducts were patent and of normal calibre. Microscopy of the liver 
demonstrated biliary stasis, mainly with pericentral localization. Multiple petechiae were 
seen in the gastric mucosa, the bladder mucosa and subepicardially. 
This patient would have died from hemorrhage, if not treated promptly by 
thoracotomy, laparotomy, and multiple blood transfusions. Respiratory failure also could 
have been the cause of death, if mechanical ventilation had not been started. When the 
patient was transferred to us with established pulmonary failure, prolonged mechanical 
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ventilation was necessary. Without a specific cause, renal failure developed three weeks 
after injury, hepatic dysfunction six weeks after injury, as well as cardiovascular failure, 
hemorrhagic diathesis, acalculous cholecystitis, and finally pulmonary fibrosis. Bacterial 
invasion started in the lungs and urinary tract, followed by multiple focal infections and 
ultimately positive blood cultures a few days before death. 
The general appearance in the course of illness was characterized by generalized 
permeability edema, generalized vasodilatation, high fever and the functio laesa of 
multiple organ systems, signs of a generalized inflammation in a "clinically septic" patient 
Clinical descriptions of chronic sepsis (5) and failure of multiple organ systems as 
the final common pathway in critical surgical illness first appeared 20 years ago (6,7). It 
was Baue (8) who defined a syndrome of sequential and progressive failure in the function 
of several organs such as the lungs, kidneys and liver, metabolic and hematologic disor-
ders, dysfunction of the central nervous system and finally cardiovascular dysfunction 
resulting in death. 
Carneo et al (9) described four stages in the development of organ dysfunction. 
Stage 1; 
On gross physical examination the patient appears normal. 
General appearance 
Cardiovascular function 
Respiratory function 
Renal function 
Metabolism 
Hepatic function 
Hematology 
Central nervous system 
No obvious signs 
Increased volume requirements 
Mild respiratory alkalosis 
Limited responsiveness 
Increased insulin requirements 
? 
? 
Confusion 
Stage 2; 
The patient becomes ill and shows minor organ dysfunctions. 
General appearance 
Cardiovascular function 
Respiratory function 
Renal function 
Metabolism 
Hepatic function 
Hematology 
Central nervous system 
"ill," 
Hyperdynamic, volume dependent 
Tachypnea, hypocapnia, hypoxia 
Normal urinary output, minimal azotemia 
Severe catabolism 
Increased enzyme levels 
Decreased platelet count, increased or decreased 
white blood cell count 
Variable 
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Stage 3; 
The patient is severely ill and each organ system affected requires some type of 
support. 
General appearance 
Cardiovascular function 
Respiratory function 
Renal function 
Metabolism 
Hepatic function 
Hematology 
Central nervous system 
Obviously unstable 
Shock, decreased cardiac output, edema 
Severe hypoxia 
Azotemia 
Metabolic acidosis, hyperglycemia 
Clinical jaundice 
Coagulopathy 
Decreased responsiveness 
Stage 4; 
The patient dies of failure of one or more of the life-sustaining organ systems. 
General appearance 
Cardiovascular function 
Respiratory function 
Renal function 
Metabolism 
Hepatic function 
Hematology 
Central nervous system 
Terminal illness 
Inotropes, volume "overload" 
Hypercapnia, barotrauma 
Oliguria 
Severe acidosis 
Encephalopathy 
Immature cells, coagulopathy 
Coma 
ARDS as the first expression of MOF, occurs in a wide variety of clinical 
settings, septic or hypovolemic shock being the most frequent cause. The histopathologic 
features of the lung vary depending on the time following the onset of respiratory failure 
but are quite similar from case to case, in spite of the different clinical situations in which 
they occur (10). This suggests that the histopathologic changes are the result of a final 
common pathway. 
There still is no consensus on the pathophysiology of ARDS and MOF. It is 
widely believed that bacteria and/or endotoxins are responsible and that the gut is the 
"motor" of MOF (11). Nuytinck and Goris (12) suggested a common pathophysiology of 
both syndromes and hypothesized an untoward whole body inflammatory reaction. Indeed, 
clinically a patient with MOF is characterized by fever (calor), generalized permeability 
edema (tumor), generalized vasodilatation (rubor) and a sequential loss of function of 
several organ systems (functio laesa), classical signs of inflammation. 
Evidence is slowly gathering that endogenous inflammatory compounds and cells, 
excessively activated by severe trauma, pancreatitis and/or severe bacterial infections, 
may be themselves responsible for structural damage and functional deterioration in 
remote vital organ systems (3,12,13,14). 
It is essential to better understand the underlying pathophysiology of ARDS, 
MOF and sepsis in order to find specific methods of prevention and treatment for this 
highly lethal syndrome. Though several aspects in the pathophysiology of ARDS and 
MOF have been clarified, no key factor responsible for this syndrome has yet been found. 
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1.3 PATHOPHYSIOLOGY 
1.3.1 Humoral mediators 
Many humoral mediators have been implicated in the pathogenesis of MOF such 
as the complement system, the coagulation system, the fibrinolytic system as well as the 
kallikrein-kinin system. These mediators influence the function of polymorphonuclear 
leukocytes (PMNs), macrophages, platelets and mast cells, and induce the production of a 
variety of inflammatory products. 
Zimmermann et al (IS) concluded that complement activation correlates with the 
first signs of MOF. During hemodialysis, acute leukostasis in the lung appears to be the 
result of complement activation (16,17,18). Low plasma-levels of the complement 
compounds C3 and C4 have been found in MOF patients indicating complement activation 
(19,20). Plasma C3d levels measured at admission were predictive of ARDS and MOF 
(19). 
In an experimental study in rabbits, infusion of complement activated plasma 
resulted in hyperventilation, hypocapnia, respiratory alkalosis, an acute decrease in PMN 
count and leukostasis in the lung, liver, kidney and heart resembling the early 
morphological changes in ARDS (12). Continuous infusion of complement activated 
plasma during four hours in combination with 20 minutes of hypoxia in the rabbit not only 
resulted in ARDS-like changes in the lung, but also in severe MOF-like morphological 
changes in the liver, spleen, kidney and heart (12). 
1.3.2 PMNs, oxygen radicals, elastase 
The role of PMNs in the pathogenesis of ARDS has been well documented 
(12,13,15,21-28). Release of the anaphylatoxins (C3a, C5a) leads to activation of PMNs, 
which aggregate, marginate and adhere to the endothelium, produce toxic oxygen 
intermediates (superoxide anion, hydrogen peroxide, hydroxyl radicals), proteases (elastase, 
collagenase, cathepsin G), arachidonic acid metabolites (leukotrienes, Prostaglandines, 
thromboxanes), and platelet activating factor (PAF). The primary interaction between the 
PMN and the endothelial cell barrier is mediated by the cell surface neutrophil adhesive 
glycoprotein complex CD11/CD18 (29). This complex interacts with endothelial cell 
surface intercellular adhesion molecule-1 (ICAM-1) in response to cytokines (30). Also the 
production of endothelial leukocyte adhesion molecule (ELAM-l) is increased in response 
to cytokines (31). 
Oxygen free radicals (OFR) such as superoxide anion, hydrogen peroxide, and the 
hydroxyl radical have been shown to play a significant role in acute inflammatory 
reactions (32,33). The plasma membrane is a critical site of free radical reactions. The 
unsaturated fatty acids present in membranes (phospholipids, glycolipids) and the 
transmembrane proteins containing oxidizable amino-acids are susceptible to free radical 
damage subsequently followed by an increased membrane permeability (34). The endpro-
ducts of free radical reactions with unsaturated fatty acids are detectable as lipid peroxida-
tion products. Oxygen free radicals not only are toxic for membrane lipids but also for 
unsaturated and sulfur containing proteins (35), nucleic acids (36) and collagen (37). 
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After trauma, lipid peroxidation in plasma increased, suggesting PMN oxygen 
radical release (38). Westaby et al. (39) found a correlation between the pulmonary 
sequestration of PMNs and the amount of lipid peroxidation in the lung after cardiopul­
monary bypass. In ICU patients, a steady increase of lipid peroxidation products such as 
malondialdehyde, conjugated dienes, fluorescent products and 4-hydroxynonenal was 
found with a maximum at days 9 - 12 of ICU stay (40). Schoenberg et al (32) concluded 
that oxygen free radicals seem, at least partly, responsible for the observed damage of the 
so-called shock organs. Oxygen free radical damage has also been demonstrated in lung 
injury after endotoxemia (41), ischemia (33) and reperfusion (42), as well as after 
reperfusion in liver (43,44), kidney (45) and the intestine (46). 
Elastase, a neutral protease stored in the azurophilic granules of PMNs, is 
released in response to particulate or soluble stimuli such as opsonized zymosan or 
lipopolysaccharide (LPS). Free elastase may denaturate fibrinogen, other coagulation 
factors as well as platelet and endothelial cell membrane proteins, and thus might play an 
important role in the pathogenesis of MOF (47,48). Extracellular elastase is rapidly bound 
and inactivated, mainly by (»[-proteinase inhibitor (α,-ΡΙ) (49). The resulting complex is 
detectable in blood plasma by an ELISA method (50) or by an IMAC-test (51). In several 
clinical studies, elevated serum levels of eIastase-α,-ΡΙ have been demonstrated prior to 
the development of ARDS, sepsis or MOF, in different conditions such as trauma, bums 
and peritonitis (19,51-57). The α,-ΡΙ is inactivated by oxidation caused by hydrogen 
peroxide and by myeloperoxidase from activated PMNs (58). Inactivation of α,-ΡΙ may 
thus lead to an increased activity of free elastase (59). 
1.3.3 Macrophages, TNFo, IL-1, Neopterin 
The activated macrophage is capable of producing and releasing multiple 
inflammatory products such as interleukins (ILs), tumor necrosis factor (TNF), interferon 
(IFN), complement factors, oxygen radicals, coagulation factors, proteases, lipase-binding 
proteins, bioactive oligopeptides and lipids (cyclooxygenase and lipoxygenase products), 
purine and pyrimidine products, fibroblast growth factors, platelet-derived growth factor, 
platelet activating factor (PAF), neutrophil-activating factor (NAF), and granulocyte-
macrophage colony stimulating factor (GM-CSF) (60). 
In the late seventies, Hunninghake et al (61) and Harada et al (62) pointed out the 
possible role of the macrophage in lung injury. Endotoxin-stimulation of macrophages 
induced lung damage (63). In recent years, two important secretory products of the macro­
phage, IL-1 and TNFo, have been intensively studied. Both have a multiplicity of actions 
with similar effects (60). 
TNFa directly activates PMNs (64), increases their binding to endothelial cells 
(65), enhances expression of complement receptors on PMNs (66), and induces lysosomal 
enzyme release (67). TNF also increases the production of several inflammatory mediators 
such as IL-1 (68), GM-CSF (69), PAF (70), and prostaglandins (71). Nowadays, TNF is 
believed to be a key mediator of sepsis (72). The plasma-levels of TNF in septic patients 
showed a positive correlation with clinical outcome and mortality (73,74). Administration 
of TNF to healthy human volunteers resulted in similar responses as seen in endotoxemia 
(75). TNF administration in sheep resulted in leukopenia, hypoxemia, increased micro­
vascular permeability and in increased numbers of PMNs in the lung (76). Administration 
of recombinant-TNF to experimental animals resulted in a lethal shock state very similar 
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to endotoxemia (77,78). 
Neopterin is a marker of macrophage activation (79). Pacher et al (53) found that 
high plasma-neopterin levels at admission to ICU could predict chronic sepsis versus an 
uncomplicated postoperative course. Furthermore, plasma neopterin levels in septic non 
survivors were significandy higher from day 3 - 6 after admission to the ICU as compared 
to levels found in septic survivors (53). In septic patients a positive correlation was found 
between elastase al-PI and the severity of MOF as measured by the Nijmegen MOF-score 
(19) and between neopterin and the MOF-score. A high sensitivity and specificity in 
predicting MOF could be obtained if both plasma elastase and neopterin levels were taken 
into account (53). The increased neopterin levels found in septic patients suggest the in-
volvement of macrophages in the pathophysiology of MOF. 
1.4 MORPHOLOGIC ALTERATIONS 
The most prominent and early findings seen in ARDS are sequestration and 
degranulation of granulocytes in the pulmonary microcirculation. Schlag et al (21) 
performed serial needle biopsies of the lung in polytrauma patients and found marked 
accumulation and adherence of PMNs to the pulmonary endothelium. Electron micro-
scopically, degranulation of these PMNs was observed. In a later stage, biopsies showed 
vacuolisation and swelling of the endothelium and occasionally also loss of continuity 
between endothelial cells. In the later stages, alveolar edema secondary to damage of the 
alveolar-capillary membrane was a characteristic finding. The alveolar space became filled 
with erythrocytes, PMNs alveolar macrophages, cell debris and protein-rich edema. Subse-
quently, biopsies at the time of clinically manifest ARDS showed hyaline membranes in 
the alveoli and alveolar ducts. These late stages were also characterized by fibrin 
deposition and platelet accumulation, leading to progressive and diffuse fibrosis of the 
lungs. PMN aggregation in the pulmonary capillaries could already be found within one 
hour from the onset of hypovolemic-traumatic shock (22). Autopsies in polytraumatized 
patients without direct lung injury and who died within 48 hours after injury, showed a 
significant leukostasis in all lobes of the lung (24). 
Nuytinck et al (13) studied the autopsy findings in the lung, liver, kidney, heart 
and spleen from patients who died early after injury. The lung showed signs of early 
ARDS with an increase of the number of PMNs, hemorrhage, and interstitial and intra-
alveolar edema. In a later stage, hyaline membranes and fibrosis were present. The liver 
showed an accumulation of PMNs and in an advanced stage, necrotic hepatocytes sur-
rounded by PMNs. The kidney showed vacuolar nephrotubulopathy. In the heart only 
occasionally an increased number of PMNs, interstitial and/or cellular edema, necrosis or 
hemorrhage were found. The spleen showed a pathologic accumulation of PMNs as well 
as depletion of red and white pulpa. These signs of inflammation occured independent of 
the time of death and were also found in patients who died of isolated brain injury (13). 
Experimentally, complement activation in combination with hypoxia in the rabbit 
induced similar morphologic changes in several organs (12). In the lung many PMNs were 
found in the septal capillaries as well as protein rich intra-alveolar edema. The liver 
showed an increased number of PMNs, enlarged spaces of Disse, cytoplasmatíc vacuoli-
sation and granulation of the parenchymal cells as well as interstitial edema. In the kidney, 
widening of tubuli and intratubular protein precipitation was seen as well as an increased 
number of PMNs in the glomeruli. The spleen showed a remarkable accumulation of 
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PMNs and macrophages. In the heart, focal areas of muscle fiber necrosis and interstitial 
edema were observed (12). 
1.5 OXYGEN METABOLISM 
Oxygen transport and delivery is of vital importance for the integrity of cellular 
metabolism. Border et al (80) observed resuscitated trauma patients with a high cardiac 
output, a normal arterial pOj, a decreased arterio-venous Oj difference, and increased 
lactate levels, indicating impaired 02 utilization and/or extraction and tissue-hypoxia. Also 
in ARDS-patients, Pv02 is high and lactic acidosis is present despite a high arterial 
oxygen supply (81). These patients are unable to extract more than 30 % of the oxygen 
supplied. This situation has been called pathologic oxygen supply dependency (82). 
Beerthuizen et al (79) directly demonstrated that in these critically ill patients, skeletal 
muscle p02 correlated negatively with the severity of organ dysfunction. 
Goris (83) inventorized clinical conditions associated with impaired oxygen 
extraction (IOE) and concluded that IOE seems to be an ubiquitous finding in severe 
inflammation. He suggested that IOE may in fact be a natural defense mechanism against 
the tissue hyperoxia induced by the hyperemia of inflammation. In severe inflammatory 
conditions such as ARDS, MOF and sepsis, however, IOE may be detrimental to recovery. 
1.6 THE ROLE OF BACTERIA 
In the late 1970s, MOF was thought to be the consequence of severe bacterial 
sepsis. In critically ill surgical patients with intra-abdominal infections, MOF was viewed 
as an indication for abdominal (re-)exploration (85,86). In 1980, Meakins et al (87) 
described a syndrome of "nonbacteremic clinical sepsis". These patients showed the same 
clinical course and outcome as patients with demonstrable bacteremia, while no focus of 
infection could be found. In order to explain why these patients without a focus of 
infection were septic, Meakins and Marshall (11) suggested that the "motor" of MOF is 
the gastrointestinal tract. 
Normally, the epithelium of the gastrointestinal tract, together with the gut-
associated lymphoid tissue, provides an effective barrier to the entry of microorganisms 
and endotoxin, and form the first line of defence of the mononuclear phagocyte system 
(MPS). This barrier function may be lost in critically ill patients at risk for MOF. The 
mesenteric lymph nodes (MLN) form the second line of defence of the MPS against 
organisms passing from the gastrointestinal tract to the portal venous system. The third 
MPS line of defence against systemic invasion of intestinal microorganisms consists of the 
hepatic Kupffer cells while the fourth line of defence is formed by the mononuclaer 
phagocytes in the lung. 
The upper gastrointestinal tract normally is sterile, but overgrowth may occur by 
gastric hypoacidity, administration of antacids and/or decreased small bowel motility. In 
severely ill ICU patients this results in colonization of the upper Gl-tract with gram-
negative micro-organisms (88). Furthermore, the unselective use of antibiotics favors the 
overgrowth of Enterobacteriacea (E), capable of translocating from the gut to the 
peritoneal cavity, the MLN and the portal and systemic circulation (89). Due to changes in 
the intestinal flora and the impairment of the mucosal barrier, the bowel may serve as a 
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reservoir of pathogens that can enter the portal and systemic circulation and may initiate 
or maintain the septic process leading to MOF. 
However, evidence for a causal relationship between bacterial overgrowth and 
MOF is weak. MOF also develops in patients with primarily non-bacterial problems such 
as severe pancreatitis or severe trauma before bacterial invasion is obvious and positive 
blood cultures are not a prerequisite in these patients (3,90). Furthermore, sepsis-scores 
and MOF-scores correlate equally well with outcome if bacteriological data are excluded 
(3). No single study could reliably demonstrate elevated levels of circulating endotoxin 
preceding MOF (91, 92), and neither the drainage of pus (93) nor the administration of 
antibiotics prevent or suppress MOF. Finally, in severely traumatized patients with severe 
extremity injuries, MOF is an important cause of death if fractures are treated in traction 
(94), while MOF may be prevented by early osteosynthesis of these fractures (95,96). 
From a bacteriological point of view, this is difficult to explain. 
Due to the inaccessibility of MLN and the portal system for bacteriological 
monitoring in clinical patients, the incidence and clinical relevance of translocation of gut 
bacteria to the MLN and portal system remain ill defined. 
The clinical, biochemical, morphological and oxygen-exchange features of MOF 
as described above are suggestive of severe generalized inflammation, while the invol­
vement of pathogenic microorganisms has not been clearly proven. 
1.7 THERAPEUTIC OPTIONS IN THE PREVENTION OF M O F , 
EVALUATED IN THIS THESIS. 
Though the pathophysiology of MOF is not yet well understood, a number of 
methods have been introduced to prevent MOF or to improve outcome (Fig 1). The 
concept of the gut as the "motor" of MOF prompted to treatment modalities interfering 
with the gut flora. 
Selective decontamination of the oropharynx and the GI tract (SD) by use of non­
absorbable antibiotics reduces the number of aerobic gram-negative bacilli and yeasts in 
these areas, while the anaerobic flora remains unaffected. Several clinical studies evaluated 
the efficacy of SD in ICU patients (97-104). SD significantly reduced the number of no­
socomial infections but no difference was found as to the duration of ICU stay, the dura­
tion of mechanical ventilation, the duration of hospital stay or in the incidence of MOF. In 
most studies, the amount and costs of therapeutic antibiotics administered in the SD group 
was similar as in controls. To the best of our knowledge, no experimental studies have 
been published, substantiating the efficacy of SD in the prevention of sepsis, MOF or 
death in septic animal models. 
Depletion of PMNs to prevent a septic respons is probably impracticable as 
ARDS also develops in leukopenic patients, and as especially in severely ill patients at 
risk for ARDS, MOF and sepsis, PMNs are required to phagocytize and kill invading 
micro-organisms. 
Activation of the complement system can be inhibited by rosmarinic acid (RMA), 
blocking С, convertase (105). 
Another treatment concept may be deducted from the role of OFR in the genesis 
of MOF. Superoxide Dismutase (SOD) is a metalloprotein that catalyzes the dismutation 
of superoxide anions to hydrogen peroxide (106). Catalase catalyzes the reduction of H 20 2 
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to water (107). RMA also inhibits the production of HOj by PMNs during phagocytosis 
of bacteria (108). 
Hydroxyl radicals are catched by several hydroxy! radical scavengers such as 
dimethylsulfoxide, dimethylthiourea and mannitol (109,110). Furthermore, U74006F is an 
inhibitor of lipid peroxidation in vitro and in vivo (111). The mechanism probably consists 
of scavenging of lipid hydroperoxides and superoxide radicals (111,112). The formation of 
hydroxyl radicals is catalyzed by Fe2* (113). The iron chelators dihydroxybenzoic acid 
(DHBA) (114) and desferoxamine (115) inhibit hydroxyl radical formation. 
Another approach starts from viewing hypoxia as a pivotal phenomenon in severe 
sepsis and MOF, and in helping cellular energy requirements with an alternative substrate. 
Metabolic studies in shock indicate that the organism tends to compensate for decreased 
aerobically produced energy by accelerated anaerobic glycolysis (116). Acidosis inactivates 
phosphofructokinase (PFK) resulting in a decreased carbohydrate utilization. Fructose-1,6-
diphosphate can be used anaerobically as a high-energy substrate (117) and has the 
capacity to stimulate the activity of PFK by a direct feedback mechanism. 
The presence of TNFa-receptors is a prerequisite for biological responses to 
TNFct. TNF-receptors in activated T-cells can be rapidly modulated by activators of PKC, 
resulting in a loss of TNF-binding capacity. Loss of TNF-binding capacity can be induced 
by the membrane permeable PKC activator oleyl acetyl glycerol (OAG) (118). 
The strongest evidence implicating TNF as an important mediator of MOF is that 
monoclonal antibody against TNF, binding circulating TNF, prevents the deleterious 
effects of endotoxin induced septic shock in mice (119,120). 
The use of inhibitors of the cyclooxygenase and lipoxygenase pathways, as well 
as inhibitors of many other mediators is beyond the scope of this thesis. 
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1.8 EXPERIMENTAL MODELS OF CHRONIC SEPSIS AND M O F . 
In all known large animal (dogs, sheep, pigs, baboons) models of septic shock 
and chronic sepsis, mechanical ventilation is required for the experimental animals to 
'survive' the experimental period. These models are principally utilized for studying the 
circulatory respons to a septic insult. As the MOF syndrome requires several days to 
develop, as prolonged artificial respiration would require setting up an ICU for laboratory 
animals, and as rather large numbers of animals are required for survival studies, we 
concluded that this approach was impractical. 
Experimental models of sepsis in small laboratory animals generally utilize a 
bacterial or endotoxic challenge. 
Cecal ligation and puncture (CLP) in the rat results in an early hyperdynamic 
state with fever, lethargy, tachypnea, and increased heart rate (121). The rats stop 
drinking, have a ruffled fur and some rats have diarrhea. The rats in early sepsis show 
increased blood flow to liver and kidneys, hyperinsulinemia,. and hyperglycemia. Sixteen 
hours following CLP, most rats have positive peritoneal cultures and blood cultures for 
numerous enteric organisms. 1 6 - 2 4 Hours after CLP rats are in a late hypodynamic 
phase with decreased blood flow to the organs, hypoinsulinemia, hypoglycemia, and high 
serum lactate levels. Mortality in the CLP model varies from 25 - 75 % in the first 24 
hours to 75 -95 % after 5 days, depending on the number of punctures and the diameter 
of the needle (121). 
Intraperitoneal implantation of a fecal inoculum in the rat also results in an early 
hypermetabolic response and a recovery phase at days 4 and 5 (122). Septic animals 
progressively loose weight, and develop fever during the first three days. Body 
temperature normalizes at day five following inoculation. The rats are tachypneic, tachy-
cardiac but still are normotensive. Oxygen consumption increases with 25 - 38 % on days 
1, 2 and 3 and normalizes at day 5. Metabolically, these rats have a low blood glucose, a 
mild hyperlactacidemia and reduced alanine concentrations. Bacteriologically, cultures 
from the peritoneal fluid and blood are positive for gram negative rods. Microscopically, 
an extensive intra-abdominal fibrinopurulent exudate, often with bacterial colonies, is 
present (122). 
Sepsis in the rat may be induced by intraperitoneal implantation of a sterile gauze 
subsequently contaminated with E coli and Bacteroides fragilis (123). This results in an 
elevated cardiac output, lethargy, and failure to gain weight. Intermittent intraperitoneal 
inoculation of E coli and Bacteroides fragilis in the rat results microscopically in ARDS-
like changes, though without changes in arterial oxygen tension (124). 
Fig 1 (page 22) 
Interaction between the pathophysiology of ARDS and MOF, several therapeutic options 
and the use of specific mouse strains with elastase and macrophage deficient function. 
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1.9 ZYMOSAN 
Zymosan, the insoluble polysaccharide component of the cell wall of Saccharo-
myces Cerevisiae, induces inflammation when injected into experimental animals 
(125, 126) and induces the release of a wide range of inflammatory mediators, e.g. acti­
vated complement components (127), prostaglandins and leukotrienes (128, 129), PAF 
(130), oxygen radicals (131), and lysosomal enzymes (132). Zymosan also directly 
activates macrophages and PMNs (133). Intraperitoneal injection of zymosan in mice was 
directly followed by an important increase in the number of macrophages intraperitoneally, 
followed by an influx of PMNs within 4 hours (134). From days 1 to 7, the total 
intraperitoneal cell count declined while the proportion of macrophages increased (134). 
PGEj and leukotrienes reached a peak level at 30 and 60 minutes after injection respecti­
vely (134). 
The acute reaction is dose dependent as 500 mg zymosan per 100 g body weight 
results in a high number of early death (pilot study not shown). On the contrary, 
intraperitoneal zymosan in a dose of 3 mg per 100 g body weight results in an enhanced 
host defense against infection (133). 
Zymosan is not water or lipid soluble. We therefore suspended zymosan in paraffin. The 
suspension was vibrated by high frequency to obtain a fine-grained suspension and was 
sterilized by incubation in a water bath at 100° С for 80 minutes. In the later experimental 
period several batches of zymosan were contaminated with heat resistant spore-forming 
bacteria. We therefore sterilized the zymosan by irradiation with 5 kGray. 
The suspension of zymosan in paraffin also results in a delayed phagocytosis of zymosan 
and thus in a prolonged activation of the alternative complement pathway, PMNs and 
macrophages. 
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1.10 AIM OF THIS THESIS 
The aim of this thesis was to answer the following questions: 
1. Is it possible to induce a MOF-like syndrom with an LDSO at day 12 resembling 
the findings in endotoxin or bacteria-induced MOF by means of a nonbacterial, 
nonendotoxic, local inflammatory stimulus in conventional rats (chapter 2)? 
2. If so, can this syndrome also be induced in germ-free rats (chapter 2)? 
3. What is the role of PMNs and the formation of toxic oxygen radicals in the 
pathogenesis of this syndrome (chapter 3)? If PMN-elastase in the most important 
mediator, are elastase deficient mice resistant to MOF (chapter 4)? 
If indeed an excessive generalized autologous inflammatory reaction is the cause 
of MOF, a well-directed preventive measure should significantly reduce mortality 
in this model, i.e. to 10 % or less, leaving all 12 day survivors in good health. 
Therefore a series of pharmacological interventions in rats and experiments in 
several genetic mouse strains was set up in search of such an intervention (Fig 1). 
This led to the following questions: 
4. Can MOF be prevented by selective decontamination of the gastro-intestinal tract 
(chapter S and 6)? 
5. Is it possible to prevent MOF by administration of SOD and catalase (chapter 7), 
of hydroxyl-radical scavengers, iron-chelation or complement inactivation 
(chapter 8), or a scavanger of hydroperoxide and oxygen radicals (chapter 9)? 
6. Is administration of a high-energy substrate (FDP) capable of restoring the 
activity of aerobic glycolysis and thus to decrease lactate levels (chapter 10)? 
7. If endotoxin is a key factor of MOF, would there be a difference in the severity 
of MOF between endotoxin resistant and endotoxin-sensitive mice (chapter 11)? 
8. If TNF is a key mediator of MOF, is blocking of the TNF-receptor (chapter 12) 
or binding of circulating TNF (chapter 13) succesful in reducing the severity of 
MOF? 
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Chapter 2 
MULTIPLE ORGAN FAILURE AND SEPSIS 
WITHOUT BACTERIA. AN EXPERIMENTAL MODEL. 
RJA Goris, WKF Boekholtz, IPT van Bebber, JKS Nuytmck, PHM Schillings 
Arch Surg 121: 897-901, 1986. 
2.1 SUMMARY 
Multiple organ failure is generally attributed to bacterial infection, although a 
correlation with positive blood cultures is not consistently found. Consequently, we studied 
the effect of a local non-bacterial inflammatory stimulus on distant organ functions and 
metabolism. Wistar rats were inoculated intraperitoneally with zymosan. Heart and 
ventilatory rates, oxygen consumption, and body temperature were measured. Survivors 
were killed at day 12 for blood analysis, weighting of organs, and microscopy. 
Intraperitoneal zymosan resulted in an early hyperdynamic "septic" response with a 35 % 
mortality. After a few days, oxygen consumption decreased, serum lactate levels increased, 
and the function of multiple organs deteriorated, while blood cultures remained sterile. The 
experiment was repeated in germ-free rats with similar results but a lower mortality. We 
concluded that a severe inflammatory response in itself is capable of inducing multiple 
organ failure with "sepsis". 
2.2 INTRODUCTION 
Multiple organ failure (MOF) presently is the most common cause of death in 
severely injured patients and patients with peritonitis admitted in an intensive care unit. 
Since "sepsis" was first described by Ashbaugh and Petty (1) as a highly lethal 
complication occurring in patients with adult respiratory distress syndrome (ARDS) 
receiving mechanical ventilation, no substantial improvement has been made in 
understanding or treating this syndrome. Bacteria and endotoxins have been almost 
invariably associated with this syndrome, though a consistent correlation with positive 
blood cultures and bacterial foci was found in only 33 % of trauma patients with MOF 
(2). As sepsis involves action of a bacterial stimulus as well as the reaction of the body to 
such a stimulus, it seemed worthwhile to study the inflammatory response in the absence 
of bacteria or endotoxins. 
This article describes an experimental model, demonstrating that a non-bacterial, 
non-endotoxic, local inflammatory stimulus results in functional and microscopic 
alterations in remote organs. Intraperitoneal implantation of a sterile suspension of 
zymosan and paraffin in rats resulted in a severe illness, characterized by ARDS-like 
pulmonary changes, impaired function of several organ systems, impaired oxygen 
consumption, elevated serum lactate levels, and negative blood cultures. The study was 
repeated in germ-free rats with similar results. 
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2.3 MATERIAL AND METHODS 
Zymosan, 2.5 g, was suspended by high-frequency vibration in 100 ml of liquid 
paraffin. Paraffin was utilized rather than saline to permit slower contact with the 
zymosan. The suspension was sterilized by incubation in a water bath at 100° С for 80 
minutes. Sterility was checked by inoculation in brain heart infusion growth medium 
(BHI) with 5mg/dl aminobenzoic acid, dehydrated form, 38g/1000 ml of distilled water, 
and thioglycollate medium (Bacto-Brewer) for seven days at 37° C. Before utilization, the 
zymosan suspension was warmed to 40° С and vibrated at high frequency for IS minutes. 
Preliminaiy experiments demonstrated that a dose of 100 mg of zymosan per 100 g of 
body weight resulted in severe illness in all rats, an acute mortality of 35 % within 24 
hours, and an additional mortality of IS % in the next 12 days. 
Experiment A: 
Forty male Wistar rats (body weight, 300 to 400 g) were adapted to handling and 
to all experimental measurements. Four days before the experiment, microelectrodes were 
implanted subcutaneously on the back for electrocardiographic (ECG) recording. The rats 
were kept in individual cages before and throughout the experiment and fed standard rat 
chow (Hope Farms RMH-B) and water ad libitum. The day of the experiment, the rats 
were randomized into three groups. Group 1 (20 rats) received an aseptic intraperitoneal 
injection of zymosan, suspended in paraffin (100 mg of zymosan in 4 ml of paraffin / 100 
g of body weight). Group 2 (10 rats) received an aseptic intraperitoneal injection of 4 ml 
of identically prepared paraffin / 100 g body weight. Group 3 (10 rats) were handled 
similarly and served as controls. 
In all rats, the following measurements were made on days 0, 2, 6, 9, and 12. 
Oxygen consumption (Voj) was measured in a volumetric respirator (closed system, forced 
air circulation, carbon dioxide absorbent and water absorbent in series, continuous oxygen 
supply under constant pressure). After 10 minutes of adaption in the respirometer, Vo2 was 
measured during a 15-minute period. Respiratory rate was determined visually by 
measuring the time necessary for 30 ventilations during the last five minutes the rat stayed 
in the respirometer. Heart rate was measured by ECG using the subcutaneously implanted 
electrodes. Rectal temperature was recorded digitally. 
At day 12 all surviving rats were given mild anesthesia (subcutaneous fentanyl 
citrate, 0.1 ml/kg), bled by heart puncture, which yielded S ml of blood, and placed in a 
closed space saturated with ether. Blood was utilized for determination of thrombocytes, 
leukocyte count, differential cell count, and alkaline phosphatase, alanine aminotransferase, 
creatinine, uric acid, and lactate levels. 
The rats were weighted after killing; the abdomens were then opened under sterile 
conditions and samples of peritoneal fluid were collected for bacterial culture in BHI and 
thioglycolate medium. The lungs with trachea, kidneys, liver, and spleen were dissected 
free and weighted. Relative organ weights were calculated by the following formula: 
(organ weight/body weight) χ 100. 
After fixation with 4 % formaldehyde (the lungs also intratracheally at a pressure 
of 30 cm H20), microscopic sections of these organs were prepared for staining with 
hematoxylin-eosin. 
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Experiment В: 
Twenty germ-free male Wistar rats (body weight, ± 300 g) were kept under germ-
free conditions in two isolators throughout the experiment. All experimental procedures 
were identical to those in experiment A, except for the implantation of ECG electrodes 
and measurement of heart rate, respiratory rate, body temperature, and Vo2. These 
manipulations and measurements were not performed because of the problems associated 
with handling germ-free animals in isolators and the risk of bacterially contaminating the 
experimental animals. On day 0, 6, and 12, feces were cultured on BHI and thioglycolate 
medium to identify possible contamination with microorganisms. At day 0, rats were 
randomized in two groups. Group 1 (10 rats) received intrapentoneally 100 mg of 
zymosan in 4 ml of paraffin / 100 g of body weight, group 2 4 ml of paraffin per 100 g of 
body weight intraperitoneally. 
Experiment C: 
Seventy-two male Wistar rats (body weight, 300 - 350 g) received aseptic 
intraperitoneal injections of zymosan, suspended in paraffin according to protocol. The 
survivors were randomly killed on days 1, 2, 3, 5, 8, and 12 by heart puncture, according 
to protocol for biochemical studies (results not shown) and for aerobic and anaerobic 
cultures of blood and peritoneal fluid in BHI and thioglycolate medium. 
Statistical analysis was performed with Wilcoxon's two-sample test, Friedman's 
test, and the Kmskal-Wallis test Results between groups were significant if ρ < 0.05. 
2.4 RESULTS 
All group 1 rats in experiments A and В showed symptoms of severe illness. 
They became lethargic and anorectic, hyperventilated, lost hemorrhagic fluid from the nose 
and conjunctivas, and lost liquid stools. In this phase, seven rats from experiment A and 
one germ-free rat (experiment B) died. After three days, the surviving rats improved. They 
became more active and lost no more hemorrhagic fluid or fluid stools. Also, respiration 
was closer to normal. After five days, the rats deteriorated progressively with increasing 
hyperventilation and dyspnea, elevated heart rates, and decreasing V02. 
The clinical changes observed in the germ-free (experiment B) group 1 rats were 
qualitatively identical to those in experiment A group 1 rats. Only the acute reaction (days 
0 to 3) was less severe. After a consequently less obvious period of improvement, they 
quantitatively had the same severity of illness in the late phase as the group 1 rats of 
experiment A. All control rats remained in good health throughout the experimental 
period. The general response in the experiment С rats was identical to that in the 
experiment A group 1 rats. 
In experiment A, seven group 1 rats died within 20 to 72 hours after inoculation, 
and three rats died after nine to 12 days (Table 1). In experiment B, one group 1 rat died 
early. In all seven experiment A group 1 rats that died early, positive bacterial cultures 
were obtained from the peritoneal fluid. Postmortem examination in the eight "early 
deaths" in group 1 (experiments A and B) showed signs of an extensive acute peritonitis. 
The small intestine and, to a lesser extent, the colon were swollen, hyperemic, and dilated. 
The mesenterium was hyperemic and congested. 
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Macroscopic examination showed congested lungs and pale livers. The organ 
weights as related to body weight were unchanged for the liver, kidneys, and spleen and 
slightly elevated for the lung. Microscopic examination of the lungs showed granulocyte 
aggregates in the capillaries and slight interstitial edema. The liver sinusoids were too 
large and the portal veins and venae centralis dilated. In the kidney, the distal tubuli were 
widened. The spleen showed involution of follicles and hemorrhage. 
The finding in the surviving rats were as follows. 
Table 1. TIME OF DEATH AND POSITIVE CULTURES IN EXPERIMENTS A AND B* 
Time of death 
Group 0 - 3 d 9 - 12 d Killed at day 12 
Experiment A 
1 7(7) 3(0) 10(1) 
2 0(0) 0(0) 10(0) 
3 (M0) OJO) 10(0) 
Experiment В 
1 1 (0) 0 (0) 9 (0) 
2 0_(0) 0_(0) 10(0) 
* Values are numbers of rats and, in parentheses, numbers of rats with positive bacterial 
cultures 
2.4.1 Blood Analysis 
The results of blood analysis in experiments A and В are summarized in Table 2. 
Significantly elevated thrombocyte counts, blood lactate levels, and alkaline phosphatase 
levels were found in the group 1 rats of experiments A and B. In experiment B, the 
leukocyte count was also significantly elevated in group 1 rats, but in experiment A the 
higher leukocyte count of group 1 rats was only significant when compared with the 
controls. The group 2 rats of experiment A showed unexpectedly high leukocyte counts. 
In experiment A, the alanine aminotransferase level was significantly higher in 
group 1 rats than in group 2 rats. An indication of the significance of this rise was present 
in the germ-free group 1 rats (p=O.08). No significant changes were found in uric acid 
blood levels in experiments A and B. In germ-free as well as normal rats, differential 
leukocyte counts showed a highly significant increase in polymorphonuclear granulocytes 
and a decrease in lymphocytes compared with control groups. 
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Table 2. RESULTS OF BLOOD ANALYSIS AT DAY 12 
Experiment Α Ρ Experiment В 
Alkaline phosphatase 
U/L 
Alkaline aminotransferase U/L 
Creanmne, 
mg/dl ((imoI/L) 
Une acid mg/dl (mmol/L) 
Lactate, mg/dl (μπιοΙ/L) 
Thrombocytes 
χ lOVmm' (x lO'/L) 
Leukocytes 
χ lO'Anm' (x lO'/L) 
Polymorphonuclear leukocytes, % 
Lymphocytes, % 
Group 
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0.46 
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± 
± 
± 
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23 
0 63 
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3 02 
(180 
28.3 
(3.1 
904 
13.7 
21 
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0.34 
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2.42 Organ Weights 
Weights of the lungs, liver, kidneys, and spleen all were significantly increased in 
group 1 compared with group 2 in both experiments A and В (Table 3). The group 2 rats 
in experiment A also had significantly, though only slightly so, more elevated lung 
weights than did controls. 
Table 3. RELATIVE ORGAN WEIGHTS-
Experiment A PT !~ '- •  ExperimePt В 
Croupi 
1.42±0.20 
4.69±0.15 
0.84±0.03 
0.24±0.02 
Group 2 
0.60±0.03 
4.14±0.07 
0.69±0.02 
0.15±0.01 
Group 3 
0.45±0.01 
3.77±0.21 
0.66±O.O2 
0.15±0.01 
1 vs2 
<.001 
<.010 
<.001 
<.010 
2 v s 3 
<0.1 
^'«f iroupl 
O,9W0.15 ~ 
' 4.93±0.1S 
0.941ШИ 
О34І0.О2 
Group 2 
046*0.02 
4.11*0.10 
0.70tfcO.OÎ 
0J20±0,O| 
f 
" <jtm 
<0.l 
«л« 
<ж 
* (Organ weight/body weight) χ 100 
Τ Wilcoxon's test 
2.4.3 Biologic Measurements 
The results of the biologic measurements in experiment A are summarized in Fig 
1. The data for the rats with documented secondary bacterial peritonitis were not included 
for this analysis. On all days, respiratory rate in group 1 rats was significantly more 
elevated than in group 2 and group 3 rats (Fig 1). Within group 1, the respiratory rate 
increased significantly after day 6. Heart rate was significantly elevated in group 1 rats 
compared with group 2 and group 3 rats on days 2, 9, and 12. Within group 1 the early 
rise in heart rate, the normalization at day 6, and the late rise were all significant. Oxygen 
consumption was significantly elevated in group 1 rats at day 2, and decreased signi­
ficantly on days 9 and 12 compared with group 2 and 3 rats. Within group 1 the changes 
in time were all significant. Body temperature was significantly elevated in group 1 on 
day 2 and was significantly lower than in group 2 and 3 rats on days 9 and 12. 
2.4.4 Bacteriology 
Positive bacterial cultures were obtained from the peritoneal fluid in all seven 
experiment A group 1 rats that died early and also in one group 1 rat of experiment A that 
died at day 12. The growth showed Escherichia coli and gram-positive anaerobic rods. 
Bacterial cultures of the peritoneal fluid remained negative in all other rats in experiments 
A and B. Cultures of fecal material in the germ-free rats showed no bacterial growth. One 
type of yeast, though, was found in low concentration in fecal cultures before, during, and 
at the end of the experiment. 
39 
In experiment С, 56 rats survived untili the time of sacrifice. Blood cultures 
remained negative in SS animals. In one animal, preterminal at the time of killing, a blood 
culture yielded a few colonies of Streptococcus viridans and E coli, also cultured in large 
amounts from the peritoneum. In the other experiment С rats, peritoneal fluid showed no 
growth in 36 rats, a few colonies (probably contamination) of streptococci or staphylococci 
in 14, and a tight growth of various microorganisms in five. 
Figi. 
Results of biologic measurements in 
experiment A group 1 rats (mean ± 
2SEs). Shaded area corresponds to mean 
± 2SEs for group 2 and group 3 rats. At 
day 0 there were 20 rats; at day 2, 13; 
at day 6, 13; at day 9, 12; and a day 
12, 11. 
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2.4.5 Macroscopic and microscopic findings 
In group 2 rats in experiments A and B, exploration of the peritoneal cavity 
yielded some paraffin remnants, some dispersed lipid-containing nodular granulomas a few 
millimeters in diameter, and locally some fibrous adhesions. Histologic findings in the 
examined organs were normal except for slight interstitial edema in some rats in 
experiment A group 2. 
In the group 1 rats of experiments A and B, an extensive fibroplastic peritonitis 
was found with massive adhesions. Also, lipid-containing granulomas were found locally 
as in group 2 rats. Signs of acute peritonitis, like those seen in the rats that died early, 
were not found. The lungs showed extreme hyperemia with hemorrhagic spots, and 
occasionally extensive hemorrhagic infarction. 
Microscopically, the lungs showed interstitial and intra-alveolar edema, strongly 
increased numbers of intracapillary granulocytes, and an increase in foam cells, probably 
macrophages (Fig 2). The liver showed congestion and edema and an increase in the 
number of granulocytes inside the capillaries and in Disse's space (Fig 3). The spleen 
showed an increase in granulocytes in the capillaries and in the pulpa and exhaustion of 
lymphoid tissue. In the kidneys widening of tubuli was seen, with granulation of 
cytoplasm (Fig 4). 
Fig. 2. Lung specimen showing interstitial hemorrhage and edema (at left), granulocytosis of interveolar 
capillaries, and some slightly protein-rich edema (hematoxylin-eosin, χ 270). 
41 
Fig 3. Liver specimen showing dilated central veins and capillaries, locally stuffed with granulocytes, clearly 
visible Disse's spaces, and cytoplasmic granularity of parenchymal cells (hematoxylin-eosin, χ 270) 
Cv· ·* ' 
Fig 4. Kidney specimen showing hypercellularity of glomeruli, widened capsular spaces, and tubules with 
accentuated cytoplasmic granularity. Their lumina are filled with casts (hematoxylin-eosin, χ 270). 
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2.5 DISCUSSION 
Zymosan is a potent activator of the alternative pathway of the complement 
system. As zymosan is not water soluble, the experimental model concerns local 
stimulation of inflammation. In these experiments, intraperitoneal zymosan resulted in a 
triphasic illness. In an acute reaction, the rats developed fever, dyspnea, lethargy, and an 
increased heart rate and Vo2. During this period 35 % of the experiment A group 1 rats 
died. After a period of improvement, the rats showed increasing illness with severe 
dyspnea, tachycardia, decreased Voj, lactic acidosis, leukocytosis, thrombocytosis, elevated 
alkaline phosphatase levels, and ARDS-like pulmonary changes with edema and microvas­
cular changes in the lung, liver and kidney. The alterations in the cardiovascular system, 
in metabolism with elevated serum lactate levels, ARDS, the hematologic changes, the 
hepatic function, and lethargy account for changes in six organ systems. The similarities to 
ARDS and the clinical syndrome of multiple organ failure were striking. 
The changes found in this non-bacterial model also strikingly resembled the 
findings in rat models of sepsis (3-6). Wichterman et al (3) described the cecal ligation 
and puncture method in rats, resulting in an early hyperdynamic phase with fever, le­
thargy, tachypnea, and increased heart rate and a late hypodynamic phase with high serum 
lactate levels. The clinical signs of sepsis were qualitatively the same and occurred in the 
same sequence as the 11 signs described by Wichterman et al (3). 
Lang et al (4) implanted a fecal inoculum in the peritoneum of rats. The early 
hypermetabolic response and the recovery phase at days 4 and 5 were similar to those in 
our model. As their experiment was terminated at day 5, the late changes could not be 
compared with the present model. 
Oh et al (5) described a model of chronic high-output sepsis in rats by 
intraperitoneal inoculation of a sterile gauze subsequently contaminated with E coli and 
Bacteroides fragilis. This resulted in an elevated cardiac output, lethargy, and failure to 
gain weight. The observation period was six days. 
Kirton et al (6) developed a rat model of ARDS by inducing intermittent 
peritonitis by repeated intra-abdominal implantation of gelatin capsules containing E coli 
and В fragilis. The observation period was up to eight weeks, and ARDS-like changes 
were seen microscopically, though without changes in arterial oxygen tension. 
The non-bacterial model presented in this article also conforms to the "guidelines 
for progressive and lethal sepsis models" proposed by Wichterman et al (3) except for the 
presence of microorganisms. Insulin levels, though, were not measured as in our laboratory 
no method is available for measurement of rat insulin. Also, of all chronic sepsis models 
reviewed in this discussion, insulin levels were only measured by Wichterman et al (3). 
Insulin and glucose levels were suggested by Wichterman et al to exclude changes due to 
severe dehydration and hypotension. As half of our experimental animals survived for 12 
days, severe dehydration and hypotension are unlikely to have been present. Arterial blood 
pressure and cardiac output were not measured, as indwelling catheters are mandatory but 
might induce bacterial sepsis, which could be contrary to the aim of the experimental 
model. Experiment В demonstrated that an ARDS- and MOF-like syndrome with sepsis 
can be induced in germ-free rats by a non-bacterial, non-endotoxic stimulus. 
Important also is the finding that in five experiment С rats and in eight 
experiment A group 1 rats, positive bacterial cultures were obtained from the peritoneal 
cavity, even within a few days after inoculation. As all inoculated material was bacteriolo-
gically checked, this was not the result of a technical error. Also, in none of the paraffm-
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treated rats and none of the germ-free rats were positive growths from the peritoneal 
cavity obtained. Somehow, massive stimulation of inflammation within the peritoneal 
cavity thus results in bacterial colonization of the peritoneal cavity. The subsequent increa­
sed inflammatory response to the bacterial stimulus might have led to bacterial sepsis and 
early death in these rats. 
Finally, it should be noted that the same stimulus of inflammation in rats, i.e. 
intraperitoneal zymosan, in a dosage of 3 mg / 100 g of body weight results in enhanced 
host defense against infection (7), in a dosage of 100 mg / 100 g of body weight in an 
ARDS- and MOF-like syndrome as shown in this study, and in a dosage of 500 mg / 100 
g of body weight in early death from shock as found in our pilot experiments. Enhanced 
host resistance, ARDS, MOF, and shock thus might be quantitatively different reactions to 
an identical inflammatory stimulus. This study provides evidence for our hypothesis that 
MOF is the result of a generalized autodestmctive process of inflammatory character (2). 
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Chapter 3 
NEUTROPHIL FUNCTION AND LIPID PEROXIDATION 
IN A RAT MODEL OF MULTIPLE ORGAN FAILURE. 
IPT van Bebber, WKF Boekholtz, RJA Goris, PHM Schillings, HP Dinges, 
S Bahrami, H Redi, G Schlag. 
J Surg Res 47: 471-475, 1989. 
3.1 SUMMARY 
Multiple Organ Failure (MOF) was induced by sterile intraperitoneal inoculation 
of zymosan in the rat. This results in a typical triphasic illness with maximal clinical signs 
at day 2 and 14. In this study, granulocyte superoxide production (unstimulated and 
phorbol myristic acid stimulated) was studied as well as lipid peroxidation (TBAR) in 
plasma, liver and lung tissue. Mainly TBAR levels in liver and lung tissue closely 
correlated with the triphasic clinical illness, while bacteriological data did not. It is 
concluded that the severe inflammatory response in this experimental model probably is 
the result of excessive toxic oxygen radical production. The first phase of illness may 
mainly be due to oxygen radical formation by activated PMNs, the third phase of illness 
to the production of lysosomal enzymes (proteinases) from PMNs and activated 
macrophages as indicated by elevated N-Acetyl-Glucosaminidase levels. 
3.2 INTRODUCTION 
The Adult Respiratory Distress Syndrome (ARDS) and the subsequent failure of 
multiple organ systems (MOF) concomitant with signs of generalized sepsis, presently are 
the most common causes of death in both trauma patients and peritonitis patients admitted 
in an intensive care unit. While multiple bacterial and non-bacterial causes have been 
implicated in the genesis of ARDS, multiple organ failure has generally been linked to 
bacterial invasion and endotoxins. A consistent correlation with positive blood cultures and 
bacterial foci however, could not be demonstrated in large series of trauma and peritonitis 
patients with MOF (2, 3, 13, 14). Recently it was demonstrated that by intraperitoneal 
inoculation of sterile zymosan in rats a severe generalized illness could be induced 
resulting in an early mortality of 35 %. In surviving rats a temporary improvement was 
seen, followed by ARDS like changes in the lung, deterioration of the function of the liver 
and hematologic system at day 2, lethargy, signs of generalized sepsis and a 15 % late 
mortality rate (4). In this model bacterial translocation from the gut to the peritoneal 
cavity was found in some rats, but bacteria were not necessary because the same illness 
could be induced in germ free rats (4). The findings in this animal model closely resemble 
the findings in other models of chronic sepsis in the rat (6, 7, 10, 15). 
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In the present study we investigated granulocyte superoxide production and lipid 
peroxidation in lung and liver tissue in this model of zymosan induced multiple organ fail­
ure. The peak activity of granulocyte superoxide production at day 2 and the lipid 
peroxidation in tissue found at days 2 and 14 closely correlated with the severity of 
clinical illness, characteristic of this animal model. 
3.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemicals St. Louis USA) 2.5 g was suspended in 100 ml of 
liquid paraffin by high frequency vibration. The suspension was sterilized by inoculation 
in a water bath of 100° С for 80 minutes. Before intraperitoneal inoculation the zymosan 
suspension was warmed to 40° С and vibrated at high frequency for 15 minutes. 
Thirty-five male Wistar rats (body weight 350 - 425 g) received an aseptic 
intraperitoneal injection of zymosan suspended in paraffin (100 mg of zymosan / 4 ml of 
paraffin / 100 g body weight). Five rats served as bianco controls and received no 
intraperitoneal injection. All other rats were randomly assigned to four groups for sacrifice 
at day 2, 4, 9 and 14. At the day of sacrifice, rats were anaesthetized in a closed space 
saturated with ether. They were bled by hart puncture which yielded approximately 5 ml 
of blood. The following blood analyses were performed: platelet count, leukocyte count, 
differential cell count, serum-glutamyl-phosphate-transaminase (SGPT) and lactate. 
Thiobarbituratic Acid Reactive Material (TBAR) was measured according to Satoh (11). 
One part of tissue was homogenized with 10 parts of 0.4N perchlorid acid. 1 ml of the 
resulting homogenate or plasma was mixed with 2 ml thiobarbituric acid (ТВA) reagent 
(consisting of 0.67 % TBA in 2 M Na2S04) and incubated at 100° С for 15 minutes. Cold 
samples were extracted with 3 ml amylalcohol and centrifuged. Samples were measured at 
530 nm and compared with a standard curve of malondialdehyde (MDA). 
Total complement level was determined as CH,,, according to Kabat and Meyer 
(5). N-Acetyl-Beta-D-Glucosaminidase (NAG) activity was analyzed using 3 mM p-
Nitrophenylglucopyranosid in acetate buffer (50 mM - pH 5.0) and incubated at 37° С for 
one hour. Liberated p-nitrophenol was measured at 405 nm after adding 0.3 M glycin-
sodiumhydroxide buffer (pH 10.6). 
Superoxide production by whole blood (0.1 ml diluted 1 : 5) was measured (as 
superoxide dismutase-sensitive cytochrome с reduction) according to Bellavite et al (1) in 
the absence and in the presence of phorbol myristic acid (PMA) (0.01 pg/ml final 
concentration). 
After killing, the rats were weighted and sterile samples of peritoneal fluid were 
taken, put into bacteriological vials (PORT-A-CULT, Becton Dickinson) and tested for 
bacterial growth using standard techniques. The lungs with trachea, liver, spleen and 
kidney were dissected free and weighted. Relative organ weights were calculated by the 
following formula : (organ weight/body weight) χ 100. After fixation with 4 % 
formaldehyde (the lungs also intratracheally at a pressure of 30 cm H20) microscopic 
sections of these organs were prepared for staining with haematoxylin-eosin. In performing 
the animal experiments, the National Research Council's guide for the care and use of 
laboratory animals was followed. 
Statistical analysis was performed with the Kmskal-Wallis test and Wilcoxon's 
two sample test. Differences between groups were significant if ρ й 0.05. 
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3.4 RESULTS 
All rats except the bianco controls showed the classical symptoms of severe 
illness as known in this model, with lethargy, anorexia, hyperventilation, loss of 
hemorrhagic fluid from the nose and conjunctivae, and loss of liquid stools during the first 
three days. In this acute phase 10 rats (28.5 %) died. The surviving rats improved with 
increase of activity and no more loss of hemorrhagic fluid. After 8 days, the rats 
deteriorated progressively with increasing hyperventilation and dyspnea. Late mortality in 
the third phase of illness was 11.5 % (n=4). 
спад 
>—- Superoxide Р 1Л 
(nmoi/IOsPMN) 
— - - Superoxide η si 
(nim>i/10RPMN) 
PMN '7t 
Fig 1. PMN counl (%) in relation lo unstimulated and PMA stimulated PMN superoxide formation and 
plasma CH
n
 levels 
3.4.1 Blood analysis 
The platelet count was elevated at all days measured and significantly so at day 4 
and 9. The leukocyte count was significantly decreased at day 2, the differential count 
showed a drop in the PMNs and lymphocytes while the monocyte count was increased. 
The next days, the leukocyte count was not significantly altered but PMN count was high 
(Table 1; Fig 1). The CH,, was decreased by 28 % at day 2 as compared to a standard 
pool of rat plasma (therefore no statistics could be performed) and subsequently returned 
to high control levels at day 9 and 14. 
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Table 1. RESULTS OF PMN SUPEROXIDE PRODUCTION 
O2nmole/10
8
 PMN 
Day 
0 
2 
4 
9 
14 
Unstimulated 
10.3 ± 3.0 
50.8 ± 8.7' 
3.2 ± 1.3* 
7.5 ± 1.8 
41.6 ± 28.7 
PMA-stimulated 
101.6 ± 
232.1 ± 
19.5 ± 
52.0 ± 
48.2 ± 
36.8 
58.9 
5.Γ" 
7.7 
18.9 
Leukocyte count 
8.10 ± 36.8 
1.90 ± 0.4"* 
10.03 ± 1.8 
10.00 ± 1.6 
6.30 ± 1.2 
% PMN 
39.2 ± 4.8 
24.2 ± 2.7" 
56.2 ± 3.3* 
55.7 ± 6.2 
61.8 ± 3.0* 
* Ρ á 0.06; " Ρ ¿ 0.05; *** Ρ <, 0.01 (as compared to control) 
The unstimulated PMN 02" production decreased significantly and remained below normal 
for the next days. TBAR in plasma, lung and liver tissue was significantly elevated at all 
days measured (Table 2, Fig 2). The highest levels in liver and lung tissue were found at 
day 2 and 14, the highest plasma levels at day 4. The plasma level of NAG was 
significantly decreased at day 2 as compared to all subsequent days. The SGPT was 
elevated at day 2, decreased significantly at day 4 and subsequently increased significantly 
at day 9 and 14. These changes correlated well with the TBAR levels found in liver tissue 
(Fig 3). No significant changes were found in plasma lactate levels in this experimental 
series although lactate levels at day 2, 4 and 9 were increased up to 4.48 mmol/L as 
compared to lactate levels in control rats (2.75 mmol/L) (p-value 0.11). 
Table 2. RESULTS OF THIOBARBITURATIC ACID-REACTIVE (TBAR) 
MATERIAL IN PLASMA AND TISSUE 
Day TBAR in plasma TBAR in liver tissue TBAR in lung tissue 
5.3 
229.2 
64.7 
29.4 
127.4 
± 
± 
± 
± 
± 
0.3 
5.Γ" 
29.6"* 
3.9-
15.9" 
3.3 
7.8 
47.1 
17.7 
19.8 
± 
± 
± 
± 
± 
0.6 
1.5"· 
14.7"' 
4 . 3 -
3.0" 
14.4 
226.9 
104.3 
68.8 
237.2 
± 
± 
± 
± 
± 
3.7 
66.6' 
39.2' 
9.4"' 
78.0' 
" Ρ < 0.05; " · Ρ < 0.01 (as compared to control) 
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NAG plasma (Jlg/mi/h) 
TBAR lung (nmoi/g WW) 
TBAR liver (nmoi/g WW) 
i TBAR plasma (nmoi/mi) 
14 days 
Fig 2. Lipid peroxidation (TBAR) in plasma, in lung and liver tissue, and plasma NAG levels in function of 
lime. 
SGPT(U/I) 
TBAR liver (nmoi/g WW) 
liver weighl (%) 
14 days 
Fig 3. Liver weight and plasma SGPT levels in relation to lipid peroxidation (TBAR) in the liver. 
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3.4.2 Organ weights 
Relative lung weights were significantly increased at day 9 and 14 versus at day 0 
and 2 (Table 3). Relative liver weights were increased at day 9 and 14 as compared to day 
2 (Table 3). 
Table 3. RELATIVE ORGAN WEIGHTS AND SGPT 
Day 
0 
2 
4 
9 
14 
Lung 
0.38 ± 0.01 
0.38 ± 0.02 
0.43 ± 0.02 
0.44 ± 0.02"' 
0.59 ± 0.06" 
Liver 
3.34 ± 0.20 
3.34 ± 0.11 
3.68 ± 0.19 
4.10 ± 0.08* 
3.98 ± 0 . 1 8 
SGPT (U/liter) 
22 ± 4.1 
32 ± 0.3 
8 ± 0.8" 
19 ± 1.0 
23 ± 0.9 
Ρ < 0.06; " Ρ < 0.05; " ' Ρ < 0.01 (as compared to control) 
3.4.3 Microscopic findings 
In all rats terminated at day 2, interstitial edema was consistently found in the 
lungs. Interstitial pulmonary edema was found to a greater extend in the rats that died 
spontaneously within the first 2 days. At day 4 and 9 also an increased number of PMNs 
was found in the lung capillaries. At day 14, the lungs showed extreme hyperemia with 
hemorrhagic spots, occasionally extensive hemorrhagic infarction and an increased number 
of interstitial and intra-alveolar macrophages. The liver at day 14 showed congestion and 
edema, widening of Disse's space with an increased number of Kupffer cells and PMNs, 
loss of the normal radial structure and signs of livercell necrosis. At day 2, 4 and 9 these 
signs were present to a lesser degree. The kidneys at day 9 and 14 showed sequestration 
of PMN in the glomeruli and degeneration of cells in the tubuli. At day 2, these findings 
were seen to a lesser degree. The spleen at day 14 showed exhaustion of lymphoid tissue, 
extramedullary hematopoiesis and an increased number of PMNs. 
3.4.4 Bacteriology 
Only in three of thirty-five animals a positive culture of the peritoneal fluid was 
obtained, and this finding was not related to any other parameter. 
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3.5 DISCUSSION 
In this experimental model, a severe systemic inflammatory response is induced 
by local aseptic intraperitoneal injection of zymosan. In this experimental series, the 
clinical illness induced responded well with earlier experimental series (4). The triphasic 
clinical illness with maximal clinical signs at days 2 and 14, correlated closely with the 
tissue levels of TBAR found in the lung and liver. The lowest CH,,, levels were found at 
the same time as the smallest number of circulating PMNs, but also with the highest 
PMN-activation level (superoxide production) on day 2. At the same time peak concentra­
tions of TBAR in tissue and shortly thereafter peak levels of TBAR and NAG in plasma 
were seen which might represent wash-out phenomena similar to a "hidden" acidosis. 
These elevated TBAR levels probably are related to the significantly elevated PMN 
superoxide production (ex vivo) as found in this experiment, and not due to ischemia as 
plasma lactate levels were not significantly altered. At the same time, a significant 
decrease in PMN count in peripheral blood was found, probably due to increased 
activation and possibly degradation of PMNs as a result of complement activation (drop in 
СИ,,). However, morphologically no significantly increased numbers of PMN were found 
in lung and liver tissue at this time. A similar finding was noticed in an experimental 
model of ARDS in rabbits by infusion of zymosan activated plasma, where the PMN 
count in the lung was lower in rabbits with the most severe ARDS (8). But in the rabbits 
with severe ARDS large numbers of splenic macrophages were found, filled with debris of 
PMN. Similarly PMN debris were found in Kupffer cells in a model of hypovolemic-
traumatic shock in dogs together with increased plasma levels of TBAR, but with 
significant leukostasis in the lung (12). 
In the third phase of illness at day 14 increased lung weights were found 
concomitant with clinical hyperventilation. At microscopy, findings again correlated well 
with increased lung levels of TBAR. At this time, no significant increase was found in 
stimulated and unstimulated PMN superoxide production from circulating PMNs, but there 
might have been radical production from marginated PMNs or macrophages. However, 
NAG levels at this time were significantly increased indicating release of lysosomal enzy­
mes. The increase of SGPT at day 2 followed by a rapid decrease at day 4 indicates 
severe liver cell dysfunction or even liver cell necrosis, as documented already at this time 
in the morphological specimens of the liver. Complement levels again increased as the 
result of an acute phase reaction. 
The triphasic changes especially in lung and liver tissue of TBAR and to a lesser 
extend of PMN superoxide production thus correlated well with the triphasic clinical 
illness found in this animal model. The elevated levels of NAG found from day 4 on 
indicated that the late phase of this illness may be related to the lysosomal enzyme release 
e.g. from activated macrophages or degranulating PMNs in the tissue. Beside the used 
marker enzyme NAG, there are several other lysosomal enzymes including aggressive 
proteases, e.g. PMN or macrophage elastase, which can breakdown membrane and 
interstitial structures. That the release of elastase might be one of the key enzymes for 
tissue damage could be assumed from our studies in humans, were it was the only 
inflammatory parameter significantly correlating with the degree of multiple organ failure 
(9). 
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No correlation could be found between the severity of clinical illness and the few 
positive bacteriological peritoneal fluid cultures found in this experiment. Since overall 
results, e.g. mortality, in this experimental series were similar to earlier findings (4), we 
conclude that MOF may be induced by a generalized inflammatory reaction involving the 
production of toxic oxygen radicals, and not necessarily requires a septic event 
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Chapter 4 
ZYMOSAN INDUCED MULTIPLE ORGAN FAILURE 
IN ELASTASE-DEFICIENT MICE. 
IPT van Bebber, R Beumer, RJA Goris. Published in part in "Shock, Sepsis and Organ 
Failure". Second Wiggers Bernard Conference. G. Schlag, H. Redi, J.H. Siegel, D.L. 
Traber (eds.) Springer Verlag. Berlin. New York 1990. pp 461-491 
4.1 SUMMARY 
Multiple organ failure can be induced by sterile intraperitoneal injection of 
zymosan in rats and mice, resulting in a triphasic illness with maximal clinical signs at 
days 2 and 12. In this model, activation of polymorphonucleur leukocytes correlated with 
the severity of illness at day 2. In the present experiment, we studied the effect of 
zymosan in normal mice and elastase deficient mice (C57B1/J6). Mortality rate was 
recorded. Body temperature and body weight were measured daily. Relative organ weights 
of lungs, liver, spleen and kidney were calculated. All mice reacted similarly to the 
intraperitoneal zymosan suspension and were severely ill. 
In the elastase deficient mice, early mortality rate was significantly lower, while 
late mortality was higher as compared to control mice. Total mortality was similar in both 
groups. No other significant differences were found between groups. We conclude that ela­
stase might play a role in the acute phase of multiple organ failure. 
4.2 INTRODUCTION 
The pathogenesis of the adult respiratory distress syndrome (ARDS) and the 
subsequent failure of multiple organ systems (MOF) is intensively studied but still remains 
unclear. One of the mechanisms of this fatal syndrome is the activation of the complement 
system (1), leading to aggregation of PMNs and their margination to endothelial cells 
(2,3). Subsequently, toxic oxygen species and proteolytic enzymes are released from these 
PMNs, causing damage to the endothelium resulting in permeability edema (4,5,6). 
Degranulating PMNs, endothelial swelling and interstitial edema were found in lung 
biopsies of trauma patients, especially in those who developed ARDS later on (7,8). Free 
elastase might play an important role in the pathogenesis of ARDS and MOF due to its 
extensive destructive properties on cellular structures and endothelia (9). Smedly et al (10) 
indicated a possible causal role of elastase in the process of endothelial cell injury by 
PMNs by means of an endothelial monolayer assay. In an isolated rabbit lung model, 
perfusion with PMN elastase resulted in an increase of interstitial edema which was inhibi­
ted by eglin, a potent elastase inhibitor (11). Elastase infusion in minipigs induced a 
disturbance of blood coagulation leading to hypocoagulability, pulmonary leukostasis, 
interstitial edema, progressive respiratory failure with increased pulmonary vascular 
resistance, and an increased dead space ventilation (12). 
In several clinical studies, elevated serum levels of elastase-α-Ι proteinase inhibitor 
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complex have been demonstrated in patients prior to the development of ARDS, sepsis or 
MOF, in different conditions such as trauma, bums and peritonitis (13-20). However, 
Fuhrer et al (21) could not discriminate between patients developing ARDS and those 
without severe pulmonary dysfunction by determination of elastase-α-Ι-protease inhibitor 
complex. 
MOF can be induced by a sterile intraperitoneal injection in rats and mice, 
resulting in a triphasic illness with maximal clinical signs at days 2 and 12 (22,23). The 
findings in this animal model closely resemble the findings in other models of chronic 
sepsis in the rat (24). The role of PMNs and PMN activity in the acute phase of this 
model was demonstrated (25). The first phase of illness may mainly be due to oxygen 
radical formation, the third phase of illness to the production of lysosomal enzymes 
(proteinases) from PMNs and activated macrophages as indicated by elevated N-acetyl-
glucosaminidase levels (25). 
The beige mouse has a neutral proteinase deficiency due to a decrease of both 
elastase and cathepsin G activity in circulating PMNs (26). In the present experiment we 
studied the effect of i.p. zymosan, in elastase deficient mice (C57BL/J6). This resulted in 
the triphasic illness known in this model with only a significantly lower early mortality in 
the elastase-deficient strain. The number of 12-day survivors was similar in both groups. 
4.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemicals, St. Louis) 2.5 g was suspended in 100 ml of liquid 
paraffin by high-frequency vibration. The suspension was sterilized in a water bath at 
100° С for 80 minutes. Sterility was checked by incubation on blood agar plates for two 
days at 37° С Before intraperitoneal injection the zymosan suspension was warmed to 
40° С and vibrated at high frequency for 15 minutes. 
30 Beige mice (C57BL/J6 bg.bg) (B) were obtained from Harlan OLAC Ltd. 
England. 29 Heterozygotic controls (C57BL/J6 bg/+) (H) and 16 Cpb:SE mice (Swiss) (S) 
were obtained from the central animal farm of the Nijmegen University. All mice were 
randomized in zymosan injected groups (B n=22, H n=21, S n=ll) and control groups (B 
n=8, H n=8, S n=5). Zymosan injected mice received 100 mg zymosan / 4 ml paraffin / 
100 g body weight intraperitoneally. 
At day 0, differential cell count was performed in all mice. In all mice, daily 
measurements were made of body temperature, and body weight. Clinical condition was 
observed daily. In spontaneously dying mice, aerobic cultures from the peritoneal fluid 
were taken. The lung, kidney and spleen were dissected free and weighted. Relative organ 
weights were calculated. At day 12, all surviving mice were sacrificed. Abdominal fluid 
was cultured aerobically and anaerobically. All other experimental procedures were 
identical to those in spontaneously dying mice. 
Statistical analysis was performed with the chi-square test, Kmskal-Wallis test 
and Wilcoxon's two sample test. Differences in results between groups were significant if 
ρ Ú 0.05. 
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4.4 RESULTS 
All zymosan injected mice showed the typical triphasic illness as known in this 
model. In the acute phase (day 0-3), mice were lethargic, anorectic, had a ruffled fur and 
liquid stools. In this acute phase, mortality was 8 out of 22 В mice, 13 out of 21 H mice 
and 3 out of 11 S mice. All mice improved temporarily, but deteriorated progressively 
after day 8. In the late phase of this illness, mortality was 9 out of 14 В mice, 4 out of 8 
H mice and 2 out of 8 S mice. Acute mortality rate was significantly lower and late 
mortality significantly higher in zymosan injected В mice as compared to the zymosan 
injected H mice (p = 0.0476). However, total mortality after 12 days was similar in all 
groups (Fig 1). 12-Day survival was 2 out of 22 В mice, 1 out of 21 H mice and 5 out of 
11 S mice. 
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4.4.1 Biological measurements 
In each strain, a decrease in body temperature of five or six degrees was 
measured within half an hour after the zymosan injection. Body temperature recovered in 
the В and S strain but remained low the first four days. In the В and H strain, there was a 
progressive fall of temperature from day 6 on. In the S strain, body temperature decreased 
significantly from day 9 on (Fig 2). Body weight decreased significantly during the experi­
ment in the В and H strain, while body weight in the S strain recovered from day 4 to 8 
but decreased significantly afterwards (Fig 3). Due to the small number of mice in the late 
phase of this experiment, no statistical analysis could be performed for body temperature 
and body weight in the H strain from day 8 on and in the В strain from day 11 on. 
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4.4.2 Organ weights 
As compared to controls, relative lung weights were significantly increased In В 
and S mice dying early or late, and in H mice dying late (Fig 4). Relative spleen weights 
were significantly increased in В and S mice dying late and in S mice surviving up to day 
12. The H mice however, showed a significant decrease in acute mortality as compared to 
controls. Relative spleen weights were not significantly different (Fig 5). As compared to 
controls, and to early deaths, relative kidney weights were significantly increased in В 
and H mice dying late. No significant differences were found in the S strain as compared 
to controls (Fig 6). 
Macroscopically, lungs in all strains showed severe diffuse hemorrhage and/or 
hemorrhagic spots. At day 0, no significant differences were found in differential cell 
count (data not shown). 
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4.4.3 Bacteriology 
In spontaneously dying mice, abdominal cultures were positive for a variety of 
species e.g. E coli, hemolytic E coli, enterobacter cloacae, enterococcus, streptococcus, 
staphylococcus aureus, bacillus spp. and Pseudomonas. No differences were found between 
the three mice strains. Abdominal cultures of 3 control В mice showed acinobacter, E coli 
and hemolytic E coli. The abdominal culture of one control S mouse contained proteus. 
4.5 DISCUSSION 
In Beige mice, i.p. zymosan resulted in clinical signs similar to those found in the 
control groups. Early mortality in В mice was significantly lower than in controls, while 
total mortality was similar. 
No microscopic examination of the lungs was performed as the relative lung 
weight and the macroscopic aspect of the lung are simple and reproducible parameters that 
correlate well with the histophatologic findings. The relative lung weight in В mice 
increased significantly in the acute phase. Elastase deficiency thus did not protect against 
the development of late MOF. These findings may be explained as follows. Zymosan 
induced complement activation results in an aggregation and sequestration of PMNs in the 
capillary systems. This challenge might induce a total depletion of PMNs or its precursors 
from the bone marrow or spleen as indicated by the decrease of relative spleen weight in 
all strains. Lysosomal enzymes, including elastase and cathepsin G, are synthesized 
relatively early, that is in the promyelocyte or early myelocyte stage (27,28). Takeuchi et 
al (26) demonstrated that in beige mice, precursor neutrophils of bone marrow have 
considerable elastase and cathepsin G activity, while mature bone marrow PMNs and 
blood PMNs have virtually no elastase or cathepsin G activity. This indicates that the 
mechanism for low proteinase activity is not due to an absence of enzyme synthesis, but 
rather to a loss of activity of these enzymes during PMN-maturation in the bone marrow. 
It is not unlikely that after the zymosan injection, the rapid demand for PMNs mobilizes 
immature PMNs, still containing elastase and cathepsin G activities. 
Another possible explanation may be the decreased bactericidal activity of beige 
mice (29,30). Zymosan induces a sterile peritonitis with subsequent translocation of 
bacteria to the mesenteric lymph nodes and abdominal cavity (31). Decreased bactericidal 
activity may thus lead to an increase of the septic challenge. This explanation is unlikely, 
as in this model mortality due to bacterial translocation occurs in the acute phase (22), 
while early mortality was significantly lower in beige mice. 
Another interesting finding in beige mice stimulated with opsonized zymosan or 
phorbol mynstate acetate, is that hydroxyl radical generation and luminol-dependent 
chemiluminescence are significantly lower, while the PMN-superoxide anion release was 
similar to control PMNs (32). We already described the formation of oxygen free radicals 
and lipid peroxidation in the acute phase of this experimental model (25). 
In the present experiment of zymosan induced multiple organ failure, beige mice 
showed a decreased early mortality. However, in beige mice organ damage was not 
attenuated and total mortality not decreased. We conclude that in this model of zymosan 
induced MOF, elastase-deficiency might have played a role in the acute phase, but did not 
prevent late MOF. 
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Chapter 5 
DOES SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL 
TRACT PREVENT MULTIPLE ORGAN FAILURE? 
AN EXPERIMENTAL STUDY. 
RJA Goris, IPT van Bebber, RMH Mollen, JP Koopman 
Arch Surg 126: 561-565, 1991 
5.1 SUMMARY 
Gut bacteria have been incriminated as causing or contributing to generalized 
sepsis with multiple organ failure in severely ill patients, and selective decontamination of 
the gastro-intestinal tract of enterobacteriaceae has been claimed to decrease septic 
complications in these patients. We studied the effects of selective decontamination (SD) 
of the gastro-intestinal tract on survival and organ function in an experimental model of 
sepsis with multiple organ failure. Wistar rats were inoculated intraperitoneally with 
zymosan and randomized into control or treatment groups (trimethoprim or streptomycin). 
SD effectively prevented bacterial translocation of enterobacteriaceae. However, only early 
mortality was decreased, and only so in the streptomycin treated rats. SD did not result in 
a significantly better condition of the surviving animals at day twelve. 
5.2 INTRODUCTION 
Sepsis associated with the sequential failure of multiple organ systems presently is 
one of the most important causes of death in surgical and intensive care patients. The 
mortality of MOF with sepsis still is 60 % despite optimal treatment in the Intensive Care 
Unit (ICU) and optimal antibiotic treatment. 
Ever since the work of Cuevas and Fine (1), the intestinal flora has been 
incriminated as a cause of death from peritonitis. In situations leading to MOF and sepsis, 
as in severe bums (2) in hemorrhagic shock (3), endotoxin administration (1,4), gut 
bacteria - especially enterobacteriaceae - have been demonstrated to translocate to the 
peritoneal cavity, to mesenteric lymph nodes (MLN), liver and spleen, finally causing 
septicemia. Translocation of intestinal bacteria has also been demonstrated into intra-
abdominal abscesses (5). The gut therefore has been called the motor of MOF (6). 
Prevention of the gut origin septic state (7) may consist of eliminating the 
enterobacteriaceae from the gastro-intestinal tract (1), for instance by selective elimination 
of the aerobic flora, being careful not to induce colonization by other pathogens (8,9). 
Presently, nine clinical studies have evaluated the efficacy of selective 
decontamination of the gastrointestinal tract to prevent septic complications and septic 
death in ICU patients (9-17). All nine studies have shown a highly significant decrease of 
nosocomial infections in the SD treated patients, but no difference was found in duration 
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of ICU stay, duration of mechanical ventilation or in duration of hospital stay. In most 
studies, the amount of therapeutic antibiotics administered in the SD group was similar as 
in controls. In two studies a decreased mortality was found. Though SD is utilized on a 
large scale in Dutch ICU patients today, we are not aware of a single experimental work 
studying its merits in a septic animal model. 
The present study was performed to evaluate the efficacy of SD to prevent 
'sepsis' and MOF in a rat model of sterile peritonitis induced by zymosan (18). This 
model was extensively validated by others as a suitable model of MOF (19). Two 
regimens of SD effectively prevented bacterial translocation of enterobacteriaceae. In one 
of two SD regimens this treatment resulted in a significantly lower early mortality rate and 
a higher number of twelve-day survivors. But twelve-day survivors were as 'septic' as 
untreated controls. 
5.3 MATERIAL AND METHODS 
Zymosan (Z 4250 - Sigma Chemicals, St.Louis USA) 2.5 g was suspended by 
high frequency vibration in 100 ml of liquid paraffin. The suspension was sterilized by 
incubation in a waterbath at 100° С for 80 minutes. Sterility was checked by incubation 
on blood - agar plates for two days at 37° С Before utilization, the zymosan suspension 
was warmed to 40° С and vibrated at high frequency for 15 minutes. 
Seventy-eight male Cpb:Wu (Wistar) rats (body weight 200-300 g) were 
randomly assigned to treatment and control groups. The animals were housed individually 
in metabolic cages and adapted to handling for five days prior to the actual experiment. 
All rats had free access to water acidified with HCl to pH3 and standard rat laboratory 
chow (RMH-GS pellets, Hope Farms, the Netherlands, irradiated at 1 Mrad). All rats 
received daily intragastric 2.5 ml of water. In the treatment groups the selected antibiotics 
were added to this water. 
At day 0 all rats were lightly anesthetized with ether and received an aseptic 
intraperitoneal injection of zymosan suspended in paraffin (100 mg of zymosan in 4 ml of 
paraffin / 100 g of body weight). In all rats daily measurements were made of biological 
parameters, such as respiratory rate, body temperature and body weight. Clinical condition, 
loss of hemorrhagic fluid from the nose, conjunctivae and mouth, as well as loss of liquid 
stools was noticed. Also daily rectal contents were cultured aerobically for enterobac­
teriaceae (Levine EMB, Merck). 
At day twelve all surviving rats were given mild anesthesia with ether and were 
bled by heart puncture, which yielded 5 ml of blood, utilized for leukocyte count, 
differential cell count, trombocyte count, alkaline phosphatase, alanine aminotransferase 
(AAT), uric acid and lactate. Peritoneal fluid, rectal contents, MLN and blood were 
cultured aerobically for enterobacteriaceae (Levine EMB, Merck). Peritoneal fluid and 
blood were also cultured for unspecific bacteria (sheep agar). All samples were inoculated 
one day at 37° С Anaerobic cultures of peritoneal fluid and blood, were also cultured 
anaerobically, cultures being incubated for 5 days at 37° С 
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The kidneys, liver, spleen and lungs were removed and weighted. Relative organ 
weights were calculated by the formula: (organ weight/body weights) χ 100. After fixation 
with 4 % formaldehyde (the lungs also intratracheally at a pressure of 30 cm H20), 
microscopic sections of these organs were prepared for staining with hematoxylin eosin. 
In rats dying before day 12, examination was performed as in 12 day survivors, 
except for the blood biochemistry. Also no anaerobic cultures were performed, as post­
mortal anaerobic overgrowth was expected. 
Trimethoprim was used in the same dosage as described by Koopman et al (20) 
resulting in the elimination of enterobacteriaceae from the gastro-intestinal tract. The 
administration of the antibiotics was continued throughout the experimental period as, in 
an earlier study (16), recolonization with enterobacteriaceae occurred after stopping 
treatment. Trimethoprim leaves the rest of the bacterial flora relatively unaffected, which 
is important because colonization resistance against pathogenic microorganisms depends 
on the presence of a normal microflora. Streptomycin was used based on earlier results 
(20). The influence of streptomycin on the normal intestinal ecology is important, as 
compared with trimethoprim (21). Streptomycin thus is less suitable for selective decon­
tamination because, except for enterobacteriaceae, an essential part of the other intestinal 
ñora is also eliminated. 
In experiment A, 26 rats were randomized into 12 control and 14 SD rats. SD rats 
were given 2.5 ml intragastric trimethoprim solution (20 g/1) twice daily during five days 
preceding the experiment and once daily from day 0 to 12 of the experiment. The control 
group received the same amount of intragastric water. 
In experiment B, 52 rats were randomly assigned to 26 control and 26 SD rats. 
SD rats were given 2.5 ml intragastric streptomycin solution (25 g/1) twice daily during 
five days preceding the experiment and once daily from day 0 to 12, the control group 
receiving the same amount of intragastric water. 
In each experimental series (A and B) control and SD rats were handled exactly 
alike, at the same time, and in the same space. 
Statistical analysis was performed with the Kruskal-Wallis test and Wilcoxon's 
two sample test. Differences between groups were significant if ρ < 0.05. 
5.4 RESULTS 
Faecal cultures in the trimethoprim group consistently remained free of 
Enterobacteriaceae throughout the experiment. In the streptomycin group, the faeces of all 
rats were free of enterobacteriaceae at day 0, but subsequently recolonization occurred in 
13 rats. This recolonization was with streptomycin resistant enterobacteriaceae and 
occurred only after streptomycin had been utilized during 6 weeks in the experimental 
area. Recolonization did not seem to influence the clinical condition of these rats as 
twelve-day recolonized survivors were in a similar condition as enterobacteriaceae-free 
twelve-day survivors. 
The results as to survival are shown in figure 1. In the control groups early 
mortality was 42 % in experiment A and 65 % in experiment B. Bacterial translocation of 
enterobacteriaceae to the peritoneum and/or MLN was found in the majority (experiment 
A 5/5, experiment В 12/17) of these early deaths. While early mortality was similar to 
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controls іл the trimethoprim group (5 vs. 5, ns), it was significantly lower in the strep­
tomycin treated rats (4 vs. 17, ρ < 0.01). 
In the trimethoprim group, there was no significant difference in the number of 
twelve-day survivors between SD treated and control rats. In the streptomycin group, a 
significantly higher number of rats was alive at day twelve (18 vs. 6, ρ < 0.01). However, 
in both experimental series, SD treated survivors were clinically as ill as untreated 
controls. This is demonstrated by the absence of any significant improvement of SD vs. 
controls as concerns weight loss, respiratory rate, body temperature, serum lactate levels 
and relative organ weights (table 1). The only exception was a significantly higher alkaline 
phosphatase in group A SD rats as compared to group A controls. Also the morphology of 
the organs examined was not different between SD and control rats (data not shown). 
Fig 1-2 (page 67) 
Cumulative survival in experiments A (trimethoprim; broken line indicates intraperitoneal 
zymosan in 12 rats, and solid line, intraperitoneal zymosan and oral trimethoprim in 14 
rats) and В (streptomycin; broken line indicates intraperitoneal zymosan in 26 rats, and 
solid line, intraperitoneal zymosan and oral streptomycin in 26 rats) compared with 
controls. Surviving rats were killed at day 12. 
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Table 1. RESULTS OF BIOLOGICAL MEASUREMENTS, ORGAN WEIGHTS AND BLOOD 
ANALYSIS AT DAY 12* 
Experiment A 
Day 12 Normal values Controls (n=5) Trimethoprim (n=7) 
Respiratory rate, breaths per minute 
Temperature, °C 
Body weight, G 
RW lung 
RW kidney 
RW liver 
RW spleen 
Thrombocytes, χ 10'/L 
Leukocytes, χ lO'/L 
Polymorphoneclear leukocytes 
Monocytes 
Alanine aminotransferase, U/L 
Alkaline phosphatase, U/L 
Une acid, mmol/L 
Lactate, цтоІЛ* 
0.45 ± 0.01 
0 66 ± 0.02 
3.77 ± 0.21 
0.15 ± 0.01 
819 ± 39 
8.4 ± 0.6 
... 
30 ± 1 
64 ± 2 
153.2 
36.9 
254.2 
1.23 
0.52 
4.40. 
0.27 
.41 
.02 
37.5 
79 
130 
5.4 
± 
± 
± 
± 
± 
± 
± 
... 
± 
± 
± 
± 
± 
± 
28.4 
0.2 
17J 
0.44 
0.22 
0.75 
0.07 
1.0 
0.2 
6.9 
16 
10 
1.0 
153.5 
36.6 
255.6 
0.89 
0.54 
4.12 
0.24 
1113 
11.4 
.39 
.04 
44.1 
119 
110 
5.9 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
24.4 
1.0 
17.9 
0.24 
0.22 
0.46 
0.06 
131 
4.3 
.20 
.03 
13.7 
l e ­
so 
0.2 
Experiment В 
Day 12 
Respiratory rate, breaths per minute 
Temperature, °C 
Body weight, G 
RW lung 
RW kidney 
RW liver 
RW spleen 
Thrombocytes, χ 10'/L 
Leukocytes, χ lO'/L 
Polymorphoneclear leukocytes 
Monocytes 
Alanine ammotranferase, U/L 
Alkaline phosphatase, U/L 
Une scia, mmol/L 
Lactate, цтоІД* 
Normal values 
·· 
0.45 ± 0 01 
0.66 ± 0.02 
3.77 ± 0.21 
0.15 ± 0.01 
819 ± 39 
8.4 ± 0.6 
30 ± 1 
64 ± 2 
Controls (n= 
137.3 
36.7 
230.8 
0.99 
0.45 
3.64 
0.24 
1236 
9.5 
.44 
.01 
60.8 
214 
90 
5.1 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
=6) 
31.2 
0.4 
42.5 
0.46 
0.06 
0.54 
008 
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4.2 
.15 
.02 
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273 
30 
0.6 
Streptomycin 
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36.7 
247.2 
0.91 
0.41 
3.94 
0.27 
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± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
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(n=18) 
26.6 
0.6 
24.7 
0.50 
0.03 
0.84 
0.07 
310* 
3.5 
.13 
0.1 
8.2* 
48 
20 
0.8 
' RW uidicates relative organ weight [(organ weight χ 100)/body weight). Values are means ± SDs. 
•P<0.05. * * P < 0 . 0 1 . 
5.4.1 Bacteriology 
The bacteriological data are shown in table 2. Interestingly, in no instance 
bacterial translocation of enterobacteríaceae could be demonstrated in the early deaths of 
SD treated rats, except for three positive cultures of MLN, one in an early death and one 
in a late death of both group A and B. In both rats of group B, enterobacteríaceae were 
found in the faeces. In 4 trimethoprim treated rats (one early death) and 6 streptomycin 
treated rats (3 early deaths), bacterial translocation was found with other micro-organisms 
than enterobacteríaceae. Blood cultures (aerobic and anaerobic) showed no growth, except 
for two streptomycin treated rats, one dying at day two growing streptococci and 
Pseudomonas, and another dying at day twelve, growing staphylococci. 
Table 2. SURVIVAL RATES AND POSITIVE BACTERIAL CULTURES FOR ENTEROBACTERÍACEAE* 
NO SD SD 
EXPERIMENT A 
(trimethoprim) 
Total No. of rats 
Early mortality 
(<5d) 
Late mortality 
12-day survivors 
EXPERIMENT В 
(streptomycin) 
Total No. of rats 
Early mortality 
(<5d) 
Late mortality 
12-day survivors 
No. of rats 
12 
5 
2 
5 
26 
17 
3 
6 
Abdomen 
4(1G) 
0(0) 
0(0) 
... 
10 (9SAJF,G) 
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1(0) 
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0(0) 
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2(0) 
2(0) 
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17 
3 
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Figures represent number of rats. Figures in parentheses represent positive cultures for 
other micro-organisms. SD indicates selective decontamination; MLN, mesenteric lymph 
nodes; A, streptococci: B, Pseudomonas; С, Gram-negative rods; D, Gram-positive rods; 
E, Flavobacterium meningosepticum; F, Pasteurella pneumotropica; G, Bacillus spp; and 
H, staphylococci. Streptomycin-resistent Enterobacteríaceae. 
5.5 DISCUSSION 
The present study confirms that severe local inflammation, e.g. zymosan 
peritonitis, may induce bacterial translocation preferentially of enterobacteríaceae, to the 
peritoneal cavity and mesenteric lymph nodes. SD was found highly effective in 
preventing this bacterial translocation of enterobacteríaceae, though in the streptomycin 
group emergence of resistant strains was found in 13 rats. 
SD of enterobacteríaceae may account for the significant decrease of early 
mortality found in the streptomycin group. However, as compared to controls, no 
difference in early or late mortality was found in the trimethoprim group. Also 
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recolonization with streptomycin-resistant enterobactenaceae in the faeces did not seem to 
negatively influence the clinical course. Only two positive blood cultures were found in all 
experimental animals cultured, and both were in streptomycin treated rats, the micro-
organisms cultured being other than enterobactenaceae. 
The dosage of trimethoprim used in this experiment was similar to the dosage 
recommended by Toorop-Bouma et al (22), the dosage of streptomycin as used by Wells 
et al (23). 
Already in 1972 Cuevas and Fine (1) experimentally demonstrated that kanamycin 
injected directly into the intestine prior to the onset of bacterial peritonitis reduced the 
endotoxin titers in blood to 0 or near 0, and in the peritoneal fluid, to less than half that in 
the untreated rabbits reducing the mortality rate to 50 %. In the present study, no 
endotoxin levels were measured as zymosan in itself may induce positive Limulus tests 
(24). However, at day twelve clinical, moiphological and organ weight data were not able 
to discriminate between SD and control rats. 
The same observation was made in similar experiments in germ free rats where 
early mortality after intraperitoneal zymosan was significantly lower but late illness was 
similar to conventional controls (18). These data indicate that the early mortality in this rat 
model may largely be attributed to a severe generalized inflammatory reaction including 
extensive bacterial translocation in conventional rats. In rats surviving the first days 
however, a different type of illness develops after one week which seems to be 
independent of bacterial translocation. 
It has been demonstrated that inflammatory stimuli are able to sensitize PMNs 
and macrophages to subsequent very low doses of endotoxin (25). In this model, 
intraperitoneal zymosan thus may activate macrophages making them responsive to small 
amounts of endotoxin from the gut. It has been suggested by others that even in the germ 
free rat experiment (18) tiny amounts of endotoxin present in the standard germ free 
laboratory chow may result in late MOF. However, as no significant differences were 
found in SD rats and control rats such a mechanism would be independent of the amount 
of endotoxin present. It is highly unlikely that (the severity of) MOF would be indepen-
dent of the amount of endotoxin present, if endotoxin is its cause. 
In the present experiment, SD was started five days prior to the inoculation of 
intraperitoneal zymosan. In the clinical setting however, SD would only be started at the 
time the patient is admitted with severe peritonitis, with severe trauma or with ARDS. 
This, together with the concurrently present paralysis of the gastrointestinal tract, would 
impair the therapeutic advantage of SD. 
In our view, MOF and sepsis is the result of a severe generalized auto-
inflammatory reaction to massive stimuli such as major trauma, bacterial or non-bacterial 
peritonitis, where essentially activated macrophages play a dominant role, not essentially 
bacteria or endotoxins. The present animal model of MOF and sepsis induced by 
intraperitoneal inoculation of zymosan results in the same triphasic illness as in other 
models of chronic bacterial sepsis in rats (26-29). The same illness could also be induced 
by sterile inoculation of zymosan in the peritoneal cavity of germ free rats (15). Interes-
tingly, in germ free rats the early mortality was similar to the early mortality in the 
streptomycin group, while late illness at day 12 was similar in germ free rats, conventional 
rats without, and conventional rats with SD. These findings are in agreement with our 
hypothesis that sepsis with MOF is the result of a severe generalized auto-inflammatory 
response. However, it is not excluded that with other dosages or other antibiotic regimens 
for SD more favorable results may be obtained. 
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Chapter 6 
DECONTAMINATION OF THE GASTRO-INTESTINAL TRACT BY STREPTOMYCIN 
IN AN EXPERIMENTAL MODEL OF MULTIPLE ORGAN FAILURE. 
REDUCES MORTALITY BY A MECHANISM INDEPENDENT OF 
THE PRESENCE OF ENTEROBACTERIACEAE. 
IPT van Bebber, PHM Schillings, RJA Goris. Published in part in "Shock, Sepsis and 
Organ Failure". Second Wiggers Bernard Conference. G. Schlag, H. Redi, J.H. Siegel, 
D.L. Traber (eds.) Springer Verlag. Berlin. New York 1990. pp 461-491 
6.1 SUMMARY 
In conditions leading to multiple organ failure and sepsis, gut bacteria, especially 
enterobacteriaceae, have been demonstrated to translocate to the peritoneal cavity, to me-
senteric lymph nodes, liver and spleen, finally causing septicemia. In previous 
experiments, we demonstrated that decontamination of the gastrointestinal tract effectively 
prevented translocation of enterobacteriaceae to the abdominal cavity and mesenteric 
lymph nodes in zymosan induced multiple organ failure in the rat. 
In the present experiment, we studied the long term (33 days) effects of oral 
streptomycin in this model. In contrast to the control group, no mortality was found in the 
streptomycin group, while overgrowth of enterobacteriaceae occurred in the gut of 
streptomycin treated rats. Streptomycin administration did not decrease organ damage and 
all rats of both groups showed an acute phase with severe illness. 
It is concluded that oral administration of streptomycin in this experimental model 
prevented bacterial translocation of enterobacteriaceae and significantly decreased 
mortality by a mechanism unrelated to the presence of enterobacteriaceae. 
6.2 INTRODUCTION 
In conditions leading to multiple organ failure (MOF) and sepsis, gut bacteria, 
especially enterobacteriaceae (E), have been demonstrated to translocate to the peritoneal 
cavity, mesenteric lymph nodes (MLN), liver and spleen, finally causing septicemia (1,2). 
Meakins et al (3) described a syndrome of non-bacteremic clinical sepsis in patients 
showing the same clinical course and outcome as patients with demonstrable bacteremia, 
while no focus of infection could be found. In order to explain why these patients with no 
focus of infection still showed a prolonged septic process, Meakins et al. (4) suggested 
that the gastrointestinal tract (GI) is the "motor" of MOF. 
The upper GI tract is normally sterile, but overgrowth may occur by gastric 
hypoacidity, administration of antacids, or decreased small bowel motility. In severely ill 
intensive care (ICU) patients this results in colonization with gram-negative organisms. 
Changes in intestinal flora together with impairment of the mucosal barrier, allow the 
bowel to serve as a reservoir of pathogens that may enter the portal and systemic 
circulation and thus maintain the septic process. 
73 
Selective decontamination (SD) of the GI tract has been demonstrated to decrease 
nosocomial infections in ICU patients, but did not decrease mortality, duration of ICU 
stay, mechanical ventilation time, or the amount of therapeutic antacids and antibiotics 
administered as compared to controls (5-12). 
In a previous experiment, trimethoprim and streptomycin effectively prevented 
bacterial translocation of E in the zymosan induced MOF model. In contrast to 
trimethoprim, streptomycin administration resulted in a significantly lower mortality in the 
acute phase and in a higher number of 12-day survivors (13). 
The present experiment studies the long-term effects of streptomycin 
administration as to clinical outcome, mortality and relative organ weights in an 
experimental model of zymosan induced MOF. 
6.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemicals, St. Louis) 2.5 g was suspended by high frequency 
vibration in 100 ml of liquid paraffin. The suspension was sterilized by incubation in a 
water bath at 100° С for 80 minutes. Sterility was checked by incubation on blood agar 
plates for two days at 37° C. Before utilization, the zymosan suspension was warmed to 
40° С and vibrated at high frequency for 15 minutes. 
28 Male wistar rats (body weight 250 - 300 g) were randomly assigned to a 
control zymosan group (n=14) and a streptomycin treated group (n=14). At day 0, all rats 
received a sterile intraperitoneal injection of 100 mg zymosan / 4 ml paraffin / 100 g body 
weight. Streptomycin treated rats were given 2.5 ml intragastric streptomycin solution (25 
g/L) twice daily during five days prior to the zymosan injection and once daily from day 0 
to 12 of the experiment. The zymosan controls received the same amount of intragastric 
water. 
In all rats, respiratory rate, body temperature and body weight were measured 
daily. Mortality rate was recorded. Clinical observations of activity, loss of hemorrhagic 
fluid from the nose and conjunctivae and loss of liquid stools were performed. 
Aerobic cultures of faecal material were performed at day 0, 5, 13, 23 and 33 
according to the method of van Son et al (13) in which it is possible to assess semi-
quantitatively the concentration of faecal E. Spontaneously dying rats were investigated 
bacteriologically as follows. Peritoneal fluid was cultured aerobically for E on Levine 
EMB (Merck) and for unspecific bacteria on sheep blood agar plates. Rectal contents and 
MLN were cultured for E. In spontaneously dying rats, no anaerobic cultures were perfor­
med, as post-mortal anaerobic overgrowth was expected. The lung, liver, spleen and 
kidneys were dissected free and weighted. Relative organ weights were calculated. After 
fixation with formaldehyde 4 % (the lungs also intratracheally at a pressure of 30 cm 
H20), microscopic sections of these organs were prepared for staining with hematoxylin-
eosin, Sudan, Perls and APAS. 
After 33 days, surviving rats were bled by heart puncture. Blood was utilized for 
leukocyte count, platelet count, alanine aminotransferase (AAT), alkaline phosphatase 
(AF), creatinine, uric acid and lactate levels. Bacteriological investigation was performed 
as above. Besides, the peritoneal fluid and MLN were also cultured anaerobically. Blood 
was cultured aerobically and anaerobically. Relative organ weights were calculated and 
microscopic sections of organs were performed as described above. 
74 
Statistical analysis was performed with the chi-square test, Kruskal-Wallis test 
and Wilcoxon's two sample test. Differences between groups were significant if ρ ¿ 0.05 
0.05. 
6.4 RESULTS 
All rats in both groups reacted strongly the first two days, with lethargy, anorexia, 
hyperventilation, loss of hemorrhagic fluid from the nose and conjunctivae as well as 
liquid stools. One rat in the zymosan control group died at day 2. After day 3, rats 
clinically improved; they became more active and no loss of hemorrhagic fluid was seen. 
In both groups, respiratory rate increased progressively from day 0 and significantly so 
from day 2. After 10 days, respiratory rate remained high (Fig 1). In both groups, body 
temperature increased significantly from day 2 to 4. Body temperature in the zymosan 
control group decreased significantly between days 8 to 11 and days 16 to 20. Body 
temperature in the streptomycin group only decreased significantly at days 15 and 16. 
After 20 days, body temperature in both groups returned to normal levels (Fig 2). 
Body weight in the zymosan control group was significantly decreased from days 
3 to 15, however from day 10 on, animals were growing, resulting in a significantly 
increased body weight at the end of the experiment. Body weight in the streptomycin 
treated group was slightly decreased between days 2 to 12 but increased afterwards and 
significantly so at the end of the experiment (Fig 3). In the zymosan control group, 6 out 
of 14 rats died spontaneously at days 2, 10 (2x), 12, 15 and 21 while in the streptomycin 
treated group no mortality occurred (p = 0.016) (Fig 4). 
Fig. 1. 
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6.4.1 Bacteriology 
The results of bacteriological cultures are summarized in tables 1 and 2. In 
contrast to our previous streptomycin experiments, decontamination with streptomycin S 
days prior to the zymosan injection was not effective as faecal cultures remained positive 
for E at the day of zymosan injection, quantitatively comparable with the amount of E in 
faeces of the zymosan control group (lOMO3 / g faeces). Control faecal cultures at day 5, 
13 and 23 in the streptomycin treated group even showed a 100 - 1000 fold increase in 
streptomycin resistant E as compared to the faecal cultures in the zymosan control group. 
At day 33 the amount of faecal E in both groups was similar. 
In 4 out of 6 rats dying spontaneously, aerobic cultures of peritoneal fluid were 
positive for E while 2 out of 6 cultures remained negative. In 3 out of these 6 rats, MLN 
cultures were positive for E. 
At day 33, the day of sacrifice, blood cultures and cultures of MLN remained 
negative in both groups. In sacrificed streptomycin treated rats, no positive aerobic and 
anaerobic cultures of the abdominal fluid were found. In zymosan control rats, 2 out of 8 
aerobic cultures of the abdominal fluid were positive for E, gram + rods and enterobacter 
cloacae. In 1 out of 8 zymosan control rats, anaerobic culture of the abdominal fluid was 
positive for gram positive rods. 
Fig. 2. 
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6.4J Blood analysis 
The results of blood analysis are summarized in table 3. In survivors, no 
significant differences were found in leukocyte count, platelet count, uric acid, AF and 
lactate levels between the zymosan control group and streptomycin treated group. Creati-
nine in the zymosan control group was significantly higher as compared to the 
streptomycin treated group. AAT in the zymosan group was significantly less than the 
levels found in the streptomycin treated group. 
6.4.3 Organ weights 
No significant differences were found in relative lung weight, relative liver weight 
and relative kidney weight in survivors of both groups. Relative spleen weight in the 
zymosan control group was significantly higher as compared to the streptomycin treated 
group. Relative lung weight and relative kidney weight in spontaneously dying rats of the 
zymosan control group were significantly higher as compared to the survivors of the 
zymosan control group and streptomycin treated group (Fig 5). 
6.4.4 Microscopic findings 
The lungs of spontaneously dying rats of the zymosan control group showed 
interstitial edema, protein-rich intra-alveolar edema and an increase of PMNs. The lungs of 
rats dying at day 10 - 12 also showed increase of intra-alveolar macrophages and 
hemorrhage. The lungs of surviving rats of both groups showed interstitial edema, 
occasionally intra-alveolar edema, an increase of PMN count and a higher macrophage 
count as compared to spontaneously dying rats. The lungs of survivors also showed 
siderophages, lipophages and lipogranulomas. 
The liver of rats in both groups showed congestion and edema, widening of 
Disse's space, an increase of PMNs and Kupffer cells and sporadically lipophages and 
lipogranulomas. 
The spleen of survivors in both groups showed an increased number of PMNs in 
the capillaries, an increase of siderophages, extramedullaiy hematopoiesis, occasionally 
granulomas and a slight decrease of lymphoid tissue. In spontaneously dying rats, the 
spleen showed a significant decrease of lymphoid tissue. 
The kidneys of all rats showed widening of tubuli, an increased number of PMNs 
in glomeruli, cytoplasmatic granulation and stasis of erythrocytes in the capillaries. 
6.5 DISCUSSION 
In this experimental model, a severe systemic inflammatory response is induced 
by a local sterile intraperitoneal injection of zymosan, resulting in a triphasic illness within 
12 days with pathophysiologic and histopathologic alterations resembling MOF (14,15). 
Translocation of E to the peritoneal cavity and MLN has been demonstrated previously in 
this model (16). Administration of trimethoprim or streptomycin was highly effective in 
preventing this bacterial translocation of E (16). In contrast to trimethoprim, streptomycin 
administration resulted in a significantly decreased mortality in the acute phase 
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concomitant with a significantly higher survival rate at day 12. However, in both groups, 
12 day survivors showed a severe MOF-like syndrome (16). 
The dosage of streptomycin used in this experiment was similar to the dosage 
recommended by Wells et al (17). In the present experiment, decontamination with 
streptomycin S days prior to the zymosan injection was not effective, as at day 0 all faecal 
cultures in the streptomycin treated rats showed positive cultures for E. coli in the same 
amount as in the zymosan control group. Despite continuing daily administration of 
streptomycin up to day 12, intestinal overgrowth with E occurred. The acute response (day 
0-2) to the zymosan injection was the same in all rats, with lethargy, anorexia, loss of 
hemorrhagic fluid from the nose and conjunctivae and loss of liquid stools. Respiratory 
rate in the zymosan control group was higher as compared to the streptomycin treated 
group. Clinically, rats improved in the second phase (day 3-8) although respiratory rate 
increased in both groups. The loss of body weight in the zymosan control group was 
higher as compared to the streptomycin treated group. The third phase (day 9-12), was 
characterized by a progressive deterioration with increased respiratory rate, and a 
significantly decreased body temperature in the zymosan control group. 
In this experiment, observations were continued until day 33, while in previous 
experiments surviving rats were terminated at day 12. The fourth phase, after day 12, was 
characterized clinically by an almost complete recovery. Body temperature in both groups 
returned to normal levels and body weight increased progressively. In both groups, 
respiratory rate remained at an elevated level up to the end of the experiment. Strikingly, 
no rats in the streptomycin treated group died spontaneously (p = 0.016 as compared to 
the zymosan control group) despite important overgrowth of streptomycin-resistant E. The 
lung, liver, spleen and kidney in surviving rats in both groups showed no major diffe-
rences between groups. Probably all rats had severe lung damage in the third phase, as rats 
sacrificed at day 33 showed a 40 % - 60 % increase in respiratory rate up to the day of 
sacrifice. At day 33, lungs showed an increased number of siderophages indicating earlier 
hemorrhage. No protein-rich intra-alveolar edema was found at day 33. 
As in this experiment streptomycin administration was not effective in 
suppressing or preventing colonization with E, selective decontamination of E can not 
explain the improved survival. Another explanation thus is necessary and may be given by 
a direct effect of streptomycin on macrophage function. Conflicting data have been 
reported concerning the penetration of streptomycin into macrophages. Bonventre et al 
(18) showed the impermeability of mouse peritoneal macrophages to tritiated streptomycin. 
Ekzemplyarov (19) demonstrated that streptomycin enters the macrophage slowly and in 
small amounts. In vitro, a subliminal concentration of dihydrostreptomycin, too low to in-
fluence bacterial growth, caused macrophages to ingest and kill E. coli at a higher than 
normal rate (20). On the other hand, streptomycin has been suggested to decrease host 
resistance, inhibiting antibody production and phagocytic activity of macrophages (21,22). 
Although bacteria are not necessary in the development of zymosan induced 
MOF, the presence of bacteria results in a more severe acute reaction in conventional rats 
as compared to germ-free rats (14). Assuming a beneficial role of streptomycin on the 
phagocytic activity of macrophages, it is possible that translocated bacteria are directly 
ingested resulting in a decreased septic challenge. 
In this experiment, despite an overgrowth of streptomycin resistant E, 
streptomycin prevented translocation of E to the abdominal cavity and MLN. Streptomycin 
significantly reduced the mortality rate as compared to the zymosan control group but did 
not prevent signs and symptoms of multiple organ failure. 
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Table 1. POSITIVE FAECAL BACTERIAL CULTURES TOR ENTEROBACTERUCEAE (SURVIVORS) 
Faeces 
Day 0 
Day 4 
Day 7 
Day 17 
Day 33 
η 
14 
13 
13 
9 
8 
control group 
13 
9 
11 
8 
7 
η 
14 
14 
14 
14 
14 
streptomycin 
13 
14 
14 
14 
14 
Table 2. POSITIVE BACTERIAL CULTURES FOR ENTEROBACTERIACEAE (SURVIVORS). 
Blood 
MLN 
Abdomen 
η 
8 
8 
8 
control group 
0 
0 
1(2) 
η 
14 
14 
14 
streptomycin 
0 
0 
0 
Between brackets: positive cultures for other micro-organisms 
Table 3. RESULTS OF BLOOD ANALYSIS AT DAY 33. 
Leukocytes χ lO'/L 
Platelets χ lO'/L 
Lactate pmol/L 
Uric acid mmol/L 
AATU/L 
Alkaline phosphatase U/L 
Creatinine pmol/L 
18.8 
1059 
2265 
0.08 
30 
95 
41 
± 
± 
± 
± 
± 
± 
± 
6.9 
269 
2166 
0.03 
7 
51 
5 
16.0 ± 
1126 ± 
3511 ± 
0.09 ± 
38 ± 
88 ± 
49 ± 
4.5 
277 
J 365 
0.03 
9 
25 
6 
n.s. 
n.s. 
n.s. 
n.s. 
ρ <, 0.05 
n.s. 
ρ < 0.05 
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Chapter 7 
SUPEROXIDE DISMUTASE AND CAT ALASE IN AN EXPERIMENTAL 
MODEL OF MULTIPLE ORGAN FAILURE. 
IPT van Bebber, CFJ Lieners, EL Koldewijn, H Redi, RJA Goris 
J Surg Res 52: 265-270, 1992 
7.1 SUMMARY 
Multiple organ failure (MOF) can be induced by sterile intraperitoneal injection of 
zymosan in the rat. This results in a typical triphasic illness with maximal clinical signs at 
days 2 and 12. In this model, superoxide production and lipid peroxidation closely 
correlate with the triphasic clinical illness. In the present experiment we studied the effect 
of albumin conjugated superoxide dismutase (SOD) and catatase (CAT) on lipid perox-
idation and organ damage in the acute phase (days 1 and 2). 
Lipid peroxidation in plasma was significantly decreased by SOD and CAT but 
clinical condition, mortality and organ damage did not improve. We conclude that oxygen 
radical damage is not a key factor in the pathogenesis of the acute phase of multiple organ 
failure. 
7.2 INTRODUCTION 
The adult respiratory distress syndrome (ARDS) and multiple organ failure 
(MOF) with sepsis still are the most common causes of death in both trauma and 
peritonitis patients admitted to an intensive care unit. A common pathophysiology has 
been suggested for ARDS and MOF (1). Goris et al suggested that MOF is the result of a 
generalized autodestructive process of inflammatory character (2). Neutrophil derived 
oxygen free radicals (OFR) have been shown to play a significant role in acute 
inflammatory reactions. These highly reactive agents, especially the hydroxyl radical, can 
initiate cell membrane lipid peroxidation, thereby damaging the membrane integrity. OFR 
also react with proteinaceous materials in the plasma to produce chemotactic materials that 
attract phagocytic cells and lymphocytes into the area of injury (3). The radicals can 
likewise change microvascular permeability by causing an activation of the contractile 
mechanism of endothelial cells (4). OFR are assumed to be the main cause of organ 
damage in isolated organ studies such as in lung injury (5,6,7), liver injury (8,9) and 
kidney injury (10). Schoenberg et al (11) concluded that OFR in septic shock seem, at 
least partly, to be responsible for the observed damages of the so-called shock organs in 
sepsis. 
In our rat model of multiple organ failure we recently demonstrated OFR 
formation by activated PMNs as well as lipid peroxidation in plasma and in liver and lung 
tissue especially at days 1 and 2 (12). Administration of several hydroxyl radical scaven-
gers as well as an iron chelator did not result in a favorable therapeutic effect (13). 
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Treatment with SOD and CAT interferes earlier in the OFR generation. Half life of both 
enzymes can be increased by conjugation to albumin (14). The purpose of the present 
experiment was to study in this model the effect of SOD and CAT in relation to clinical 
outcome, mortality and the amount of lipid peroxidation products formed, such as TBAR-
reactive material, fluorescent products and conjugated dienes. 
We hypothesized that if the already demonstrated production of OFR in the acute 
phase of this model is a key factor in the pathogenesis of MOF, scavenging of these OFR 
had to improve clinical outcome and to decrease mortality. 
7.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemicals, St Louis), 2.5 g, was suspended in 100ml of liquid 
paraffin by high frequency vibration. The suspension was sterilized in a water bath at 
100° С for 80 min. Before intraperitoneal injection the zymosan suspension was warmed 
to 40° С and vibrated at high frequency for 15 min. 
Determination of thiobarbituric acid reactive material (TBAR): plasma and tissue 
TBAR material was quantified as malondialdehyde (MDA) by an improved modification 
of the TBA-test. Briefly, 0.5 ml of EDTA-plasma or 10 % tissue homogenate (in 1.25 % 
KCL) were incubated with 2 ml trichloric acid (1 %) and 1 ml of 0.67 % TBA for 1 hour 
at 100° С After cooling to room temperature the pink pigment was extracted with 4 ml 
butanol/pyridine (15:1 v/v) and measured either fluorimetrically (EX 532 nm, EM 555nm) 
or spectrophotometrically (Ε,^-Ε^)· Standard calibration was achieved with 
malondialdehyde-bis (diethylacetal). 
Determination of fluorescent products: 0.3 ml of plasma was extracted with 
CHCLj/MeOH (2:1), evaporated to dryness and redissolved in 2 ml n-hexane. 
Fluorescence measurements were carried out on a Hitachi F-4000 spectrofluorimeter. 
Determination of conjugated dienes: preparation of the solution is similar to that 
of fluorescent products; measurement was carried out at 233 nm. 
SOD was extracted from the bovine liver and conjugated to human albumin by a 
modification of Wong et al (15). 4 mg of SOD was incubated with 30 mg albumin in 1 ml 
0.02M NaH2P04 and 8 μΐ of 12.5 % glutaraldehyde. 8 μΐ of 12.5 % glutaraldehyde was 
added again after 2.5 hours. Incubation temperature was 4° С and total incubation time 
was 4 hours. The reaction was ended with 12 mg of glycin. The obtained pool of 
conjugates was separated in two fractions gelchromatographically (Sephadex G-200): a 
high molecular weight (HMW) (300kD-630kD) and a low molecular weight (LMW) 
(150kD-260kD) fraction. 1 ml of solution contains 6.300 U of SOD, measured according 
Misra and Fridovich (16). 
CAT was extracted from the bovine liver and conjugated to human albumin in a 
similar way as SOD: 5 mg of CAT and 30 mg of albumin were dissolved in 2 ml 0.02M 
NaH2P04. 0.5 ml of this solution was incubated with 5 μΐ of 12.5 % glutaraldehyde for 2.5 
hours at 4° С The reaction was ended with 12 mg of glycin. The obtained pool was 
separated in one fraction with a molecular weight of 115kD gelchromatographically. 1 ml 
of solution contains 20.000 U of CAT, measured according Beers and Sizer (17). 
N-Acetyl-B-D-glucosaminidase (NAG) activity was analyzed using 3 mM p-
nitrophenylglucopyranoside in acetate buffer (50 mM, pH 5.0) and incubated at 37° С for 
1 hour. Liberated p-nitrophenol was measured at 405 nm after adding 0.3 M glycinsodium 
hydroxide buffer (pH 10.6). 
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Ninety-one male Wistar rats (body weight, 230-280 g) were randomly assigned in 
4 groups. Group 1 (n=10) served as a bianco control group and received no intraperitoneal 
injection. 3 Groups received an intraperitoneal injection of zymosan suspended in paraffin 
(100 mg of zymosan / 4 ml of paraffin / 100 g body wt). 
Group 2 (n=27) served as a zymosan control group and received no treatment 
with SOD/CAT. Group 3 (n=27) and 4 (n=27) rats received SOD (LMW) / CAT and SOD 
(HMW) / CAT respectively. Surviving rats were sacrificed after 24 and 48 hours. (Table 
1). 
SOD (2.400 U / 0.4 ml / 100 g body wt) and CAT (8.000 U / 0.4 ml / 100 g 
body wt) were given 3 hours before the ip. zymosan injection intraperitoneally, 8 hours 
after the ip. zymosan injection subcutaneously and repeated 24 hours after the ip. zymosan 
injection subcutaneously in rats sacrificed after 48 hours. In all rats, body weight, body 
temperature and respiratory rate were measured daily. Mortality rate was recorded. At the 
day of sacrifice, rats were anesthetized in a closed space saturated with ether and were 
bled by heart puncture. Blood was utilized for leukocyte count, differential cell count, 
TBAR, fluorescent products and conjugated dienes. TB AR was also measured in lung and 
liver tissue. 
Statistical analysis was performed with the chi-square test, Kruskal-Wallis test 
and Wilcoxon's two-sample test Differences between groups were regarded significant if 
ρ й 0.05. 
Table 1. MORTALITY 
Group N Zymosan SOD/CAT Sacrifice 
Day 1 Day 2 
Mortality 
N % 
Blanco control 10 - - 10 
Zymosan control 27 + - 8 11 8 30 
SOOJLMW/CAT 27 + + 4 4 19 70* 
SODÇHMW/CAT 27 + + 7 7 13 48 
* Ρ < 0.05 when compared to zymosan control 
7.4 RESULTS 
All rats except the bianco controls showed symptoms of severe illness in the 
acute phase of this model such as lethargy, anorexia, hyperventilation, loss of hemorrhagic 
fluid from the nose and conjunctivae, and loss of liquid stools the first 2 days. Mortality 
rate in the zymosan control group was 30 %, in the SOD (LMW/CAT treated group 70 % 
which is significantly higher when compared to the bianco control group. Mortality rate in 
the SOD^n^/CAT treated group was 48 % (Table 1). Respiratory rate was increased in all 
groups when compared to bianco controls (Fig 1A). Body weight at day 2 decreased in all 
zymosan treated and zymosan control groups and was highest in the zymosan control 
group (Fig IB). Body temperature decreased strongly in all groups at day 1, recovered in 
the zymosan control and SOD^MW/CAT treated group at day 2 but remained at a subnor­
mal level in the 5 0 0
а м
 /САТ treated group (Fig 1С). 
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Fig la. 
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Fig le. 
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7.4.1 Blood analysis 
The leukocyte count in all groups was significantly decreased at days 1 and 2 
when compared to bianco controls. No significant differences were found between treated 
groups and the zymosan control group (Fig 2A). The differential cell count in the zymo­
san control group showed a significant decrease in PMNs at day 1 as compared to the 
bianco control and SOD/CAT treated groups. The drop in PMNs in the zymosan control 
group was significant at day 1 and only significant at day 2 in the zymosan control and 
SOD (HMW/CAT treated group (Fig 2B). The plasma level of NAG was increased in all 
groups when compared to bianco controls (Fig 3). 
TBAR in plasma at days 1 and 2 was significantly increased in the zymosan 
control group and treated groups when compared to bianco controls and was highest in 
the zymosan control group at day 2. TBAR in the SOD/CAT treated groups at day 2 
decreased significantly when compared to the zymosan control group (Fig 4A). Fluo­
rescent products were significantly increased in SOD (LMW/CAT treated rats at day 1 and 
in the zymosan control rats and SOD(HMW)/CAT treated rats at day 2 (Fig 4B). Conjugated 
dienes were significantly increased in SOD^MW/CAT treated rats at day 1 and in zymosan 
control rats and SOD ( H M W ) /CAT treated rats at day 2 (Fig 4C). TBAR in lung tissue at 
day 1 was slightly but not significantly increased in the zymosan control group and 
treated groups as compared to bianco controls while at day 2, no differences were found 
between groups (Fig 5A). TBAR in liver tissue was significantly increased in the zymosan 
control rats and SODÇHMW/CAT treated rats at day 2 (Fig 5B). 
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Fig 2a. 
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7.4.2 Microscopic findings 
In all rats sacrificed at days 1 and 2, interstitial edema was consistently found in 
the lungs. In all rats that died spontaneously at days 1 and 2, also capillary stasis of 
erythrocytes in the lung was present. In all rats the liver showed congestion, edema and in 
some cases local necrosis. Exhaustion of lymphoid tissue was found in the spleen of all 
rats. In the kidney, slight degeneration of tubuli was found. No major differences were 
found in histopathologic findings between treated and untreated rats (data not shown). 
7.5 DISCUSSION 
In this experimental model, a severe systemic inflammatory response is induced 
by local intraperitoneal injection of zymosan. Oxygen radical production and lipid 
peroxidation have been shown to play a role in the acute phase in this model especially at 
days 1 and 2 (12). Administration of hydroxyl radical scavengers e.g. mannitol, DMSO 
and DMTU did not result in a favorable therapeutic effect (13). Interfering in an earlier 
phase in the oxygen radical production is another option: SOD converts superoxide to 
peroxide and CAT converts peroxide to water. Many experiments confirm the beneficial 
role of SOD when administered in short term lethal rat or mice endotoxemia (18,19,20). 
Theoretically, administration of SOD alone may induce an overload of H202 with 
subsequent formation of hydroxyl radicals. To decrease the possible hydroxyl radical 
formation we preferred SOD in combination with CAT. 
Half life of unconjugated SOD and CAT is approximately 6 and 4 minutes 
respectively. Conjugation with albumin, as described earlier, increases half life of SOD 
and CAT up to 15.4 and 7.7 hours respectively when injected directly i.v. (21). In a pilot 
study, i.p. injection of conjugated SOD and CAT showed a peak activity in blood after 3 
hours. Conjugated SOD injected s.c. showed a delayed peak blood level between 6 and 16 
hours. Conjugated CAT injected s.c. also reached its peak activity after 6 hours but peak 
activity was maintained for 24 hours (21). Thus, to avoid disturbances in the intrape-
ritoneal uptake of conjugated SOD and CAT after i.p. zymosan, these enzymes were 
injected s.c. 
In the acute phase of this animal model, peripheral leukocytes and PMNs 
decreased significantly in all groups. The PMN count in the zymosan control group at day 
1 was significantly lower as compared to the SOD and CAT treated groups. A possible 
explanation is the scavenging of OFR and thus a decreased level of chemotactic 
substances (22). The aggregated PMNs are in an activated state producing OFR which 
oxidate unsaturated fatty acids with formation of lipid peroxidation products. As OFR 
production is not measurable after administration of exogenous SOD and CAT (pilot data 
not shown), OFR production was not measured in this experiment 
TBAR-reactive materials in plasma of zymosan control rats at days 1 and 2, and 
conjugated dienes and fluorescent products at day 2 are significantly increased when 
compared to bianco controls. SOD and CAT treated groups showed a significant decrease 
of TBAR-reactive material in plasma at day 2 when compared to the zymosan control 
group. Otherwise, conjugated dienes and fluorescent products in plasma in the zymosan 
control group only increased significantly at day 2, while the SOD^mw/CAT treated group 
showed a significant increase of these products at day 1. 
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Conjugated dienes and fluorescent products in plasma were significantly 
decreased in the SOD^w/CAT group when compared to the zymosan control group and 
SODQOW/CAT treated groups. Though SOD and CAT have been proven to decrease lipid 
peroxidation in this model, no improvement was found in clinical illness and mortality. In 
a pilot study, administration of conjugated SOD and CAT i.p. in normal rats did not 
change the clinical condition, relative organ weights or microscopic findings as compared 
to bianco control rats. Administration of high molecular complexes of bovine SOD, 
bovine CAT and human albumin in a zymosan injected (e.g. immune compromised) rat 
may give reactions that can even worsen the clinical outcome resulting in an increased 
mortality. Continuous infusion with unconjugated SOD and CAT may avoid this side 
effect. The difference in mortality between SOD^aw/CAT and SOD^M^/CAT may be 
explained by the extravasation of the low molecular weight complex through micropores, 
too small for high molecular complexes, thus creating a higher tissue oncotic pressure and 
increased interstitial edema. 
Fig3. 
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Another possible explanation is the inactivation of SOD by H202 and the 
inactivation of CAT by superoxide radicals as described by Fridovich et al (23,24). 
Protective intracellular mechanisms are present but may be insufficient when a high 
amount of SOD and CAT is administered. In the present experiment this is very unlikely 
as SOD and CAT have been proven to decrease lipid peroxidation in plasma. 
The results of these experiments confirm that OFR play a role in the acute 
phase of multiple organ failure in this model, though their scavenging does not improve 
survival and morphological alterations. 
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Fig 4b. 
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Chapter 8 
HYDROXYL RADICAL SCAVENGERS, IRON CHELATION AND C3 
CONVERTASE INHIBITION IN AN EXPERIMENTAL MODEL OF MULTIPLE 
ORGAN FAILURE. 
IPT van Bebber, R Meulemans, J Beaumont, PHM Schillings, RJA Goris. 
Published in part in "Shock, Sepsis and Organ Failure". Second Wiggers Bernard 
Conference. G. Schlag, H. Redi, J.H. Siegel, D.L. Traber (eds.) 
Springer Verlag. Berlin. New York 1990. pp 461-491 
8.1 SUMMARY 
Multiple organ failure (MOF) was induced by sterile intraperitoneal inoculation of 
zymosan in the rat This resulted in a typical triphasic illness with maximal clinical signs 
at days 2 and 12. In this model, polymorphonuclear granulocyte (PMN) superoxide 
production and lipid peroxidation closely correlated with the triphasic clinical illness. We 
studied the therapeutic effect of hydroxyl radical scavengers, an iron chelator and a 
complement-inhibitor in this experimental model. Longterm administration of these drugs 
did not influence the mortality or severity of MOF. Clinically, rats were severely ill in all 
groups. Though the role of oxygen free radicals in this experimental model has been 
demonstrated, administration of hydroxyl radical scavengers did not result in a favourable 
therapeutic effect. 
8.2 INTRODUCTION 
The syndrome of adult respiratory distress syndrome (ARDS) and subsequent 
failure of multiple organ systems (MOF) with sepsis presently is the most common cause 
of death in both trauma and peritonitis patients admitted to an intensive care unit (1). 
MOF with clinical signs of generalized sepsis is commonly attributed to bacterial sepsis, 
though positive blood cultures and bacterial foci could not consistently be demonstrated in 
large series of trauma and peritonitis patients with MOF (2,3). 
Neutrophil derived oxygen free radicals (OFR) have been shown to play a signifi-
cant role in acute inflammatory reactions (4) and have been implicated in the etiology of 
MOF (5,6). The toxic effects of OFR involve the induction of peroxidation of cell 
membrane phospholipids, resulting in an increased permeability of membranes (7) and 
endothelial-lined surfaces (8,9). It has been demonstrated that intraperitoneal injection of 
sterile zymosan in rats induces a triphasic illness with clinical, biochemical and 
morphological alterations, closely resembling MOF (10,11). The findings in this animal 
model closely resemble the findings in other models of chronic sepsis in the rat such as 
cecal ligation and puncture (12,13,14,15), while these changes could be induced in 
conventional as well as in germ-free rats (10). In this rat model we recently demonstrated 
OFR formation by activated PMNs as well as lipid peroxidation (16). We therefore 
hypothesized that free radical scavengers might decrease the deleterious effects of OFR 
and improve survival. Also iron chelation may prevent hydroxyl radical formation as Fe?* 
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catalysis the decomposition of superoxide and H2Oj into hydroxyl radicals. As zymosan 
directly activates the anaphylatoxins (C^CsJ (17), blocking Cj might decrease or prevent 
complement activation and subsequent activation of PMNs with OFR formation. 
In the present experiment, we investigated the role of hydroxyl radical scavengers 
(HRS) (mannitol, dimethylsulfoxide, dimethylthiourea) an iron chelator (dihydroxybenzoic 
acid) and an inactivator of the complement system (rosmarinic acid). In the present expe­
riment no beneficial effects were found and outcome was not improved. We conclude that 
interfering with the action of OFR by means of HRS or an ironchelator or a complement 
inhibitor in the dosages given, is not effective in preventing MOF in this animal model. 
8.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemicals, St. Louis) 2,5 g was suspended in 100 ml of liquid 
paraffin by high-frequency vibration. The suspension was sterilized in a water bath at 
100° С for 80 minutes. Sterility was checked by incubation on blood-agar plates for two 
days at 37° С Before intraperitoneal inoculation the zymosan suspension was warmed to 
40° С and vibrated at high frequency for 15 minutes. 
8.3.1 Hydroxyl radical scavengers (Experiment A) 
Forty-three male Wistar rats (body weight, 245 - 350 g) were cannulated for 
continuous intravenous (i.v.) drug administration. For this purpose rats were anesthetized 
i.p. with pentobarbital sodium (55 mg / kg body weight), and subsequently given inhala­
tion anesthesia with a mixture of 400 ml Oj/min, 500 ml N20/min and fluothane. The 
right jugular vein was cannulated with a silastic catheter (ID 0,5 mm -ED 1,0 mm) 4 days 
prior to the zymosan injection. The rats were kept in individual cages before and 
throughout the experiment and fed standard rat laboratory chow (Hope Farms RMH-B) 
and water ad libitum. Rats were randomized into four groups all receiving zymosan i.p., 
suspended in paraffin (100 mg zymosan / 4 ml of paraffin / 100 g body weight). Directly 
afterwards continuous i.v. drug administration was started, and continued throughout the 
experimental period of 12 days. The daily amount of medication for each individual rat 
was dissolved in saline to a total volume of 5 ml. Group 1 rats (n=ll) received 5 ml 
saline i.v. daily from days 0 to 12 and served as controls. Group 2 (n=10) received 
dimethylsulfoxide (DMSO) i.v. (200 mg / 100 g body weight). Group 3 (n=12) received 
mannitol i.v. (200 mg / 100 g body weight). Group 4 (n=10) received dimethylthiourea 
(DMTU) i.v. (20 mg / 100 g body weight). 
In all rats daily measurements were made of biological parameters as respiratory 
rate, urinary volume, loss of hemorrhagic fluid from the nose and conjunctivae, and 
presence of liquid stools. Body weight was measured at days 0 and 12. In spontaneously 
dying rats, aerobic cultures from the peritoneal fluid were taken. The lung, liver, spleen 
and kidney were dissected free and weighted. Relative organ weights were calculated by 
the formula [ (organ weight / body weight) χ 100 ]. After fixation with 4% formaldehyde 
(the lungs were also fixed intratracheally at a pressure of 30 cm Н
г
О), microscopic 
sections were prepared for staining with hematoxylin-eosin. 
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At day 12 all surviving rats were placed in a closed space saturated with ether 
and bled by heartpuncture. The following blood analyses were performed: platelet count, 
leukocyte count, differential cell count, alkaline phosphatase, alanine aminotransferase 
(AAT), urea, creatinine, uric acid and lactate levels. Blood and abdominal fluid were 
cultured aerobically and anaerobically on blood-agar plates. Relative organ weights of 
lung, liver, spleen and kidney were calculated and microscopic sections of these organs 
prepared. 
8.3.2 Hydroxyl radical scavenger, iron chelation, complement inhibition 
(Experiment B) 
Fifty-four male Wistar rats (body weight, 240 - 315 g) were randomized into four 
groups. All experimental procedures were identical to those in the first experiment. All 
rats received zymosan i.p. at day 0 in the dosage already mentioned. Group 1 (n=13) 
received 5 ml saline i.v. daily from day 0 to 12 and served as controls. Group 2 (n=14) 
received DMSO i.v. (200 mg / 100 g body weight). Group 3 (n=15) received 2,3,-
dihydroxybenzoic acid (DHBA) i.v. (10 mg / 100 g body weight). Group 4 (n=12) 
received rosmarinic acid (RMA) i.v. (100 mg / 100 g body weight). Statistical analysis 
was performed with the Kruskal-Wallis test and Wilcoxon's two-sample test. Results 
between groups were significant if ρ ¿ 0.05. 
8.4 RESULTS 
All rats, including those receiving treatment, showed the classical triphasic illness 
known in this model (10). The results as to survival are shown in table 1. Although the 
mortality rate in the control group in experiment A and В and the DMSO group in 
experiment В was lower, these differences were not statistically significant. No statistically 
significant difference was found in respiratory rate although DMSO treated rats had the 
lowest rate in the late phase of illness in both experiments. No significant differences were 
found in urinary volume. 
Table 1. MORTALITY 
Group 
Mortality 
Experiment A Controls 
DMSO 
Mannitol 
DMTU 
11 
10 
12 
10 
13 
14 
15 
12 
1 
3 
4 
4 
3 
3 
7 
7 
9 
30 
33 
40 
23 
21 
47 
58 
Experiment В Controls 
DMSO 
DHBA 
RMA 
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8.4.1 Body weight and organ weights 
Loss in body weight was minimal in expenment A controls and DMSO treated 
rats, and significantly more loss in body weight was found in expenment A DMTU treated 
rats. In expenment B, no significant weight loss was found between groups (Table 2). In 
experiment A relative liver weight was significantly increased in DMTU treated rats as 
compared to controls, DMSO and Mannitol treated rats. In experiment В relative liver and 
spleen weight were significantly increased in RMA treated rats versus controls. Other 
organ weights did not show significant changes. The lowest relative lung weights were 
found in DMSO treated rats in both experimental series (p й 0.10) (Table 3). 
Table 2. BODY WEIGHT IN SURVIVORS 
Day 0 Day 12 
Expenment A Controls 
DMSO 
Mannitol 
DMTU 
261.2 ± 26.9 
254.4 ± 22.0 
252.3 ± 33.7 
262.1 ±29.3 
258.5 ± 32.5 
252.9 ± 22.4 
235.0 ± 33.0 
220.9 ±35.8 ' 
Experiment В Controls 
DMSO 
DHBA 
RMA 
286.3 ± 25.1 
294.3 ± 16.3 
300.3 ± 14.7 
285.6 ± 6.8 
267.1 ±27.7 
268.3 ± 19.7 
267.8 ± 23.2 
266.8 ± 14.2 
* Ρ ¿, 0.05 (as compared to controls) 
Tabic 3. RELATIVE ORGAN WEIGHTS IN SURVIVORS 
Lung Liver Spleen Kidney 
Experiment A Controls 0.84 ± 0.40 
DMSO 0.70 ± 0.26 
Mannitol 1.23 ± 0.80 
DMTU 0.97 ± 0.63 
4.45 ± 0.41 
4.25 ± 0.33 
4.13 ±0.68 
4.93 ± 0.92* 
0.26 ± 0.05 
0.27 ± 0.07 
0.25 ± 0.08 
0.23 ± 0.06 
0.85 ± 0.07 
0.85 ± 0.02 
0.82 ± 0.06 
0.88 ± 0.06 
Experimente Controls 1.14 ±0.39 
DMSO 0.96 ± 0.42 
DHBA 1.29 ± 0.43 
RMA 1.20 ± 0.35 
3.41 ± 0.38 
3.66 ± 0.38 
3.44 ± 0.49 
0.26 ± 0.07 
0.28 ± 0.05 
0.26 ± 0.06 
3.83 ±0.34* 0.48 ±0.22* 
0.86 ± 0.13 
0.85 ±0.13 
0.79 ± 0.03 
0.90 ± 0.04 
* Ρ S 0.05 (as compared to controls) 
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8.4.2 Bacteriology 
In both experimental series, blood cultures were negative in all 12 day survivors. 
In experiment A, positive bacterial cultures of the abdominal fluid were found in 10 out of 
12 rats that died spontaneously. All rats sacrificed at day 12 had negative cultures of the 
abdominal fluid. In experiment B, positive bacterial cultures of the abdominal fluid were 
found in 4 out of 20 rats that died spontaneously. Three out of 34 rats sacrificed at day 12 
had positive bacterial cultures of the abdominal fluid. 
8.4.3 Blood analysis 
The results of blood analysis in experiment A and В are summarized in table 4 
and 5. In experiment A, the uric acid level was significantly decreased in DMTU treated 
rats as compared to controls and DMSO treated rats. DMTU treated rats also had 
significantly lower thrombocyte counts as compared to controls. In experiment B, the uric 
acid level was significantly decreased in RMA treated rats versus controls. Lactate levels 
were significantly increased in DHBA treated rats versus controls and RMA treated rats. 
No other significant changes were found between controls and treated rats in both experi­
ments. 
Table 4. RESULTS OF BLOOD ANALYSIS AT DAY 12 (EXPER[MENT A) 
Group 
Controls 
DMSO 
Mannitol 
DMTU 
Controls 
DMSO 
Mannitol 
DMTU 
Creatinine 
pmol/L 
38.6 ± 6.9 
35.2 ± 3.7 
41.8 ± 6.0 
36.3 ± 5.6 
Uric acid 
mmol/L 
0.09 ± 0.03 
0.10 ±0.01 
0.10 ± 0.05 
0.05 ± 0.03 
Urea 
mmol/L 
7.7 ± 0.9 
7.0 ± 0.9 
8.5 ± 2.9 
7.4 ± 1.7 
Lactate μιηοΙ/L 
3798 ± 1212 
3160 ± 531 
3966 ±1189 
3362 ± 1369 
Alk. Phos. 
U/L 
173.9 ± 262.4 
173.0 ± 121.9 
85.4 ± 24.3 
72.7 ± 23.4 
Trombocytes 
χ lO'/L 
1551 ± 241 
1522 ± 607 
1374 ± 177 
1229 ± 235 
AAT U/L 
35.2 ± 6.0 
34.9 ± 6.0 
39.3 ± 5.0 
33.7 ± 7.7 
Leukocytes 
χ lO'/L 
12.6 ± 4.8 
12.5 ± 2.3 
12.7 ±6.1 
15.3 ± 2.8 
Ρ á 0.05 (as compared to controls) 
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8.4.4 Microscopic findings 
In experiment A and В the general microscopic findings were qualitatively similar 
with those found in earlier experiments (10). The lungs showed interstitial and protein rich 
intra-alveolar edema, intra-alveolar hemorrhage and an increase in PMNs and macropha­
ges. The liver showed congestion and edema, widening of Disse's space and an increase in 
the number of Kupffer cells and PMNs. The spleen showed an exhaustion of lymphoid 
tissue, an increase of extramedullary hematopoiesis and an increase of PMNs. In the kid­
ney's widening of tubuli was seen with granulation of the cytoplasm, and an increase of 
PMNs in the glomeruli. 
In experiment A, lungs of mannitol treated rats showed an increase of intra-alveo­
lar edema and an increase in the number of interstitial and intra-alveolar macrophages as 
compared to controls, DMSO and DMTU treated rats. In DMTU treated rats PMNs in the 
liver were strongly increased. In DMSO, DMTU and mannitol treated rats, sequestration of 
PMNs in the glomeruli was more extensive than in control rats. 
In experiment B, lungs of DHBA and RMA treated rats showed an increase of 
intra-alveolar edema as compared to controls and DMSO treated rats. The intra-alveolar 
and interstitial hemorrhage was more obvious in DHBA treated rats. In the liver of RMA 
treated rats, stasis of erythrocytes was more obvious when compared with the other groups 
while PMNs were decreased. 
Table 5. RESULTS OF BLOOD ANALYSIS AT DAY 1 2 (EXPERIMENT B) 
Group 
Controls 
DMSO 
DHBA 
DMTU 
Controls 
DMSO 
Mannitol 
DMTU 
Creatinine 
pmol/L 
41.7 ± 4.8 
42.4 ± 4.6 
41.9 ± 8.6 
40.0 ± 1.2 
Uric acid 
mmol/L 
0.12 ± 0.04 
0.10 ± 0.02 
0.10 ± 0.02 
0.09 ± 0.02 
Urea 
mmol/L 
6.4 ± 0.9 
6.4 ± 1.1 
7.3 ± 1.1 
7.2 ± 1.0 
Lactate pmoI/L 
3781 ± 772 
4298 ± 1324 
4867 ± 1509 
3738 ± 403 
Alk. Phos. 
U/L 
84.6 ± 22.3 
75.2 ±22.1 
69.6 ± 12.1 
64.8 ± 13.1 
Trombocytes 
χ lO'/L 
1319 ± 392 
1207 ± 333 
1331 ± 350 
1079 ± 458 
AATU/L 
29.7 ± 4.0 
30.6 ± 6.0 
29.5 ± 3.7 
31.0 ± 1.9 
Leukocytes 
χ 107L 
16.2 ± 4.7 
14.7 ± 4.5 
16.0 ± 3.3 
14.0 ±4.1 
* Ρ £ 0.05 (as compared to controls) 
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8.5 DISCUSSION 
Oxygen free radicals are highly reactive oxygen species that can interact with 
almost any cellular component (18). Especially the hydroxyl radical is an extremely reac-
tive, unstable and powerful oxidant (19). In this 12-day experimental model of MOF, 
oxygen free radicals and lipid peroxidation have been demonstrated in the acute period 
(day 0 - 3) of the triphasic illness (16). 
DMSO has widely been used as a hydroxyl radical scavenger. Because cell 
membranes are highly permeable to DMSO, it has the potential to scavenge both intra-
cellular and ex-tracellular free radicals (20). DMSO has been used to decrease the effects 
of ischemia to the brain (21,22), to protect the bowel against ischemia in the rat (23,24), 
to reduce OFR induced pulmonary capillary endothelial permeability (25) and increase 
PaOj and 0 2 saturation in ARDS patients (26). Beilke et al (27) demonstrated that DMSO 
significantly suppresses the production of superoxide, hydrogen peroxide, and 
hypochlorous acid by human PMNs stimulated with either phorbol myristate acetate or 
opsonized zymosan. In this in vitro study, the optimal dosage of DMSO (100 - 300 
mmol/L) inhibited the oxidative function of stimulated PMNs but not their viability. 
Hypertonic mannitol has been used in patients with ARDS, resulting in an 
increase in cardiac output and effective alveolar ventilation (28), and in an increased 
oxygen consumption in the peripheral tissues (29). Weigelt et al (30) performed a 
randomized double-blind clinical trial to assess methylpredmsolone as prophylaxis of 
ARDS, using a placebo containing mannitol. The incidence of ARDS was 64 % in the 
steroid-treated group and 33 % in the placebo group. 
Fox et al (31) described a possible role of DMTU as a hydroxyl radical 
scavenger. In vitro, DMTU blocked 79 % of OH production by PMNs, without interfering 
with other PMN functions. In an isolated rat lung model perfused with activated PMNs or 
100 % 02, DMTU prevented pulmonary edema in respectively 70 % and 83 %. DMTU 
also had beneficial effects in endotoxin-induced ARDS in pigs (32) and in hyperoxia-
induced lung edema in rats (33). No beneficial effects could however be demonstrated in 
in vivo studies on paraquat toxicity in rats (34) and endotoxemia in sheep (35,36), as treat-
ment with DMTU was associated with increased lung injury and mortality while also renal 
and hepatic toxicity was noticed. 
In Fenton's reaction, generation of OH is catalyzed by Fe 2+ (H202 + Fe2+ —» OH 
+ OH" + Fe**). The iron chelator DHBA interferes in this reaction. In vitro studies showed 
the ability of DHBA to inhibit cell-membrane peroxidation, suggesting a scavenging 
function of free radicals. The para-situated hydroxy groups of DHBA have the capability 
of reacting with free radicals to form longer-lived semi-quinones which subsequently react 
with another free radical to form quiñones (37). By competing with microbial siderophores 
for the available extracellular iron, DHBA also exerts a bacteriostatic effect on pathogenic 
bacteria in the peritoneal cavity following peritonitis (38). In the CLP rat model, DHBA 
alone had no effect, but when used in combination with gentamicin a statistically signifi-
cant improvement in survival was achieved (39). 
RMA specifically inhibits complement activation by blocking Cj convertase (40). 
RMA also inhibits cyclooxygenase formation and the production of chemiluminescence 
and HJOJ by human PMNs during phagocytosis of bacteria (41). Administration of RMA 
in endotoxin treated rabbits, inhibited complement activation by 70 % but did not influ-
ence leukopenia or the formation of pulmonary edema (42). Nuytinck et al (43) using a 
rabbit ARDS model by infusing zymosan activated plasma, concluded that RMA inhibits 
103 
pulmonary edema and attenuates morphologic signs of inflammation. All the agents 
mentioned above have been used in vitro or in short-term in vivo studies with good, poor 
or even deleterious effects. 
In the present experimental series, the untreated zymosan injected rats showed the 
triphasic clinical illness known in this model (10). In the acute phase (day 0-3), signs of 
lethargy, anorexia, hyperventilation, loss of hemorrhagic fluid from the nose and 
conjunctivae and loss of liquid stools were observed. The rats improved temporarily up to 
day 8 and deteriorated progressively afterwards with increasing mortality. Clinically, rats 
in all treated groups were severely ill. The loss of body weight was higher in DMTU 
treated rats as compared to controls. Significantly higher lactate levels were found in 
DHBA treated as compared to control rats, probably reflecting more severe tissue hypoxia. 
Chronic DHBA toxicity studies initiated in normal rats in a dosage up to 200 mg/kg/day 
orally did not result in toxic effects (44). Up to 70 % of orally administered DHBA is 
excreted in the urine within 6 hours. Renal dysfunction may thus lead to higher serum 
DHBA levels. The high mean level of alkaline phosphatase in experiment A control rats 
was due to an exorbitant value in one rat In experiment A DMSO treated rats alkaline 
phosphatase levels rose above 100 U/L indicating possible hepatotoxicity. 
A modest result was achieved in DMSO treated rats. Though not significant, 
DMSO rats had the lowest relative lung weights as compared to controls (p <. 0.10) and 
other treatment groups, particularly mannitol and DHBA. Microscopic alterations in the 
lung and relative lung weight were highest in mannitol rats. 
Thus, longterm administration of hydroxy! radical scavengers, an iron chelator or 
a complement inhibitor in the dosages utilized, was not effective in preventing or 
attenuating a MOF-like syndrome in this experimental model. As OFR activity was clearly 
documented within this model, this result was unexpected. Possible explanations are that 
the drug administration started only after the zymosan injection. Therefore, it is not unlik-
ely that tissue perfusion was not optimal and that the drug did not reach the cell 
membrane in a sufficient amount to protect against OFR damage. Also, a secondary 
radical may have been formed after reaction with the added hydroxyl radical scavenger, 
which may in itself react as a toxic species. An example of this is the generation of 
methyl radicals and methyl peroxy radicals after reaction of OH with DMSO (45). 
Another possible explanation is the longterm administration of the drugs itself. In 
combination with liver and kidney dysfunction, dnig-half-life may have been increased. 
The half-life of DMTU 500mg/kg intraperitoneally in rats was 34 h (33), while this dosage 
resulted in renal and hepatic toxicity as well as increased lung injury (35,36). We reduced 
the DMTU dosage to 200mg/kg; nevertheless DMTU treated rats showed the highest 
weight loss, significantly increased relative liver weight and a mortality rate of 40 %. 
Mannitol treated rats in experiment A showed the highest relative lung weights as compa-
red to controls. Mannitol cannot move across cell membranes, is distributed in equal 
concentrations in plasma and interstitial fluid and is rapidly excreted by the kidney. Renal 
insufficiency, even of a mild degree, impairs the clearance of mannitol, leading to an 
expansion of the extracellular volume resulting in congestive heart failure and pulmonary 
edema (46,47). Mannitol may also induce renal failure (48). 
Though the formation of OFR in this experimental model has been demonstrated 
(16), administration of hydroxyl radical scavengers, an iron chelator and a complement 
inhibitor did not result in a favorable therapeutic effect. 
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Chapter 9 
THE OXYGEN RADICAL SCAVENGER U74006F IN AN 
EXPERIMENTAL MODEL OF MULTIPLE ORGAN FAILURE 
GAP Nieuwenhuijzen, IPT van Bebber, RIA Goris 
9.1 SUMMARY 
The effect of the novel non-glucocorticoid 21-aminosteroid inhibitor of lipid 
peroxidation U74006F was examined in a model of Multiple Organ Failure (MOF). MOF 
was induced by sterile intraperitoneal injection of zymosan in the rat This resulted in a 
typical triphasic illness with documented oxygen radical production and lipid peroxidation. 
In this experiment U74006F did not significantly improve the clinical condition, mortali­
ty-rate or organ damage. Thus, inhibition of lipid peroxidation by U74006F has not been 
successful in preventing or attenuating MOF in this model. 
9.2 INTRODUCTION 
Despite of advances in intensive care medicine, the Adult Respiratory Distress 
Syndrome (ARDS) and the subsequent Multiple Organ Failure (MOF) are still the most 
common causes of death of patients with severe trauma or peritonitis, who need admission 
to an intensive care unit (1). Bacterial sepsis has been generally advocated as the cause of 
this sequential deterioration of organ functions (2). But in large series of trauma patients 
with MOF no consistent correlation with bacterial sepsis could be demonstrated (3). 
Recently we developed an experimental rat model of MOF with intraperitoneal inoculation 
of sterile zymosan (4). This resulted in a chemical peritonitis and a triphasic illness. An 
acute hyperdynamic "septic" response with a 35 % mortality-rate, a phase of recovery and 
a third phase with severe pulmonary ARDS-like changes, liver function disturbances, lactic 
acidosis and microvascular changes in lung, liver and kidney with a IS % late 
mortality-rate. This triphasic illness resembled the clinical MOF-syndrome and could also 
be induced in germ free animals (4). Especially in the acute phase of this model, oxygen 
radical production and lipid peroxidation in plasma, liver and lung tissue are playing ал 
important role (5). 
Our hypothesis is that MOF is not the result of bacterial invasion but of an 
exaggerated generalized inflammatory response to conditions as severe trauma or 
peritonitis. Severe activation of the complement system (6) leads to margination and 
activation of polymorphonuclear leukocytes (PMNs), which release mediators, proteolytic 
enzymes and toxic oxygen radicals. Oxygen radicals can initiate lipid peroxidation of cell 
membranes and severely damage endothelial cells. This will cause an impairment of the 
microcirculation, microvascular thrombosis, changes in vascular permeability and 
subsequently generalized permeability edema (7-9). 
In other models of sepsis and septic shock, beneficial effects have been reported 
from the administration of superoxide dismutase or catatase and hydroxy! radical 
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scavengers such as dimethyl-thiourea, N-acetylcystein, dimethylsulfoxide and 2,3 dihy-
droxy-benzoic acid in combination with gentamicin (10-12). 
Recently superoxide dismutase and catatase conjugated to albumin have been 
applied in our model. This resulted in a decrease of lipid peroxidation but no improvement 
of clinical illness or mortality-rate was seen (S). As these conjugates might be potentially 
toxic a non-toxic inhibitor of the lipid peroxidation might have a favorable effect on the 
illness. 
U74006F is a new very potent inhibitor of lipid peroxidation in vitro and in vivo (13). It 
is part of a new class of therapeutic agents called the 21-aminosteroids, or lazaroids. It has 
the ability to inhibit lipid peroxidation without having glucocorticoid side effects, like 
methylprednisolone which is another known inhibitor of lipid peroxidation. The 
mechanism of this inhibition probably consists of a vitamin Ε-like scavenging of lipid 
hydroperoxides together with the scavenging of superoxide radicals (13,14). 
This article describes the effect of U74006F on the clinical signs, mortality-rate 
and organ damage of MOF in our model. 
9.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemicals, St Louis, USA) 2.5 g, was suspended by high 
frequency vibration in 100 ml of liquid paraffin. This suspension was sterilized by 
incubation in a water bath at 100° С for 80 minutes. Before utilization, the zymosan 
suspension was warmed to 40° С and vibrated at high frequency for 15 minutes. Sterility 
was controlled by incubation on a blood-agar medium. 
U74006F (Upjohn Company, Kalamazoo, USA) was obtained as an intravenous 
solution of 1,5 mg/ml and used in a recommended dose of 3 mg/kg i.v. initially, followed 
by 2 mg/kg i.v. three times a day. As vehicle served the U0000 solution from the same 
company. 
Two days before the experiment forty male Wistar rats (body weight 235-335 g) 
received a cannula for i.v. injection into the internal jugular vein and were randomly 
assigned into two groups of twenty rats. The rats were kept in individual cages and fed 
with standard rat chow and water ad libitum. 
On day 0, the U74006F group received a bolus of 3 mg/mL U74006F i.v. and the vehicle 
group a bolus of 3mg/mL U0000 i.v. Thirty minutes later all rats received an aseptic intra­
peritoneal injection of the zymosan suspension (100 mg of zymosan/4 ml of paraffin/lOOg 
body weight). After the zymosan injection the U74006F group received three times a day 
2mg/mL U74006F i.v. and the vehicle group the same dosage of U0000 i.v. 
In all rats, the following measurements were done daily from two days before the 
experiment untili twelve days after the start of the experiment: assessment of the clinical 
condition, body weight, rectal temperature, respiratory rate and mortality rate. 
When a rat died, the abdomen was opened under sterile conditions and samples of 
peritoneal fluid were collected for bacterial culture. The lungs with trachea, kidneys, liver 
and spleen were dissected free and weighted. Relative organ weights were calculated by 
the following formula: relative organ weight = (organ weight/body weight) χ 100. 
On day 12 all surviving rats were anesthetized in a closed space saturated with 
ether and bled by heart puncture and treated as above. Blood was used for bacterial 
culture. 
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Statistical analysis was performed with Wilcoxon's two sample test and the 
Kruskal-Wallis test. Differences were significant if Ρ ¿ 0.05. 
9.4 RESULTS 
9.4.1 Clinical condition and biological measurements 
All rats in both groups became severely ill shortly after the zymosan injection. 
They became lethargic, anorectic, lost hemorrhagic fluid from the nose and conjunctivae 
and lost liquid stools. In this acute phase seven rats died in each group (35 %). After three 
days all surviving rats improved, but after five days their clinical condition progressively 
deteriorated. At day 12 ten U74006F rats (50 %) and 11 vehicle rats (55 %) survived. 
The mean body weight of the rats had a similar course in both groups. A slight 
elevation of the body weight was seen on day 1, due to the zymosan injection, the 
following days the bodyweight showed a progressive decline. 
The mean respiratory rate showed a progressive rise in both groups. No 
significant differences were noted between both groups. 
In both groups the mean rectal temperature showed a rapid decline on the first 
day, followed by an improvement until! day 3 and finally a slow decline till the end of the 
experiment. No significant differences were noted between both groups. Figures 1 and 2 
summarize the biological measurements and mortality. 
9.4.2 Bacteriology 
In both groups all rats that died early had positive peritoneal bacterial cultures. 
The growth showed Escherichia coli and gram positive anaerobic rods. All rats that died 
later had negative peritoneal bacterial cultures. 
9.4.3 Macroscopic findings and organ weights 
In both groups the "early deaths" showed an extensive acute peritonitis. The gut 
was swollen, hyperemic and dilated. The lungs were slightly congested. 
In both groups post-mortem examination of the surviving rats showed an 
extensive fibroplastic peritonitis with massive adhesions and locally lipid-containing 
granulomas. There were no signs of acute peritonitis as in the "early deaths". The lungs 
showed extreme hyperemia with hemorrhagic spots and occasionally an extensive 
hemorrhagic infarction. The mean relative lung weight was significantly elevated 
compared with the "early deaths". All other organs were enlarged and their mean relative 
organ weights were significantly elevated compared with the "early deaths". 
In both groups there were no significant differences between the early deaths and 
the twelve day survivors as to any mean relative organ weight (Fig 3). 
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9.5 DISCUSSION 
In this experimental model, the local sterile intraperitoneal injection of zymosan 
induced a triphasic generalized inflammatory response as seen in earlier experiments (4). 
In the present experiment we utilized U74006F in a long term model of Multiple 
Organ Failure. No toxic effects of U74006F were noticed. U74006F did not influence the 
clinical outcome as measured by the clinical condition, rectal temperature and respiratory 
rate, nor did it influence the organ damage, as measured with relative organ weight. The 
relative organ weight is a good indicator of the organ damage because it has been shown 
to correlate well with the microscopic findings as edema and congestion of PMNs in the 
tissues (4). U74006F did not alter the mortality-rate of MOF in this model. 
U74006F has been shown in other short term experiments to inhibit lipid 
peroxidation and to improve recovery in experiments of central nervous trauma, cerebral 
ischemia, subarachnoidal hemorrhage, hemorrhagic shock and tissue ischemia (13-18). In 
these experiments, U74006F did not show any unfavorable toxic side effects. 
In models of septic shock, oxygen radical formation has been demonstrated 
(11,19) and inhibition of lipid peroxidation has been shown to have beneficial effects 
(10-12,20). 
While oxygen radicals are being produced in this long term model (5), prevention 
of lipid peroxidation by U74006F did not have any beneficial effect. Oxygen radical 
formation thus can only partly explain the organ damage in MOF. It seems that other 
lethal mediators, like neutrophil derived proteases and macrophage activation, might play a 
more important role in the general inflammatory response induced in this MOF-model. 
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Chapter 10 
FRUCTOSE 1-6 DIPHOSPHATE IN AN EXPERIMENTAL MODEL OF 
MULTIPLE ORGAN FAILURE. A PILOT STUDY. 
IPT van Bebber, HWHJ van Tits, RJA Goris 
10.1 SUMMARY 
Multiple organ failure was induced by a sterile intraperitoneal injection of 
zymosan/paraffin in the rat. It was hypothesized that in this model exogenous fructose 1-6 
diphosphate administration may restore the activity of glycolysis by intervening in the 
Embden-Meyerhoff pathway both as a metabolic regulator and as a high-energy substrate. 
Continuous i.v. administration of FDP in this model of multiple organ failure did not 
attenuate the severity of illness or decrease mortality. 
10.2 INTRODUCTION 
In any type of shock, endogenous energy production is severely decreased as a 
result of hypoperfusion and/or impaired oxygen utilization. Metabolic studies in shock 
indicate that the organism tends to compensate for decreased aerobically produced energy 
by accelerated anaerobic glycolysis (1). This initial burst of glycolytic activity is reflected 
by progressive metabolic acidosis secondary to elevated serum lactate levels. The resultant 
acidosis in turn progressively inhibits the Embden-Meyerhoff pathway, an alternative 
source of energy production in ischemia and hypoxia, by inactivation of the pH-sensitive 
rate-limiting enzyme phosphofructokinase (PFK) (2). 
Fructose-1,6-diphosphate (FDP) is an intracellular metabolite which plays a direct 
role in regulating many metabolic pathways. It enhances carbohydrate utilization by 
stimulating glycolysis while simultaneously inhibiting gluconeogenesis. FDP prevents 
glycogen breakdown and stimulates its synthesis. Lipid metabolism also is affected by 
FDP, which stimulates synthesis of fatty acids, triglycerides and phospholipids while 
inhibiting glycerol utilization (3). PFK synthesizes ГОР. On the other hand, PFK activity 
in normoxic, hypoxic and ischemic conditions can be influenced directly by the presence 
of FDP. FDP has the capacity to stimulate the activity of PFK by a direct feedback 
mechanism, and at the same time can be used anaerobically as a high-energy substrate. 
Use of FDP to enhance energy production by the Embden-Meyerhoff pathway in ischemia 
and shock has been assessed in a number of experiments. FDP administration in an 
experimental model of myocardial ischemia induced by occlusion of one coronary artery, 
improved left ventricular filling pressures and cardiac output, attenuated ECG-assessed 
myocardial injury, and significantly increased ATP and creatine phosphate in the ischemic 
myocardium (4). Following a one hour normothermic cardiac arrest in the dog, FDP 
administered directly or 30 minutes afterwards, resulted in pressure and contractility equal 
to those recorded during the pre-ischemic period (S). Myocardial injury induced by 
temporary occlusion of one of the major branches of the left coronary artery could be 
reduced by ГОР administration. This resulted in a decreased infarct size and an increased 
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cardiac output, arterial pressure, myocardial contractility and in a higher survival rate 
(6,7). 
Rats treated with FDP prior to or after an ischemic renal insult, showed 
significant functional and histologic protection of the kidney (8,9). FDP administered in a 
hemorrhagic shock model in the dog prevented circulatory collapse and attenuated tissue 
damage in several organs. Survival was found to be related to prevention of ATP and 
creatinine phosphate depletion in heart, lungs, intestines, liver and kidney cortex (10,11). 
Administration of FDP to endotoxin treated dogs restored mean arterial pressure, 
prevented intestinal fluid loss and preserved urinary output (12). Rats in traumatic shock 
showed significantly improved survival after FDP treatment (13). FDP treatment, espe­
cially in patients with substantial myocardial damage, increased cardiac index, attenuated 
ischemic myocardial injury, prevented ventricular airhythmias and reduced mortality (14). 
FDP treatment of patients with ARDS resulted in some beneficial effects on systemic 
hemodynamics and pulmonary function (15). FDP treatment to patients in traumatic shock 
decreased pulmonary vascular resistance (16). 
ARDS and multiple organ failure (MOF) can be induced by a sterile intrape­
ritoneal injection of zymosan in the rat, resulting in a triphasic illness with 
pathophysiologic and histopathologic alterations during 12 days (17,18). In the late phase 
(day 8-12) of this model, elevated lactate levels and decreased oxygen consumption are 
found (17). Increased oxygen free radical formation with lipid peroxidation is shown in the 
acute phase of this model (day 0-2) (19). FDP may also inhibit the generation of superox­
ide and hydrogen peroxide (20,21). 
In the present experiment, we studied the effects of FDP treatment on clinical 
outcome and mortality in this model. 
10.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemicals, St. Louis) was irradiated with 5 kGray; 2.5 g was 
suspended in 100 ml of liquid paraffin by high frequency vibration and sterilized at 
100° С Sterility was checked by incubation on blood agar plates for two days at 37° C. 
Before intraperitoneal injection the zymosan suspension was wanned to 40° С and 
vibrated at high frequency for 15 minutes. 
Fructose-1,6-diphosphate (FDP) (Sigma Chemicals, St. Louis) was dissolved in 
saline (10 % solution). The dosage for each rat was individually calculated daily. 
Twenty-three male Wistar rats (body weight, 300 - 325 g) were cannulated for 
continuous intravenous drug administration. For this purpose, rats were anesthetized i.p. 
with pentobarbital sodium (55 mg / kg body weight), and subsequently given inhalation 
anesthesia with a mixture of 400 ml Oj/min, 500 ml N20/min and fluothane. The right 
jugular vein was cannulated with a silastic catheter (ID 0.5 mm, ED 1.0 mm) 4 days prior 
to the zymosan injection. The rats were kept in individual cages before and throughout the 
experiment and fed standard rat laboratory chow and water at libitum. 
Rats were randomized into two groups all receiving 100 mg zymosan / 4 ml 
paraffin / 100 g body weight i.p. Group 1 (n=12) rats received FDP 35 mg / 100 g body 
weight i.v. 15 minutes prior to the zymosan injection and administration was continued 
with 50 mg FDP / 100 g body weight / 24 hours during 12 days. Group 2 (n=ll) rats 
served as controls and received an equal concentration of glucose/saline (10 % solution) in 
the same schedule as group 1. 
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The clinical condition was observed, respiratory rate was measured daily. Body 
weight was recorded at day 0 and 12. Mortality rate was recorded. In spontaneously dying 
rats, aerobic cultures were taken from the peritoneal fluid. The lungs, liver, spleen and 
kidney were dissected free and relative organ weights were calculated. The lungs were 
examined macroscopically. At day 12, surviving rats were bled by heart puncture and 
blood was utilized for leukocyte count, differential cell count and lactate levels. 
Abdominal fluid was cultured aerobically and anaerobically. All other experimental 
procedures were identical to those in spontaneously dying rats. Because of the small 
numbers of 12-day survivors, no statistical analysis was performed. 
10.4 RESULTS 
All zymosan injected rats were severely ill and there was no difference in clinical 
condition between groups. In the acute phase (day 0 - 2 ) rats were lethargic, anorectic and 
had loss of hemorrhagic fluid from the nose and conjunctivae and loss of liquid stools. In 
this acute period, 9 out of 12 FDP rats (75 %) and 7 out of 11 control rats (64 %) died 
spontaneously. Surviving rats improved temporarily but deteriorated progressively. In both 
groups, 2 rats survived the experimental period (Fig. 1). 
Respiratory rate increased with time in both groups (Fig 2). The mean decrease in 
body weight in rats dying in the late phase (day 9-12) and in the sacrificed group was 15 -
20 % (Table 1). 
Relative lung, liver and spleen weights were increased in the late mortality con-
trol group and in day-12 survivors of both groups (Table 2). The lungs of rats dying late 
and of day-12 survivors showed extensive hemorrhage. 
Leukocyte count, differential cell count and lactate did not show major 
differences between the day-12 survivors in both groups (Table 3). 
Bacterial cultures of the abdominal fluid remained negative in 3 rats dying at day 
1, in 1 rat dying at day 8 and in all day-12 survivors. The abdominal cultures of the other 
spontaneously dying rats were positive for E coli, proteus, streptococcus fecalis and 
enterobacter cloaca. 
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Table 1. WeCHT LOSS 
Ν 
acute mortality N late mortality 
Ν 
survivors day 12 
Glucose 7 
FDP 9 
+2 
-5 
-53 
-51 
2 
2 
-47 
-50 
Table 2. RELATIVE ORGAN WEIGHTS 
N 
Lung 
Liver 
Spleen 
Kidney 
acute 
Glucose 
7 
0.60 
3.65 
0.16 
0.76 
mortality 
FDP 
9 
0.73 
3.88 
0.14 
0.73 
late 
Glucose 
2 
0.95 
5.61 
0.31 
0.93 
mortality 
FDP 
1 
0.62 
3.67 
0.15 
0.87 
survivors 
Glucose 
2 
1.38 
4.81 
0.39 
0.80 
day 12 
FDP 
2 
1.25 
4.78 
0.35 
0.87 
Table 3. BLOOD PARAMETERS (IN DAY-12 SURVIVORS) 
Lactate (pmol/l) 
Leukocytes (lO'/l) 
PMNs (%) 
Lymphocytes (%) 
Glucose 
n = 2 
3604 
14.7 
45 
652 
FDP 
n = 2 
3181 
12 
54 
43 
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10.5 DISCUSSION 
Hidden tissue hypoxia and excessive serum lactate levels have been demonstrated 
in shock states and in patients with MOF (22,23,24), while elevated serum lactate levels 
are also found in animal models of chronic sepsis e.g. in this present model (17). During 
ischemia or hypoperfusion, phosphofractokinase (PFK) is inhibited by acidosis, 
inactivating the Embden-Meyerhoff pathway which is an alternative source of energy 
production in ischemia and hypoxia. One approach to bypass this metabolic block is to 
provide exogenous ГОР to stimulate PFK by a direct feedback mechanism as an 
anaerobical high-energy substrate. One molecule of glucose metabolized anaerobically, 
produces two molecules of ATP while one molecule of ГОР metabolized anaerobically 
produces four molecules of ATP. Lactate production remains the same, although the 
quantity of ATP produced is doubled. 
In this experimental model of MOF, FDP showed no beneficial effects in clinical 
outcome and mortality. To avoid osmotic differences between both groups, control rats 
were given glucose in the same osmolarity as FDP in the treatment group. Rats in both 
groups however, were severely ill showing a higher mortality rate in the acute phase as 
compared to previous experiments (17,19). Relative lung, liver and spleen weights were 
increased in rats surviving the experimental period. Macroscopically, the lungs in day-12 
survivors showed extensive hemorrhage. Relative organ weights and macroscopic aspects 
of the lungs are simple and reproducible parameters that correlate well with biochemical 
and biological parameters (17,19). 
Due to the small number of rats dying late or surviving 12 days, no statistical 
analysis could be performed with regard to relative organ weights, respiratory rate, body 
weight and hematologic parameters. 
The concentration of FDP we used was in accordance with the dosage used by 
Markov et al (16), showing beneficial effects in hemorrhagic, traumatic and endotoxic 
shock. The dosage of FDP we used did not exceed the LD,,,. The LD,,, of FDP when 
administered IV to dogs at the rate of 500 mg / min is approximately 5.18 to 6 g/kg. 
Significant increases in the rate of colloidal carbon clearance from the blood 
observed in FDP treated rats indicates that this agent exerts an influence on the phagocytic 
activity of the reticuloendothelial system (25). The high early mortality in this 
experimental series may thus be due to an increased phagocytosis of zymosan particles, 
and thus to increased stimulation of the immune system. However, no differences were 
found in mortality rate between the FDP treated and glucose treated rats. On the other 
hand, Cohn and Morse (26) have reported that functional and metabolic properties of 
polymorphonuclear leukocytes as well as the efficiency of continuing ingestion of bacteria 
and particles depends mainly on the availability of glucose. This may account for the 
deleterious effect in both groups. 
We conclude that long-term administration of FDP in a chronic model of MOF 
does not attenuate the severity of illness or decrease mortality. 
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Chapter 11 
ENDOTOXIN-SENSmVITY IS NOT ESSENTIAL IN THE PATHOGENESIS 
OF MULTIPLE ORGAN FAILURE. AN EXPERIMENTAL STUDY. 
IPT van Bebber, RHG Speekenbrink, PHM Schillings, RJA Goris. 
Prog Clin Biol Res 308: 419-423, 1989 
11.1 SUMMARY 
Bacteria and their endotoxins are believed to play a key role in the pathogenesis 
of multiple organ failure. However, multiple organ failure may be induced by 
intraperitoneal zymosan in normal rats as well as in germ free rats, indicating that bacteria 
are not a prerequisite in the pathogenesis of multiple organ failure. Endotoxin responsive 
Swiss, Black and СЗН/HeN mice, as well as endotoxin hypo-responsive СЗН/HeJ mice, 
were injected intraperitoneally with zymosan. Mortality rates were recorded. Body weights 
and temperatures were measured daily. After sacrificing, the relative organ weights of 
lung, spleen and kidney were measured. Routine histopathologic examination of these 
organs and the liver were performed. СЗН/HeN mice were in a slightly better condition 
when compared to СЗН/HeJ mice. We conclude that endotoxin-sensitivity and thus 
endotoxin probably is not essential in the pathogenesis of multiple organ failure. 
11.2 INTRODUCTION 
Bacteria and endotoxins are believed to play a key role in the pathogenesis of 
multiple organ failure (MOF). However, in MOF patients, blood cultures often remain 
negative (1,2). MOF also develops in patients with primarily non-bacterial problems such 
as severe pancreatitis or severe trauma before bacterial invasion is obvious. No single 
study has reliably demonstrated elevated levels of endotoxin preceding MOF (3,4). 
In normal rats, as well as in germ free rats, a MOF-like syndrome can be induced 
by intraperitoneal zymosan, showing that microorganisms are not a prerequisite in the 
pathogenesis of this syndrome (5). However, it has been suggested that zymosan sensitizes 
macrophages to very low doses of endotoxin (6). Endotoxins, present in standard labo­
ratory chow and/or drinking water, may therefore have contributed to the development of 
MOF in germ-free rats. Since it is technically impossible to provide endotoxin-free chow 
to the rats, we therefore set up an experiment with endotoxin-sensitive Swiss, Black and 
СЗН/HeN mice, and with endotoxin hypo-responsive СЗН/HeJ mice. 
Endotoxin is lethal for most mouse strains within 72 hours (LD,,,
 ж
 100 pg Esche­
richia coli K235 endotoxin) (7). Resistance to the lethal effects of endotoxin was one of 
the first phenomena demonstrated in СЗН/HeJ mice (8,9,10). The mutation responsible for 
the inability of СЗН/HeJ mice to respond to the lipid A moiety of endotoxin (Hpopolysac-
charide, LPS), has been mapped to a single gene located on the fourth chromosome (11). 
СЗН/HeJ macrophages also exhibit defective responses to endotoxin-induced proliferation 
of В lymphocytes (12,13), proliferation of splenic Τ lymphocytes (14), inhibition of 
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phagocytosis (15), glucose metabolism (16), fibroblast glucose metabolism (17), 
prostaglandin synthesis (18), tumor cytotoxicity (19), activation of the complement cascade 
(20), interleukin-1 (1L-1) production (21), hemorrhagic necrosis in subcutaneous sarcomas 
(22,23), interferon production (24) and colony stimulating factor production (25). In the 
СЗН/HeN, Swiss and Black strain, no abnormal macrophage function or endotoxin hypo-
responsiveness has been demonstrated. 
11.3 MATERIALS AND METHODS 
Zymosan (Sigma Chemicals, St. Louis) was irradiated with 5 kGray to kill spore-
forming micro-organisms. Zymosan, 2.5 g, was suspended by high frequency vibration in 
100 ml of liquid paraffin and incubated in a water bath at 100° С for 80 minutes. Sterility 
of the zymosan suspension was checked by incubation on blood-agar plates for two days 
at 37° С Before intraperitoneal (i.p.) injection, the zymosan suspension was warmed to 
40° С and vibrated at high frequency for 15 minutes. 
Black and Swiss mice were obtained from the central animal farm of the 
University of Nijmegen. СЗН/HeN and СЗН/HeJ mice were obtained from Charles River 
Wiga GmbH, West Germany and from Bomholtgard Ltd, Denmark, respectively. 
11.3.1 Experiment I 
Twenty male mice each of Black, СЗН/HeN and СЗН/HeJ strains were randomly 
assigned to experimental (n=15) or control (n=5) groups. All experimental mice received 
an aseptic i.p. injection of zymosan, suspended in paraffin (25 mg of zymosan in 1 ml of 
paraffin per 25 g body weight) at day 0. Control mice were not injected. The effect of 
paraffin in rats has been described previously and no significant differences were found 
when compared to control animals (5). For 13 consecutive days (day 0 - 12) body weights 
and temperatures were measured daily and recorded. The mortality rates were also 
recorded. 
11.3.2 Experiment II 
Twenty male mice each of Swiss, СЗН/HeN and СЗН/HeJ strain were randomly 
assigned to experimental (n=15) or control (n=5) groups. All experimental mice received 
zymosan i.p. (Img/g body weight). Body weights and temperatures were measured daily. 
The mortality rates were recorded. Surviving mice were sacrificed at day 12 and anaerobic 
and aerobic cultures made of abdominal fluid. In spontaneously dying mice, aerobic but 
not anaerobic cultures were taken since post-mortem anaerobic overgrowth can be 
expected. Lungs, spleen and kidneys were dissected free and weighted. Relative weights of 
these organs were calculated by the following formula: [ (organ weight/body weight) χ 
100 ]. Macroscopic examination of the lungs was performed. After fixation with 4 % 
formaldehyde (the lungs also intratracheally at a pressure of 30cm H20), paraffin sections 
were prepared for routine histopathologic examination of the lung, spleen, kidney and the 
liver in a semiquantitative way. The pathologist was blinded with regard to the 
experimental groups. 
126 
Statistical analysis was performed with the chi-square test, Kruskal-Wallis test 
and Wilcoxon's two-sample test. To compare the increase in relative organ weights, we 
used the straight forward statistical comparison of the quotient of means between two 
strains. Differences between groups were considered significant if ρ ^ 0.05. 
11.4 Results 
Clinically, all zymosan treated mice reacted strongly. In the first two days, mice 
were lethargic, anorectic, had diarrhoea and showed a ruffled fur. They recovered from 
this condition within two days and seemed to be in good health up to day 6 - 8 . From that 
period on, all Black and Swiss mice deteriorated progressively. Clinically, most C3H/HeJ 
and СЗН/HeN mice remained healthy during the 12-day experiment. 
11.4.1 Biological measurements 
Body temperature decreased about two or three degrees within half an hour after 
zymosan injection, increased during the first day and then remained at a subnormal level 
in experiment II СЗН/HeN and СЗН/HeJ mice. In experiment II Swiss mice however, 
body temperature decreased significantly from day 9 on when compared to СЗН/HeN and 
СЗН/HeJ mice (Fig 1A). Body weight increased by one gram in all experimental mice at 
day 0 due to the i.p. zymosan/paraffm suspension. Body weight decreased by 10 % in the 
first two days in all mice and recovered to the starting-weight in experiment II СЗН/HeN 
and СЗН/HeJ mice. In experiment II Swiss mice, body weight decreased progressively, a 
statistical significance being present from day 7 on (Fig IB). The course of body 
temperature and body weight in experiment I Black mice were similar with those in 
experiment II Swiss mice. No differences in body temperatures and weights were seen in 
experiment I and II СЗН/HeN and СЗН/HeJ mice (data not shown). 
In experiment I, mortality was low in the acute phase (day 0-2). At the end of 
experiment I, mortality was 13 out of 15 Black mice, 3 out of 15 СЗН/HeN mice and 2 
out of 15 СЗН/HeJ mice (Fig 2A). In experiment Π no mortality was found in the acute 
phase. All СЗН/HeN mice survived the experiment. Late mortality (day 8-12) was 2 out of 
15 СЗН/HeJ mice and 11 out of 15 Swiss mice (Fig 2B). 
11.4.2 Bacteriology 
In experiment Π, no bacterial translocation to the abdominal cavity could be 
demonstrated in СЗН/HeN mice. In one СЗН/HeJ mouse dying in the first phase, E coli 
was cultured from the peritoneal fluid. In two other СЗН/HeJ mice sacrificed at day 12, a 
few colonies of Staphylococcus xylosus and Staphylococcus aureus were cultured from the 
peritoneal cavity. Positive peritoneal fluid cultures were also found in 2 Swiss mice dying 
spontaneously; in one mouse hemolytic E coli was cultured, in the other E coli and 
Providencia pettgeri. No correlation was found between the presence of positive bacterial 
cultures and any other parameter. 
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11.4.3 Organ weights (experiment Π) 
Relative lung weights were significantly higher in Swiss control mice when 
compared to СзН/HeJ and СзН/HeN control mice. Relative spleen weights were 
significantly higher in CjH/HeJ control mice when compared to Swiss and CjH/HeN 
control mice. Relative kidney weights were significantly higher in СзН/HeJ control mice 
when compared to Swiss control mice and almost so when compared to СзН/HeN control 
mice (p=0.06). 
Relative lung weights were significantly increased in Swiss and C3H/HeN 
experimental mice when compared to controls (Fig ЗА). 
Relative spleen weights were significantly increased in all experimental strains when 
compared to their controls (Fig 3B). The increase in the relative spleen weight in Swiss 
experimental mice was significant when compared to the СЗН/HeN experimental mice. 
Relative kidney weights were significantly decreased in СЗН/HeJ experimental mice and 
almost so in СЗН/HeN experimental mice (p=0.06) when compared to controls (Fig 3C). 
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Fig 3b. 
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11.4.4 Macroscopic and microscopic findings (experiment Π) 
Macroscopic examination of the lungs revealed considerable differences between 
the strains. In the lungs of Swiss mice, severe diffuse hemorrhage was found in 13 cases 
and hemorrhagic spots in one case. Only one Swiss mouse had unaffected lungs. In 
СЗН/HeJ mice, the hemorrhage was less extensive with diffuse hemorrhage in two mice 
and hemorrhagic spots in five mice. Eight СЗН/HeJ mice had unaffected lungs. In 13 out 
of 15 СЗН/HeN mice no hemorrhage was found while in two hemorrhagic spots were 
found (Table 1). Microscopically, the lungs of the experimental Swiss mice showed 
interstitial and protein rich intra-alveolar edema, increased numbers of intra-capillary 
polymorphonuclear leukocytes (PMNs) and intra-alveolar macrophages, and most lungs 
showed extensive hemorrhage (Fig 4). Lungs of СЗН/HeN and СЗН/HeJ mice showed 
interstitial edema and increased numbers of PMNs and macrophages. Hemorrhage and 
protein rich intra-alveolar edema was limited in 7 СЗН/HeJ mice and almost absent in the 
СЗН/HeN mice (Fig 5). The liver of all experimental mice showed congestion and edema, 
widening of Disse's space and an increased number of Kupffer's cells. In Swiss mice 
however, extensive karyorrhexis and necrosis was found (Fig 6). In СЗН/HeN and 
СЗН/HeJ mice, the mitotic activity of hepatocytes was increased and was twice as much in 
СЗН/HeJ mice as in СЗН/HeN mice (Fig 7). The spleen of СЗН/HeN and СЗН/HeJ mice 
showed an increased extramedullaiy hematopoiesis while this was poor in Swiss mice. 
Exhaustion of lymphoid tissue in the spleen of СЗН/HeN and СЗН/HeJ mice was less 
pronounced when compared to Swiss mice. Kidney's in all strains showed an increased 
number of PMNs in the glomeruli with granulation of cytoplasm in tubular cells. 
Table 1. MACROSCOPIC ASPECTS OF LUNGS (ALL MICE EXPERIMENT II) 
extensive hemorrhage hemorrhagic spots no hemorrhage 
Swiss 13 1 1 
СЗН/HeJ 2 5 8 
СЗН/HeN 0 2 13 
11.5 DISCUSSION 
In this experimental model, a severe systemic inflammatory response is induced 
by a local aseptic intraperitoneal injection of zymosan with clinical, biochemical, 
morphological and bacteriological alterations resembling multiple organ failure (5). 
Recently, Steinberg et al (26) confirmed the usefulness of this model and concluded that it 
fulfills the criteria for a model of multiple organ failure. 
In the acute phase (day 0 - 2), all zymosan treated mice clinically showed the 
same response, characterized by loss of body weight, decreasing body temperature, 
lethargy and diarrhoea. This acute response was very similar to the response of rats 
injected with similar doses of zymosan i.p. in which this acute illness was associated with 
complement activation, activated PMNs, oxygen radical production and lipid peroxidation 
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in plasma, lung and liver tissue (27). Relative organ weights and histologic findings are 
simple and reproducible parameters that correlate well with biochemical and biological 
parameters as described previously (3). In our experience, it is justified to diagnose organ 
failure in this model with these parameters. As СЗН/HeJ mice are hypo-responsive to 
endotoxin, and as no differences were found when compared to Swiss, Black and 
СЗН/HeN mice, endotoxin and/or endotoxin sensitivity is probably not important in the 
acute phase response in this experimental model. 
All mice improved up to day 6. After day 6, progressive deterioration was found 
in Swiss mice as reflected by weight loss, a drop in body temperature and an increased 
mortality. Only Black and Swiss mice showed the classical zymosan induced triphasic 
illness known in this model (5). We expected that both СЗН/HeJ and СЗН/HeN mice 
would respond in a similar way to i.p. zymosan as Black and Swiss mice. Unexpectedly, 
both СЗН/HeJ and СЗН/HeN mice were resistant to multiple organ failure in this experi­
mental model. 
In this model of zymosan induced generalized inflammation, bacterial 
translocation has been found to the abdominal cavity as well as to mesenteric lymph nodes 
(5,29). In the present experiment, no significant differences were found in bacterial 
translocation to the abdominal cavity between the endotoxin-responsive and endotoxin-
hypo-responsive strains. 
Bacterial translocation to the abdominal cavity was never found in СЗН/HeN 
mice, while 3 out of 15 СЗН/HeJ mice had positive abdominal fluid cultures. These fin­
dings suggest that bacterial translocation does not necessarily depend on endotoxin or 
endotoxin sensitivity. 
Surprisingly, endotoxin hypo-responsive СЗН/HeJ mice showed a slightly -
though not significantly - increased incidence of hemorrhagic spots in the lungs, higher 
relative lung weights and a higher mortality as compared to endotoxin responsive 
СЗН/HeN mice. Since the QH/HeJ strain is endotoxin resistant and since no significant 
differences were found between both strains, we conclude that endotoxin-sensitivity and 
thus probably endotoxin is not essential in the pathogenesis of multiple organ failure. LPS 
antibody was not measured as the mechanism of endotoxin-resistance is a genetic one. 
We assume that resistance to zymosan induced multiple organ failure in СЗН/HeJ 
and СЗН/HeN mice is receptor dependent. Opsonized zymosan is bound to Fc and C3b 
receptors. The Fc receptor also regulates the activity of macrophages and PMNs (30). 
Activation of macrophages by endotoxin is decreased if the Fc and/or C3b 
receptors are blocked. Macrophages in the СЗН/HeN strain are activated by endotoxin, 
indicating a normal Fc and C3b receptor function (31). Vogel and Fertsch (32) demonstra­
ted a decreased Fc receptor function in СЗН/HeJ mice, reflected by a decreased 
endogenous production of interferon. Unopsonized zymosan is bound to mannose/N-acetyl-
D-glucosamin and complement receptors (33,34). Binding of unopsonized zymosan to 
these receptors leads to a respiratory burst (35). Dysfunction of these receptors to zymosan 
has been demonstrated in the СЗН/HeJ mouse. Such dysfunction in the СЗН/HeN strain is 
likely but has not yet been demonstrated. 
Further studies will be performed to understand the inhibited response to zymosan in 
СЗН/HeJ and СЗН/HeN mice. 
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Fig 4. Lung of a Swiss mouse showing intra-alveolar hemorrhage (H), protein-rich edema 
(Pr), macrophages (M) and granulocytosis of interalveolar capillaries (Î). 
(Hematoxylin-eosin, χ 480). 
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Fig 5. Lung of a СЗН/HeN mouse showing intra-alveolar protein-poor edema (Pp) and 
macrophages (M), and granulocytosis of interalveolar capillaries (T). (Hematoxylin-
eosin, χ 480). 
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Fig 6. Liver of a Swiss mouse showing diffuse liver cell degeneration and early necrosis 
(karyorrhexis). (Hematoxylin-eosin, χ 480). 
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Fig 7. Liver of a СЗН/HeN mouse showing moderate signs of liver cell degeneration 
(vacuolisation) and liver cell regeneration (mitosis (M)). (Hematoxylin -
eosin, χ 480). 
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Chapter 12 
l-OLEYbl-ACETYL-GLYCEROL IN AN EXPERIMENTAL MODEL OF 
MULTIPLE ORGAN FAILURE. A PILOT STUDY. 
IPT van Bebber, GBGJ van Rooij, RJA Goris 
12.1 SUMMARY 
Multiple organ failure was induced by a sterile intraperitoneal injection of 
zymosan/paraffin in the rat. In this model plasma levels of TNF are evaluated. It has been 
shown that oleyl acetyl glycerol (OAG) activates protein kinase С resulting in a decrease 
of TNF-binding capacity in vitro. We studied the effects of several dosages of OAG in 
this model. No beneficial result was seen as to clinical outcome. The mortality rate in the 
high-dosage OAG group was 100 %. 
12.2 INTRODUCTION 
Tumor necrosis factor (TNF) may represent the primary afferent signal that 
initiates many of the metabolic responses associated with sepsis and endotoxemia (1) and 
thus may play a role in the pathogenesis of the adult respiratory distress syndrome 
(ARDS) and subsequent multiple organ failure (MOF). In patients developing sepsis in the 
ICU, Damas et al (2) found a correlation between TNF plasma level and sepsis severity 
as well as with mortality. Intravenous administration of recombinant human TNF induces 
the same type of cardiovascular, hematologic, inflammatory and metabolic alterations that 
are found in endotoxic or septic shock (3). The strongest evidence implicating TNF as the 
principal mediator of MOF is that anti-TNF prevents the deleterious effects of 
endotoxemia and gram-negative shock (4). Like other cytokines, TNF-alpha confers its 
signal to target cells via binding to specific cell surface membrane receptors (5). There is 
general agreement that the presence of TNF-alpha receptors is a prerequisite for biologi­
cal responses to TNF-alpha, as cells with deficiency of TNF-receptors are TNF resistant 
(6). TNF receptors in activated T-cells can be rapidly modulated by activators of protein 
kinase С (PKC), resulting in loss of TNF-binding capacity, suggesting that PKC plays a 
key role in the control of TNF sensitivity (7). Unglaub et al (8) demonstrated that loss of 
TNF-binding capacity can be induced by the membrane permeable PKC activator oleyl 
acetyl glycerol (OAG), suggesting a direct phosphorylation of the receptor proteins which 
is effective at the level of TNF-receptor expression. 
MOF can be induced by a sterile intraperitoneal injection of zymosan in the rat, 
resulting in a triphasic illness with pathophysiologic and histopathologic alterations 
(9,10,). After an intraperitoneal zymosan injection in Swiss mice plasma TNF increased 
after one hour (11) to levels also found after endotoxin administration (12). In the present 
experiment we studied the effects of OAG on mortality and clinical outcome in this 
model. 
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12.3 MATERIAL AND METHODS 
Zymosan (Sigma Chemical, St. Louis) was irradiated with S kGray; 2.5 g was 
suspended in 100 ml of liquid paraffin by high frequency vibration and sterilized at 
100° С Sterility was checked by incubation on blood agar plates for two days at 37° С 
Before intraperitoneal injection the zymosan suspension was warmed to 40° С and 
vibrated at high frequency for 15 minutes. 
l-Oleyl-2-acetyl-glycerol (Sigma Chemicals) was dissolved in ethyl ether and 
glycerol 85 % (20/ig OAG/ml solution). The daily dosage for each rat was calculated 
individually and added to 1 or 5 ml total volume with saline and glycerol 85 % (3:1 v/v). 
The first problem is the dosage of OAG. Unglaub et al (10) incubated Τ cells with 100 
μΜ OAG / ml (= 39,8 ^g/ml). At this concentration OAG did not influence cell 
viability. An optimal protein phosphorylation in platelet activation was found at 100 μg 
OAG / ml (13). We studied the effect of a linear increase in dosages of OAG on 
mortality and clinical illness in this experimental model. To prevent a high viscosity in 
the high OAG concentration groups, the solution was dissolved to a total amount of 5 ml. 
The administered dosage of glycerol 85 % is not toxic in normal experimental animals. 
Twenty-three male Wistar rats (body weight, 300 - 325 g) were cannulated for 
continuous intravenous drug administration. For this purpose, rats were anesthetized i.p. 
with pentobarbital sodium (55 mg / kg body weight), and subsequently given inhalation 
anesthesia with a mixture of 400 ml Oj/min, 500 ml NjO/min and fluothane. The right 
jugular vein was cannulated with a silastic catheter (ID 0.5 mm, ED 1.0 mm) 4 days 
prior to the zymosan injection. The rats were kept in individual cages before and 
throughout the experiment and fed standard rat laboratory chow (Hope Farms RMB-H) 
and water at libitum. 
Rats were randomized into seven groups all receiving 100 mg zymosan / 4 ml 
paraffin / 100 g body weight i.p. Within 10 minutes continuous i.v. drug administration 
was started and continued throughout the experimental period of 12 days. Group 1 rats 
(n=3) received 1 ml of saline i.v. daily from days 0 to 12 and served as a control group 
for group 2, 3 and 4. Group 5 (n=3) received 5 ml of saline/glycerol (3:1) and served as 
a control group for group 6, 7 and 8. Group 2 (n=3), 3 (n=3) and 4 (n=3) received 35 
ng, 350 ng and 3.5 μg OAG / 100 g body weight respectively in a total volume of 1 ml 
saline/glycerol (3:1). Groups 6 (n=2), 7 (n=3) and 8 (n=3) received 3.5 μg, 35 /tg and 
350 μg OAG / 100 g body weight respectively in a total volume of 5 ml saline/glycerol 
(3:1). 
12.4 RESULTS 
All rats, including those receiving treatment, showed the classical illness known 
in this model (11). The first two days rats hyperventilated, were lethargic and anorectic, 
had loss of hemorrhagic fluid from the nose and conjunctivae and had liquid stools. In 
this acute phase, all rats in group 5, 7 and 8 died spontaneously as well as 2 out of 3 rats 
in group 1, 1 out of 3 rats in group 3 and 4, and 1 out of 2 rats in group 6. Group 2 
showed no acute mortality and only 1 out of 3 at day 8 (Table 1). Rats surviving the 
experimental period of 12 days were sacrificed; lungs were examined macroscopically and 
showed extensive hemorrhage and an increase in relative organ weight (data not shown). 
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Table 1. MORTALITY 
Group nr. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
OAG/100 g 
Control 
35 ng 
350 ng 
3.5/ig 
Control 
3.5 Mg 
35 μ 6 
350 μ& 
Ν 
3 
3 
3 
3 
3 
2 
3 
3 
Mortality (early) 
2 
-
1 
1 
3 
1 
3 
3 
Mortality (late) 
-
1 
-
-
-
-
-
-
12.5 DISCUSSION 
In vitro studies showed the beneficial role of protein kinase С activators e.g. 
OAG to down regulate TNF-binding capacity. However, no in vivo studies are known. 
In all treated and untreated groups, rats reacted strongly with the highest 
mortality in group 5, 7 and 8. 
PKC is a strong second messenger and its activation depends on Ca2+ as well as 
phospholipids and diaglycerol. OAG can be readily intercalated into intact cell membranes 
and dispersed in the phospholipid bilayer, directly activating PKC (13). The role of PKC 
in stimulus-response coupling has been shown for a wide variety of cell types and for 
many other cellular processes (14) such as in inflammation and immune systems. Neutro­
phil response to PKC may induce superoxide generation (15,16) and lysosomal enzyme 
release (17). Platelets react with serotinin release (18), lysosomal enzyme release (19), 
arachidonate release (20) and tromboxane synthesis (21). Basophils and mast cells release 
histamine (22,23) and Τ and В lymphocytes are activated (24,25). In this experimental 
model of multiple organ failure, PMN oxygen radical production, lipid peroxidation and 
lysosomal enzyme release correlated well with the triphasic clinical illness and with the 
morphologic alterations (26). Goris et al suggested that MOF is the result of a generalized 
autodestructive inflammation (27). The above mentioned PKC-induced responses in the 
inflammatory systems may actually increase the reaction to the septic challenge of 
zymosan and thus explain the high mortality in the high OAG concentration groups. We 
conclude that although OAG can decrease TNF-binding capacity in vitro, OAG 
administered in an in vivo model of MOF leads to increased mortality, possibly due to an 
excessive stimulation of PKC. 
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Chapter 13 
TUMOR NECROSIS FACTOR AND MONOCLONAL ANTI-TNF 
IN AN EXPERIMENTAL MODEL OF MULTIPLE ORGAN FAILURE. 
IPT van Bebber, LH Ferner, WA Buurman, RJA Goris 
13.1 SUMMARY 
Multiple organ failure (MOF) was induced by sterile intraperitoneal injection of 
zymosan in the mouse. This resulted in a typical triphasic illness with maximal clinical 
illness at days 2 and 12. We studied the effect of monoclonal antibody anti-tumor necrosis 
factor (TN3) in this experimental model. Mortality rate was recorded. Body weight and 
body temperature were measured daily. Relative organ weights of lung, spleen and kidney 
were calculated. Lungs were examined macroscopically. A single bolus injection of TN3 
3.5 hrs prior to the zymosan injection did not influence mortality or organ damage after 12 
days. 
13.2 INTRODUCTION 
The adult respiratory distress syndrome (ARDS) and subsequent multiple organ 
failure (MOF) still is responsible for 60-80 % mortality in intensive care patients. 
Nuytinck et al (1) suggested a common pathophysiology of both syndromes. Despite 
intensive investigations, their pathogenesis remains unclear. Recent evidence suggests that 
the biosynthesis and release of endogenous cytokines especially tumor necrosis factor 
(TNF), trigger the inflammatory responses of MOF. TNF has been shown to possess 
various immunomodulatory properties by enhancing inflammatory and immune processes 
in many different ways. Michie et al (2) concluded that TNF may represent the primary 
afferent signal that initiates many of the metabolic responses associated with sepsis and 
endotoxemia. Damas et al (3) found a correlation between TNF plasma level and sepsis 
severity score as well as with mortality in patients developing sepsis in the ICU. On the 
contrary, de Groóte et al (4) showed that TNF levels did not predict ARDS, shock 
disseminated intravascular coagulation, renal failure or mortality. 
Intravenous administration of recombinant human TNF induces the same type of 
derangements in cardiovascular, hematologic, inflammatory and metabolic functions that 
are found in endotoxic or septic shock (5,6). Endotoxin injected in normal human 
volunteers resulted in peak serum TNF levels within 90 min after challenge (7). 
Administration of TNF in rabbits resulted in an increased trans-endothelial passage of 
albumin (8), and in guinea pigs in an increased pulmonary permeability and edema (9) 
suggesting that TNF might contribute to the pathogenesis of acute lung injury. TNF 
directly activates polymorphonuclear leukocytes (PMN) (10,11,12), stimulates Chemotaxis 
of immunocompetent cells and increases their binding to endothelial cells (13,14,15) and 
enhances expression of complement receptors on neutrophils (16,17). Besides these 
cellular effects, TNF increases production of several inflammatory mediators such as plate 
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let activating factor (18), prostaglandins and collagenase (19) and the colony stimulating 
factor GM-CSF (20). The strongest evidence implicating TNF as a mediator of MOF is 
that TN3 prevents the deleterious effects of endotoxemia or gram-negative septic shock. 
Mice passively immunized against TNF are protected against the lethal effects of 
endotoxemia (21). Baboons, given a lethal intravenous dose of E coli two hours after TNF 
monoclonal antibodies, did not develop septic shock or the associated pulmonary edema 
and ventilatory failure and survived the septic challenge (22). 
In the present experiment, we studied the effects of anti-TNF administered prior 
to a strong inflammatory challenge, on mortality and clinical outcome in a rat model of 
multiple organ failure. 
13.3 MATERIAL AND METHODS 
Zymosan (Sigma chemicals, St. Louis) 2.S g was suspended in 100 ml of liquid 
paraffin by high frequency vibration. The suspension was sterilized in a water bath at 
100° С for 80 minutes. Sterility was checked by incubation on blood agar plates for two 
days at 37° С Before intraperitoneal injection the zymosan suspension was warmed to 
40° С and vibrated at high frequency for 15 minutes. 
Monoclonal antibody TN3 (obtained from Celltech, Slough, UK) 0.5 mg/ml was 
buffered in a phosphate buffer. 
33 Male Swiss mice were randomly assigned to three groups. Group 1 (n=4) 
served as a bianco control group. Group 2 (n=14) and 3 (n=15) received 100 mg zymosan/ 
4 ml paraffin / 100 g body weight intraperitoneally. Group 3 was treated with 0.5 ml TN3 
(= 12.5 pg/g body weight), group 2 received only 0.5 ml phosphate buffered saline (PBS). 
Both TN3 and the PBS were injected intraperitoneally 3.5 hours prior to the zymosan 
suspension. 
In all mice daily measurements were made of body temperature and body weight 
and clinical condition was observed from day 0 to 12. In mice dying before the end of the 
experimental period, aerobic cultures from the peritoneal fluid were taken. The lung, 
kidney and spleen were dissected free and weighted. Relative organ weights were 
calculated. The lungs were examined macroscopically. At day 12 surviving mice were 
placed in a closed space saturated with ether and bled by a retro-ocular puncture. 
Abdominal fluid was cultured aerobically and anaerobically. All other experimental 
procedures were identical to those in the spontaneously dying mice. 
Statistical analysis was performed with the Kruskal-Wallis test and Wilcoxon's 
two sample test. Differences between groups were significant if ρ á 0.05. 
13.4 RESULTS 
All zymosan injected mice were severely ill and showed no differences in clinical 
condition between groups. In the acute phase (day 0-2) mice were lethargic, anorectic, had 
a hunched back, a ruffled fur and diarrhoea. They improved temporarily but deteriorated 
progressively after day 8. No significant differences were found in mortality rate: 5 out of 
14 zymosan mice and 6 out of 15 anti-TNF treated mice died before day 12 (Fig 1). 
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Body temperature decreased significantly from 37.5° С to 34° С in group 2 and 3 
and remained at this level for at least 2 hours (Fig 2A). Body temperature normalized 
from day 3 to 8 but again decreased significantly in group 2 from day 8 to 12 and in 
group 3 from day 9 to 12 reflecting the clinical condition (Fig 2B). Body weight was 
significantly decreased at all days in group 2. Although body weight in group 3 decreased, 
this decrease was not significant as compared to day 0 (Fig 3). 
Abdominal cultures of spontaneously dying mice were positive in 2 out of 5 
group 2 mice and 5 out of 6 group 3 mice. Most frequently, E coli and enterobacter 
cloacae were cultured, sporadically also staphylococcus aureus and pasteurella pneu-
motropica. 
Relative lung weights and relative spleen weights of surviving mice were 
significantly increased in group 2 and 3 as compared to the bianco control group. No 
significant differences were found between the zymosan and the TN3 treated group (Fig 
4). Macroscopically, lungs of all sacrificed group 2 and 3 mice showed extensive 
hemorrhagic spots or even total hemorrhage. 
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13.5 DISCUSSION 
Zymosan induced MOF in the rat and mouse has already extensively been studied 
(23,24). This non-bacterial, non-endotoxic local inflammatory stimulus results in functional 
and micrpscopic alterations in remote organs in normal rats as well as in germ-free rats 
(23). The role of polymorphonuclear leukocytes, oxygen free radicals and lipid 
peroxidation has been demonstrated in the acute phase of this illness (25). The same type 
of illness may be induced in Swiss mice but hardly in endotoxin-resistant C3H/HeJ mice 
and endotoxin responsive QH/HeN mice (26). Exogenous TNF administration in СзН/HeJ 
and CjH/HeN mice results in toxic effects resembling those after endotoxin administration 
(27). 
Asmuth et al (28) showed increased TNF plasma levels 1 hour after 
intraperitoneal zymosan injection in Swiss mice, comparable to TNF plasma levels found 
after endotoxin administration (7,29, 30). Administration of TN3 prior to the zymosan 
injection in Swiss mice significantly decreased the acute mortality (28). However, no 
results are known concerning the long-term effect of TNF in this model. 
In the present experiment no beneficial effect was seen on mortality rate, clinical 
condition, body temperature, relative lung and spleen weight as well as macroscopic 
hemorrhage in the lungs. TNF has strong pyrogenic properties (31), although mice passi­
vely immunized against TNF still became febrile, ill and distressed (21). TNF stimulates 
endothelial cells to release IL-1 (32,33), having a wide variety of toxic effects broadly 
overlapping TNF effects (34). As IL-1 may be directly produced by activated macrophages 
without TNF interference, it may induce effects similar to TNF, but not influenced by 
TN3. 
We conclude that, although the role of TNF in sepsis and MOF has been proven by many 
authors, TN3 is not successful in preventing MOF in a long term model of zymosan 
induced MOF. 
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Chapter 14 
SUMMARY AND CONCLUSIONS. 
This summary presents the results of our experiments in order to give answer to 
the questions already stated in 'The aim of this thesis" (chapter I 1.10). 
Is ît possible to induce" a MOF-like syndrotne jcesemblitig thfc findings i» endotoxit» of 
bacteria-indue«! MOF by means of a non«bücteriaL, non-endotoxie, local inflammatory 
stimulus in conventional tats ss well as in germ free rats (chapter 2)7 
The first aim of the present thesis was to develop an experimental animal model 
of MOF mimicking as closely as possible the clinical syndrome, and other small 
laboratory animal models of bacteria or endotoxin induced chronic sepsis, by utilizing a 
non-bacterial, non-endotoxic, "chemical" stimulus. Therefore we induced prolonged 
activation of the alternative complement pathway and continuous macrophage activation in 
rats and mice by an intraperitoneal injection of zymosan suspended in paraffin. 
In our experimental series, zymosan in a dosage of 100 mg suspended in 4 ml of 
paraffin per 100 g body weight, resulted in a triphasic illness. The first two days - the 
acute phase - rats were lethargic, anorectic, had a ruffled fur and hunched back, developed 
tachypnea and tachycardia, increased oxygen consumption, fever, showed loss of 
hemorrhagic fluid from the nose and conjunctivae, diarrhoea or no fecal production. 
In this acute phase, mortality generally was 30 %. Biochemically, this period was 
characterized by a decrease of CH,,, which indicates complement activation. Complement 
activation resulted in a sequestration of PMNs which was reflected by a significant 
decrease of circulating PMNs. The production of oxygen radicals increased, resulting in a 
significant increase at day 2 in plasma lipid peroxidation products such as thiobarbituratic 
acid reactive material (TBAR), conjugated dienes and fluorescent products. SGPT 
increased at day 2 but decreased significantly at day 4 reflecting severe liver cell dys-
function or even liver-cell necrosis. 
Bacteriologically, most rats dying in this acute period, showed bacterial 
translocation of gram-negative aerobic rods to the peritoneal cavity as well as to MLN. 
At day 2, interstitial edema was consistently found in the lungs. Interstitial pulmonary 
edema was more extensive in the rats that died spontaneously within the first two days. At 
day 2, the liver showed slight signs of liver-cell degeneration and occasionally clusters of 
liver-cell necrosis. At day 2, the spleen showed an exhaustion of lymphoid tissue. 
After this acute period, rats improved up to day 8 or 9 and were more active, 
were no longer anorectic, had no more loss of hemorrhagic fluid and had normal stools. In 
general, no mortality occured in this second period. 
Biochemically, N-acetylglucosaminidase (NAG) increased from day 4 on, 
indicating lysosomal enzyme release from activated macrophages or degranulating PMNs. 
The number of circulating PMNs returned to normal levels. TBAR in lung and liver tissue 
decreased but still showed elevated levels as compared to bianco controls. Plasma lipid 
peroxidation still increased possibly due to a wash-out phenomena. 
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Bacterial translocation to the abdominal cavity and MLN rarely occurred in this 
period. Microscopically, interstitial edema in the lung increased, as well as the number of 
PMNs in the lung capillaries. Signs of liver cell degeneration increased with time when 
compared to microscopic alterations at day 2. Also the number of Kupffer cells increased. 
At day 9, the kidney showed sequestration of PMNs in the glomeruli and degeneration of 
cells in the tubuli. 
The third phase of this syndrome (day 9-12) was characterized by an increased 
severity of illness with severe dyspnea, tachycardia, decreased oxygen consumption, 
decreasing body temperature, loss of body weight, anorexia, lethargy and a 15 % mortality 
rate. Biochemically, this third phase was characterized by lactic acidosis, increased levels 
of alkaline phosphatase, and increased numbers of thrombocytes and leukocytes. Bacterial 
translocation was rarely found in this late phase. Morphologically, extensive alterations in 
lung, liver, kidney and spleen were found. The relative organ weights were significantly 
increased. The lung showed extensive interstitial edema, protein-rich intra-alveolar edema, 
hemorrhage, and increased numbers of PMNs and macrophages. The liver showed liver-
cell degeneration with areas of liver cell necrosis, an increased number of PMNs, 
widening of Disse's space and an increased number of Kupffer cells. In the kidney, wide-
ning of tubuli was seen with degeneration of cells of tubuli and an increased number of 
PMNs in the glomeruli. The spleen showed exhaustion of lymphoid tissue, extramedullary 
hematopoiesis, and an increased number of PMNs. 
In the long term experiment, rats surviving the third phase recovered. Their body 
temperature returned to normal, body weight increased and their activity returned to 
normal. Only respiratory rate remained high. Lungs of rats sacrificed at day 33 showed 
interstitial edema, occasionally intra-alveolar edema, an increased number of PMNs and a 
higher macrophage count as compared to rats dying in the third phase. The presence of 
siderophages in the lung found in long term survivors suggested an active clearance of 
extravascular erythrocytes. 
An aseptic non-bacterial inflammatory stimulus given intraperitoneally, thus 
resulted in remote organ dysfunction. The alterations in the cardiopulmonary system, in 
oxygen utilization, in renal and hepatic functions, the hematologic changes and the 
lethargy account for changes in seven organ systems. The similarities to the clinical 
syndrome of MOF are striking. 
The clinical, bacteriological, biochemical and microscopical alterations in this 
model of zymosan induced generalized inflammation (ZIGI-model) closely resemble the 
findings in other rat models of bacteria or endotoxin induced sepsis (1,2) (Table I). 
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Table I. Biological and microscopical data in the zymosan induced generalized inflammation (ZIGI) model 
compared to the cecal ligation and puncture (CCP) model and fecal inoculation model 
ZIGI-model CLP-model fecal inoculation 
Follow-up (rat) 12-33 days (rat) 5 days (rat) 5 days 
OBSERVATION PERIOD DAY 0 -
Lethargy 
Tachypnea 
Tachycardia 
Oxygen consumption 
Blood loss 
Fever 
Weight loss 
Diarrhoea 
Ruffled fur 
Mortality % 
BT blood 
BT peritoneum 
Glucose day 1 
Glucose day 2 
Insulin day 1 
Insulin day 2 
Lactate 
OBSERVATION PERIOD DAY 12 
Lethargy 
Tachypnea 
Oxygen consumption 
Tachycardia 
Fever 
Weight loss 
Ruffled fur 
Lactate 
Microscopical alterations 
- lung 
- liver 
- spleen 
- kidney 
5 
+ 
+ 
+ 
increase 
+ 
+ 
+ 
+ 
+ 
30 
+/-
+ 
7 
7 
7 
7 
7 
-33 
+ 
+ 
decrease 
+ 
-
+ 
+ 
increase 
+ 
+ 
+ 
+ 
25 
+ 
+ 
+ 
? 
? 
+ 
7 
+ 
+ 
-95 
+ 
+ 
increase 
decrease 
increase 
decrease 
increase 
? 
? 
7 
? 
? 
7 
? 
? 
7 
7 
? 
? 
+ 
+ 
+ 
increase 
? 
+ 
+ 
? 
? 
24-76 
+ 
+ 
increase 
decrease 
? 
? 
increase 
7 
7 
7 
7 
7 
? 
? 
7 
7 
7 
? 
? 
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Recently, Steinberg et al (3) confirmed the usefulness of this model and concluded 
that it fulfills the criteria for a model of MOF. Steinberg performed an in depth study of 
the renal function, cardiopulmonary function, hepatocyte metabolism, and gut bacterial 
translocation. 
- Renal function: decreased urinary output, increased serum creatinine, decreased 
creatinine clearance, hematocrit: increased at day 1 and normal at day 3. 
- Cardiopulmonary function: increased respiratory rate, decreased mean arterial 
blood pressure, decreased arterial oxygen tension. 
- Hepatocyte metabolism: decreased microsomal protein content, decreased 
cytochrome P450. 
- Bacterial translocation: to the peritoneal cavity, the spleen, the liver, the MLN, 
and to the portal venous blood and hepatic venous blood with a maximum at day 
1 but still present at day S. 
Deitch et al (4) have recently shown in mice that i.p. zymosan induced gut 
mucosal injury, BT, sepsis, and mortality in a dose dependent way. 
Mainous et al (5) showed that 10 mg i.p. zymosan per 100 g rat resulted in BT 
only to the MLN, whereas at a zymosan dose of 50 mg per 100 g rat the translocating 
bacteria spread systemically. They concluded that both the route and extent of BT are 
based on the magnitude of the inflammatory insult, with the portal blood being the major 
route of BT to systemic organs. 
To exclude bacterial interference, we repeated the experiment in germ-free rats. 
The results were qualitatively the same, all surviving rats showing MOF-like changes at 
day 12. However, the acute reaction was less severe with a significantly lower acute 
mortality rate. This indicates that BT in conventional rats might be related to the early 
30 % mortality rate. 
Are elastasendeficient mice resistant to MOF (chapter 4)? 
To investigate the role of PMN-elastase in zymosan induced MOF, zymosan was 
injected in el as tase deficient mice. Strikingly, these mice showed a decreased acute 
mortality, but at day 12, organ damage and mortality were comparable with those in 
conventional control mice, probably indicating the importance of PMN related organ 
damage in the early inflammatory phase. 
Can MOF in the ZIGI-model be prevented Ъу SD (chapter 5 and 6)? 
Gut bacteria have been incriminated as causing or contributing to generalized 
sepsis with MOF in severely ill patients, and selective decontamination of the gastro­
intestinal tract (SD) has been shown to decrease septic complications in these patients, but 
not to prevent MOF. In our model, rats were decontaminated with two regimens of 
antibiotics before the zymosan injection was given. SD was highly effective in preventing 
ВТ of enterobacteriaceae (E) to the peritoneal cavity and to the MLN, even when 
overgrowth with streptomycin-resistant E in the gut occurred. SD with streptomycin - not 
with trimethoprim - resulted in a significantly higher number of 12-day survivors although 
clinical illness was as severe as in control rats. The difference in survival rate between the 
trimethoprim decontaminated and the streptomycin decontaminated rats thus could not be 
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explained by BT of E, as E were eliminated in both groups before zymosan was injected, 
while recolonization with E in streptomycin treated rats did not alter the clinical course 
and outcome. 
In a long-term follow-up experiment, streptomycin resulted in an important 
intestinal overgrowth of streptomycin-resistant E. However, no translocation to the 
peritoneal cavity or MLN was found at the end of the experiment. Again, the streptomycin 
group showed a significantly higher survival rate as compared to control rats. Assuming a 
beneficial role of streptomycin on the phagocytic activity of macrophages, it is possible 
that in the streptomycin treated group translocating bacteria are directly ingested resulting 
in a decreased septic challenge. As macrophages may themselves be responsible for the 
BT of E (6), another explanation may be that streptomycin alters macrophage activity, thus 
decreasing BT of E. 
The early mortality in the streptomycin treated group was comparable with the 
early mortality found in the germ-free experiment. At day 12, zymosan injected 
conventional rats, zymosan injected germ-free rats and zymosan injected rats treated with 
SD were clinically in the same severe condition. This confirms our hypothesis that MOF is 
the result of a severe generalized auto-inflammatory reaction. 
Is it possible to prevent MOF in the ZIGI-model by administration of SOD and Catalase 
(chapter 7), bydroxyl radical scavengers, irou-chelatiou or complemeot inactivauon 
(chapter 8}f or a scavenger of hydroperoxide and oxygen radicals (chapter 9)? 
The role of PMNs in the pathogenesis of MOF has been well documented. The 
acute phase of this experimental model showed an increase of oxygen radical production 
and an increase of lipid peroxidation products in plasma and in lung and liver tissue. 
Combined therapy with superoxide dismutase and catalase significantly decreased the 
amount of lipid peroxidation, although no improvement was found in clinical illness or in 
acute phase mortality. Even an increased mortality rate was found in the SOD low 
molecular group suggesting that the conjugates utilized had unfavorable side effects. 
The use of hydroxyl radical scavengers (DMSO, DMTU, Mannitol) by continuous 
12 day i.v. infusion, did not result in a lower mortality rate, an improved clinical condition 
or decreased morphologic alterations as compared to untreated control ZIGI-rats. It is not 
excluded that, with other dosages, more favourable results may be obtained, though the 
dosages utilized are generally recommended. The same results and remarks concern the 
use of an iron chelator (DHBA), an inactivator of С3 convertase (RMA) and U74006F. 
Is administration of a high-energy substrate capable to restore the activity of aerobic 
glycolysis and thus to decrease lactate levels (chapter 10)? 
FDP, as a direct energy source in the energy production by the Embden-
Meyerhoff pathway, was administered in an "optimal" dosage. Despite favorable effects in 
other shock models, FDP did not attenuate signs of MOF in the ZIGI-model. 
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If endotoxin is a key factor of MOF» would there be a difference in the severity of MOF 
betweço eodotoxituresisumt mice audi eadotoxin-sensitive mkeXcfcapter 11},? *,*• 
In recent years, the pivotal role of the macrophage in sepsis and MOF has been 
discussed. In our model, intra-alveolar macrophages in the lung and Kupffer cells in the 
liver are abundantly present in rats and mice, sacrificed at day 12. 
Although a MOF-like syndrome in germ-free rats can be induced aseptically, it 
has been suggested that zymosan sensitizes macrophages to very low doses of endotoxin 
(7). Endotoxin present in the standard laboratory chow and/or drinking water, may thus 
explain the development of MOF in germ-free rats. Zymosan injected in СЗН/HeJ and 
СЗН/HeN mice resulted in a significantly lower acute and overall mortality rate and in 
significantly decreased morphologic changes in the lung and liver. All twelve day 
survivors were in reasonably good health. In both strains, the liver even showed an 
increase of mitotic activity indicating liver cell regeneration. As no significant differences 
between both strains were found, we concluded that endotoxin sensitivity and thus 
endotoxin is not essential in the pathogenesis of MOF. It has been demonstrated in vitro 
that C3HeJ macrophages can not be stimulated by zymosan (8). Dysfunction of the Fc and 
C3b receptor to zymosan has been demonstrated in the СЗН/HeJ mouse. Dysfunction in 
the СЗН/HeN strain is likely but has not yet been demonstrated. 
If TNF is a key mediator of MOF» is blocking of the TNF-receptor (chapter it) or binding 
of circulating TNF (chapter 13) successful in reducing úit severity ôf MOF? 
Recent evidence suggests that the biosynthesis and release of endogenous 
cytokines, especially TNF, trigger the inflammatory reaction typical of MOF. As the 
СЗН/HeJ strain shows a defective translation of TNF messenger-RNA into the protein 
TNF, an attenuated response to zymosan in this strain may be explained by a deficient 
TNF-expression. Oleyl acetyl glycerol (OAG) down regulates TNF-binding capacity in 
vitro by activating protein kinase С (PKC). OAG administered in several dosages, 
however, did not prevent MOF in the ZIGI model but resulted in an increased mortality, 
possibly due to a PKC-enhanced response to zymosan. 
In the ZIGI model administration of monoclonal anti-TNF (TN3) antibody prior 
to the zymosan injection did not influence mortality or organ damage in this model after 
12 days. Probably other cytokines e.g. IL-1, having a wide variety of toxic effects broadly 
overlapping TNF- effects, may explain the poor results of TN3. 
Several puzzling observations were made during the experiments, prompting 
further in depth study. But as one of the aims of the study was to find a way to decrease 
mortality in the ZIGI-model to less than 10 %, all 12-day survivors being healthy, we 
continued exploring new methods of prevention. Finally, these requirements were met by 
the СЗН/HeJ and СЗН/HeN mice. Further studies are necessary to determine why 
СЗН/HeJ and СЗН/HeN strains are hypo-responsive to zymosan, and if modulation of 
macrophages in their reaction to inflammatory stimuli may be a clinically usefull method 
to prevent and/or treat MOF. 
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SAMENVATTING 
Hoofdstuk 1 beschrijft de klinische relevantie van het multiple organ failure 
syndroom (MOF). Ondanks uitgebreid onderzoek is er nog geen communis opinio m.b.t. 
de pathophysiologie van dit syndroom. Nuytinck et al (1) veronderstellen een "total body 
inflammatory reaction" aangezien de MOF patiënt zich klinisch manifesteert met 
ontstekingskenmerken zoals koorts (calor), oedeem (tumor), vasodilatatie (rubor), en 
orgaanfunctie stoornissen (functio laesa). De inleiding geeft een opsomming van factoren 
die een rol (kunnen) spelen bij het MOF syndroom: humorale mediatoren, granulocyten 
(PMNs), macrofagen, zuurstofradicalen, elastase, tumor necrosis factor, interleukinen en 
neopterine. De patho-morfologie van aangedane organen wordt besproken. Het 
zuurstofmetabolisme wordt gekenmerkt door een zogenaamde supply dependency. De rol 
van bacteriën in de Pathogenese van MOF is dubieus. Een aantal dierexperimentele 
modellen m.b.t. chronische sepsis en MOF worden beschreven. Nadeel van deze studies is 
dat het septisch beeld in deze dieren wordt geïnduceerd door bacteriën en/of endotoxinen. 
Uitgangspunt van onze studie was het ontwikkelen van een model waarbij m.b.v. een 
aseptische, niet-bacteriële, niet-endotoxische stimulus het beeld van MOF in de rat en muis 
wordt geïnduceerd. Als stimulus werd zymosan gesuspendeerd in paraffine, 
intraperitoneaal ingespoten. Enkele eigenschappen van zymosan, een onoplosbaar 
polysaccharide van de gist Saccharomyces Cerevisiae, worden besproken. 
Hoofdstuk 2 beschrijft het primaire doel van deze studie, nl. het ontwikkelen van 
een dierexperimenteel model waarin m.b.v. een niet-bacteriële, niet-endotoxische locale 
inflammatoire stimulus het beeld van een MOF syndroom wordt geïnduceerd, gelijkend op 
het syndroom geïnduceerd m.b.v. bacteriële en endotoxische stimuli. Zymosan 
gesuspendeerd in paraffine geeft een verlengde activatie van de alternatieve route van de 
complement cascade en leidt tot macrophagen aktivatie indien het intraperitoneaal in de rat 
en muis wordt ingespoten. 
Intraperitoneale toediening van zymosan in een dosis van 100 mg gesuspendeerd 
in 4 ml paraffine per 100 gram lichaamsgwicht, resulteert in een trifasisch ziektebeeld: 
De acute fase (dag 0-2) wordt gekenmerkt door lethargie, anorexie, tachypneu, 
tachycardie, verhoogde zuurstofconsumptie, koorts, verlies van bloedig vocht uit de ogen 
en neus, diarree of obstipatie. De mortaliteit in de acute fase is gemiddeld 30%. 
Biochemisch wordt deze fase gekenmerkt door een daling van CH50 hetgeen een maat is 
voor complement aktivatie. Complement aktivatie resulteert in een opeenhoping van PMNs 
in de capillairen hetgeen weerspiegeld wordt in een significante daling in het aantal 
circulerende PMNs. De zuurstofradicaal produktie is toegenomen hetgeen resulteert in een 
significante stijging van lipide peroxidatie produkten in plasma op dag 2 zoals 
thiobarbituurzuur (TBAR), geconjugeerde dienen en fluorescentie produkten. SGPT is 
verhoogd op dag 2 en daalt significant op dag 4, hetgeen een maat is voor ernstige 
levercel stoornissen en/of levercelnecrose. 
De meeste ratten die in deze acute fase sterven, vertonen bacteriële translocatie 
(BT) van gram negatieve bacteriën naar zowel de vrije buikholte als naar de mesenteriale 
lymfklieren. In de longen wordt interstitiëel oedeem gevonden. De lever laat tekenen van 
levercel degeneratie zien en sporadisch gebieden met levercelnecrose. In de milt is het 
aantal lymffollikels afgenomen. 
160 
Na deze acute fase is er een periode van herstel van dag 3 tot dag 8, waarin de 
rat actiever wordt, voedsel tot zich neemt en geen verlies van bloedig vocht of diarree 
heeft. In deze fase is er vrijwel geen mortaliteit. Vanaf dag 4 is er een stijging te zien van 
N-acetyl-glucosaminidase, een teken van verhoogde lysosomale enzymaktiviteit van 
macrophagen, en van degranulerende PMNs. Het aantal circulerende PMNs is in deze fase 
genormaliseerd. Het gehalte aan TBAR in long- en leverweefsel is t.o.v. de acute fase 
afgenomen, maar nog steeds verhoogd Lo.v. controle waarden. Het gehalte aan plasma 
lipide peroxidatieprodukten is verhoogd, mogelijk tg.v. een wash-out fenomeen. BT naar 
de vrije buikholte of naar de MLN treedt zelden op. In de long is zowel het interstitiëel 
oedeem als het aantal PMNs toegenomen. De levercel degeneratie is toegenomen alsmede 
het aantal Kupffercellen. In de glomeruli van de nier is een toename van PMNs, alsmede 
een degeneratie van niertubuluscellen. 
De derde fase laat een verergering van het ziektebeeld zien met ernstige dyspneu, 
tachycardie, afgenomen zuurstof consumptie, daling van de lichaamstemperatuur, anorexie, 
verlies van lichaamsgewicht, lethargie en een mortaliteit van gemiddeld 15%. 
Biochemisch word deze fase gekenmerkt door lactaat acidóse, stijging van het 
alkalisch fosfatase en stijging van het aantal circulerende trombocyten en PMNs. BT treedt 
nu zelden op. Morfologisch zijn er sterke veranderingen in de long, lever, nier en milt. De 
relatieve orgaangewichten zijn sterk toegenomen. Microscopisch wordt de long gekenmerkt 
door uitgebreid interstitiëel oedeem, eiwitrijk intra-alveolair oedeem, bloedingen en een 
toename van PMNs en macrophagen. De lever laat sterke levercel degeneratie danwei 
levercel necrose zien, verbreding van de ruimte van Disse en een toename in het aantal 
PMNs en Kupffercellen. De niertubuli zijn verwijd met degeneratie van de tubuluscellen. 
De glomeruli laten een toename zien van het aantal PMNs. De milt wordt gekenmerkt 
door een afname van het aantal lymffollikels, extramedullaire haematopoiëse en een 
toename in het aantal PMNs. 
In het 33 dagen durende experiment (hoofdstuk 5) blijkt dat ratten die de derde 
fase overleven, zich verder herstellen; de lichaamstemperatuur normaliseert, het 
lichaamsgewicht neemt toe en de lichaamlijke activiteit normaliseert. De 
ademhalingsfrequentie blijft onveranderd hoog. De longen van ratten opgeofferd op de 33e 
dag laten interstitiëel oedeem zien, sporadisch intra-alveolair oedeem en een toename van 
het aantal PMNs en macrofagen t.o.v. ratten die in de derde fase overleden. De 
aanwezigheid van siderophagen in de long suggereert afbraak van bloed t.g.v. eerder 
opgetreden longbloedingen. 
Een aseptische, niet-bacteriële ontsteking die intraperitoneaal wordt toegediend, 
resulteert in dit model in functiestoornissen van organen die buiten de buikholte gelegen 
zijn. De veranderingen in het cardiopulmonale systeem, in zuurstofconsumptie, in nier- en 
leverfuncties, de hematologische veranderingen alsmede de lethargie representeren 
veranderingen in zeven orgaansystemen. De gelijkenis met het klinisch syndroom MOF bij 
de mens zijn treffend. 
De klinische, bacteriologische, biochemische en microscopische veranderingen in 
dit door zymosan geïnduceerde model van gegeneraliseerde ontsteking lijken sterk op de 
bevindingen van andere experimenten van door bacteriën of endotoxinen geïnduceerde 
sepsis in de rat (2,3) (Hoofdstuk 14 Table I)). 
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Steinberg et al (4) bevestigden de bruikbaarheid van dit model en concludeerden 
dat het voldoet aan de eisen die gesteld worden aan een model voor het bestuderen van 
het MOF-syndroom. Zij verrichtten in het hier beschreven model een diepgaande studie 
naar de nierfunctie, cardiopulmonale functie, levercelmetabolisme en BT door de darm. De 
nierfunctie liet een verminderde urine produktie, een stijging van het serum kreatinine en 
een daling van de kreatinine klaring zien. De cardiopulmonale functie liet een toename van 
de ademhalingsfrequentie en een daling van de gemiddelde bloeddruk en arteriële 
zuurstofspanning zien. Het levercelmetabolisme liet een vermindering van het lysosomale 
eiwitgehalte en cytochroom P450. BT werd aangetoond naar de vrije buikholte, lever en 
milt, de mesenteriale lymfklieren en naar het portale bloed. BT trad vooral op op de eerste 
dag en in geringe mate tot de vijfde dag. 
Deitch et al (5) beschreven dat de mate van darmmucosa beschadiging, van BT, 
sepsis en mortaliteit in het muizenmodel afhankelijk is van de hoeveelheid i.p. toegediende 
zymosan. 
Mainous et al (6) toonden aan dat 10 mg zymosan i.p. per 100 gram rat 
resulteerde in BT naar de mesenteriale lymfklieren, terwijl een dosering van 50 mg 
zymosan per 100 gram resulteert in een systemische BT. Zij concludeerden dat de route en 
mate van BT afhankelijk is van de ontstekingsstimulus en dat de portale flow de 
belangrijkste route is van BT naar de overige organsystemen. 
Dit onderzoek werd herhaald bij kiemvrije ratten om na te gaan of het MOF 
syndroom ook opgewekt kon worden in afwezigheid van bacteriën. De kiemvrije 
proefdieren gaven kwalitatief hetzelfde ziektebeeld te zien als bij conventionele 
proefdieren. Alle ratten die de 12 dagen follow-up periode overleefden lieten op MOF 
gelijkende veranderingen zien. Echter in de acute fase waren deze dieren minder ziek, 
resulterend in een significant lagere acute mortaliteit t.o.v. conventionele ratten. Dit 
impliceert dat BT bij normale ratten verantwoordelijk kan zijn voor de 30% mortaliteit in 
de acute fase. 
Hoofdstuk 4 beschrijft het effect van zymosan geïnduceerde MOF in elastase-
deficiënte muizen. De mortaliteit in de acute fase in deze muizengroep was significant 
lager t.o.v. de controle groep, maar op de 12e dag was de orgaan schade en mortaliteit 
vergelijkbaar met die van de controle groep. Dit impliceert het belang van PMNs in de 
acute fase. 
Hoofdstuk 5 en 6 bespreken het effect van Selectieve Darm Decontaminatie 
(SDD) op het ontwikkelen van MOF in dit diermodel. 
Darmbacteriën worden verantwoordelijk gesteld voor het veroorzaken van - danwei 
deelname in - het ontstaan van gegeneraliseerde sepsis en MOF bij ernstig zieke patiënten. 
SDD is effectief gebleken in het verminderen van septische complicaties maar niet in de 
preventie van MOF. In ons model werden de ratten vooraf aan de i.p. zymosan injectie 
gedecontamineerd met streptomycine of trimethoprim. Deze decontaminatie bleek effectief 
te zijn in de preventie van translocatie van darmbacteriën naar de vrije buikholte en 
mesenteriale lymfklieren, zelfs bij overgroei van streptomycine-resistente darmbacteriën. 
SDD met streptomycine (niet met trimethoprim), resulteerde in een significant betere 
overleving alhoewel het klinisch beeld van MOF net zo ernstig was als bij niet 
gedecontamineerde ratten. Het verschil in overleving tussen de trimethoprim 
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gedecontamineerde en streptomycine gedecontamineerde ratten kon niet verklaard worden 
door BT van darmbacteriën, aangezien deze darmbacteriën waren geëlimineerd ten tijde 
van de zymosan injectie, terwijl recolonisatie van streptomycine-resistente darmbacteriën 
in de behandelde ratten niet leidde tot een verandering in het klinisch beloop. 
In een 33 dagen durend experiment resulteerde darmdecontaminatie met 
streptomycine in een forse intestinale overgroei van streptomycine-resistente 
darmbacteriën. Hierbij werd geen translocatie naar de vrije buikholte of mesenteriale 
lymfklieren gevonden. Wederom resulteerde decontaminatie met streptomycine in een 
betere overleving t.o.v. de controle groep. Indien men aanneemt dat streptomycine de 
phagocytose van macrophagen stimuleert, dan is het niet denkbeeldig dat in streptomycine 
behandelde ratten de getransloceerde bacteriën direct worden gephagocyteerd en derhalve 
de septische stimulus doen verminderen. Aangezien aangetoond is dat macrophagen zelf 
een rol kunnen spelen bij BT (7), is het ook denkbaar dat streptomycine de aktiviteit van 
de macrophagen veranderd, hetgeen kan resulteren in een verminderde BT van 
darmbacteriën. De mortaliteit in de acute fase van de streptomycine behandelde groep was 
vergelijkbaar met die van de kiemvrije ratten. Echter op de 12e dag van het experiment 
was het ziektebeeld net zo ernstig bij normale ratten, kiemvrije ratten en 
gedecontamineerde ratten. Deze bevinding bevestigt onze hypothese dat MOF het resultaat 
is van een ernstige gegeneraliseerde auto-inflammatoire reactie. 
Hoofdstuk 7 beschrijft het effect van zuurstofradicaal scavengers, superoxide 
dismutase (SOD) en catalase bij het ontstaan van MOF in dit model. Hoofdstuk 8 
beschrijft het effect van hydroxylradicaal scavengers, ijzerchelatie en 
complementinactivatie en hoofdstuk 9 het effect van een hydroperoxide- en 
zuurstofradicaal scavenger. 
De zuurstofradicaal productie in de acute fase van het ZIGI-model was 
toegenomen, hetgeen resulteerde in een stijging van lipiden peroxidatieproducten in plasma 
en in long- en leverweefsel. De combinatie van SOD en catalase resulteerde in een 
significante daling van lipide peroxidatie produkten, hoewel geen verbetering werd gezien 
in de ernst van het ziektebeeld of de mortaliteit in de acute fase. De mortaliteit was zelfs 
toegenomen in de laag moleculaire SOD-groep, hetgeen een ongunstig effect van de 
toegediende conjugaten impliceert 
Het toedienen van hydroxylradicaal scavengers (DMSO, DMTU, mannitol) per 
continue infuus gedurende 12 dagen resulteerde niet in een verminderde mortaliteit of in 
een betere klinische conditie of in minder ernstige morfologische veranderingen in 
vergelijking met onbehandelde ratten. Het betekent echter niet dat met andere doseringen 
geen betere resultaten verkregen kunnen worden. De hier gebruikte doseringen waren 
echter de algemeen geadviseerde doseringen. Dezelfde resultaten en gemaakte 
kanttekeningen golden ook voor het gebruik van de ijzerchelator DHBA, de inactivator 
van C3 convertase RMA en U740006F. 
Hoofdstuk 10 beschrijft het effect van fructose-1-6-difosfaat (FDP), een hoog 
energetisch substraat voor de door de Embden-Meyerhoff reactie gestuurde energie 
produktie, en derhalve in staat tot herstel van de aërobe glycolyse. Ondanks de gunstige 
effecten van ГОР in andere shock modellen en de gehanteerde "optimale" dosering, was 
FDP in het ZIGI-model niet effectief in het verminderen van het MOF syndroom. 
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De rol van macrophagen in de Pathogenese van sepsis en MOF neemt in de 
huidige literatuur een centrale plaats in. In het ZIGI-model zijn intra-alveolaire 
macrophagen in de long en Kupfferse cellen in de lever zowel in de rat als muis 
overvloedig aanwezig op de 12e dag. Hoewel het MOF syndroom in kiemvrije ratten kon 
worden geïnduceerd, weid gesuggereerd dat zymosan de macrophagen gevoeliger maakt 
voor endotoxine in zelfs zeer lage dosering (8). Endotoxinen aanwezig in het voedsel en/of 
drinkwater kunnen derhalve verantwoordelijk zijn voor het ontstaan van MOF bij 
kiemvrije ratten. Indien endotoxine een sleutelrol speelt in de Pathogenese van MOF, 
zouden endotoxine-resistente muizen minder of niet gevoelig moeten zijn voor zymosan 
geïnduceerde MOF. Hoofdstuk 11 beschrijft het resultaat van zymosan geïnduceerde MOF 
in endotoxine-resistente (СЗН/HeJ) en in endotoxine-gevoelige (СЗН/HeN) muizen. 
Lp. zymosan toegediend aan СЗН/HeJ en СЗН/HeN muizen leidde tot een 
significant lagere acute en overall mortaliteit en significant minder morfologische 
veranderingen in de long en lever dan in Swiss en Black muizen. Alle muizen van beide 
stammen die het 12 dagen durende experiment overleefden waren in een redelijke conditie. 
De lever in beide muizenstammen liet een verhoogde mitotische aktiviteit zien hetgeen 
levercel regeneratie betekent Aangezien er geen significante verschillen tussen beide 
muizenstammen werd gevonden, concluderen wij dat endotoxine gevoeligheid - en 
derhalve endotoxinen - niet essentieel zijn in de Pathogenese van MOF. Verondersteld 
wordt dat de verminderde gevoeligheid van het door zymosan geïnduceerde MOF 
syndroom in beide stammen receptor afhankelijk is. Immers Leu et al (9) beschreven dat 
macrophagen van СЗН/HeJ muizen in vitro niet te stimuleren zijn met zymosan. Mogelijk 
daarom ontwikkelen deze muizen geen MOF syndroom. 
Hoofdstuk 12 en 13 beschrijven het effect van oleyl-acetyl-glycerol (OAG) 
hetwelk de TNF receptor blokkeert, en anti-TNF dat circulerend TNF bindt, op de emst 
van MOF in het ZIGI-model. Er zijn steeds meer aanwijzingen dat de biosynthese en 
vrijzetting van endogene cytokinen, met name van TNF, de ontstekingsreactie die typisch 
is voor het MOF syndroom triggeren. De СЗН/HeJ stam heeft een defect in de translatie 
van TNF messenger-RNA in TNF. De verminderde respons van deze muizenstam op 
zymosan zou verklaard kunnen worden door een deficiënte TNF-expressie. OAG 
vermindert in vitro de TNF-bindingscapaciteit door het proteïne kinase С (PKC) te 
activeren. OAG in verschillende doseringen in het ZIGI-model voorkwam echter MOF 
niet, maar resulteerde in een verhoogde mortaliteit, mogelijk t.g.v. een door het PKC 
gemedieerde verhoogde respons op zymosan. 
Toediening van monoclonaal anti-TNF (TN3) voor de zymosan injectie in het 
ZIGI-model, had geen invloed op de mortaliteit of orgaanschade gedurende de 12 dagen 
follow-up. Een mogelijke verklaring is dat andere cytokinen zoals IL-1 met een 
werkingsspectnim welke de TNF-effecten deels overlappen, mede verantwoordelijk zijn 
voor de toxische effecten. 
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Observaties gedurende deze reeks experimenten hebben weliswaar vragen 
beantwoord, maar ook veel vragen opgeroepen. Een van de belangrijke doelstellingen in 
deze studie was het reduceren van de mortaliteit in het ZIG I-model tot 10% en minder, 
waarbij de overlevenden na 12 dagen in goede conditie dienden te zijn. Diverse 
therapeutische benaderingen werden onderzocht om dit doel te bereiken. Uiteindelijk werd 
de beoogde mortaliteitsreductie bereikt bij СЗН/HeJ en СЗН/HeN muizen. Aanvullende 
studies zijn noodzakelijk om te onderzoeken waarom beide muizenstammen verminderd 
gevoelig zijn voor zymosan geïnduceerd MOF, en of modulatie van macrophagen in hun 
reactie op inflammatoire stimuli van klinische betekenis kan zijn in de preventie of 
behandeling van MOF. 
SLOTCONCLUSIES 
„» Het ontstaan van Multiple Orgaa Failure is niet objigaat gecotreleerd aan de 
aanwezigheid van bacteriën en/of çndotoxinen. 
- Multiple Organ Failure is het resultaat van een gegeneraliseerde 
ootstekingsreactie. 
- Multiple Organ Failure kan mogelijk voorkomen worden, danwei vcmdrtdetd 
in ernste indien (overmatige) macrophagen-activarie wordt vermeden. 
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LIST OF ABBREVIATIONS 
AAT 
AF 
Alfa-1-PI 
APAS 
ARDS 
ATP 
В strain 
BHI 
Body wt 
C3, C4 
C3a, c3d, C5a 
C3H/HeJ 
C3H/HeN 
C57/BVJ6 
CAT 
CD11/CD18 
CH50 
CLP 
DHBA 
DMTU 
E 
E coli 
ED 
ELAM-1 
FDP 
Fi02 
GI-tract 
GM-CSF 
H strain 
HA 
HMW 
i.p. 
i.v. 
ICAM-1 
ICU 
ID 
IFN 
IL-1 
IOE 
ISS 
KCl 
LDW 
LDH 
LMW 
LPS 
MDA 
MLN 
Alanine amino transferase 
Alkaline phosphatase 
Alfa-1-proteinase inhibitor 
A-per jodie acid schiff 
Adult Respiratory Distress Syndrome 
Adenosine Triphosphate 
Beige mice 
Brain heart infusion (growth medium) 
Body weight 
Complement factors 
Complement split products 
Endotoxin hyporesponsive mouse strain 
Endotoxin responsive mouse strain 
Elastase deficient mice (beige mice) 
Catalase 
Neutrophil adhesive glycoprotein complex 
Total complement level 
Cecal ligation and puncture 
2,3-Dihydroxybenzoic acid 
Dimethylthiourea 
Enterobacteriaceae 
Escherichia coli 
External diameter 
Endothelial leukocyte adhesion molecule-1 
Fructose-l, 6-diphosphate 
Inspired oxygen fraction 
Gastro-intestinal tract 
Granulocyte-macrophage colony stimulating factor 
Heterozygotic controls of beige mice 
Hydrogen peroxide 
High molecular weight 
Intrapertoneal 
Intravenous 
Intercellular adhesion molecule-1 
Intensive care unit 
Internal diameter 
Interferon 
Interleukin-1 
Impaired oxygen extraction 
Injury severity score 
Kaliumchloride 
Lethal dose (50 % mortality) 
Lactic dehydrogenase 
Low molecular weight 
Lipopolysaccharide 
Malondialdehyde 
Mesenteric lymph nodes 
166 
MOF 
MPS 
NAF 
o2 OAG 
OFR 
PAF 
Pa02 
PEEP 
PFK 
PKC 
PMA 
p0 2 
Pv02 
RMA 
S strain 
S.C. 
SD(D) 
SGOT 
SGPT 
SOD 
ТВА 
TBAR 
TN3 
TNF 
U74006F 
vo2 ZIGI 
Multiple Organ Failure 
Mononuclear phagocyte system 
Neutrophil activating factor 
Oxygen 
Oleyl-acetyl-glycerol 
Oxygen free radical(s) 
Platelet activating factor 
Arterial oxygen pressure 
Positive end experiatory pressure 
Phosphofructokinase 
Protein kinase С 
Phorbol myristic acid 
Oxygen pressure 
Venous oxygen pressure 
Rosmarinic acid 
Swiss mice 
Subcutaneous 
Selective decontamination 
Serum glutamyl oxaalacetaat transaminase 
Serum glutamyl pyruvaat transaminase 
Superoxide dismutase 
Thiobarbituratic acid 
Thiobarbituratic acid reactive material 
Monoclonal antibody anti-tumor necrosis factor 
Tumor necrosis factor 
non-glucocorticoid 21-aminosteroid inhibition of lipid peroxidation 
Oxygen consumption 
Zymosan Induced Generalized Inflammation 
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CURRICULUM VITAE 
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